Is exposure to formaldehyde in air causally associated with leukemia?—A hypothesis-based weight-of-evidence analysis by Rhomberg, Lorenz R et al.
555
Contents
Abstract ................................................................................................................................................................................... 555
1.  Introduction and background .......................................................................................................................................... 557
2.  Hypothesis-based weight-of-evidence (HBWoE) evaluation ........................................................................................ 558
2.1.  Overview of approach .................................................................................................................................................... 558
2.1.1.  Hill Criteria and the concept of “accounts” ............................................................................................................... 559
2.2.  HBWoE methodology ..................................................................................................................................................... 561
3.  Overview of HBWoE as applied to formaldehyde and leukemogenesis ....................................................................... 562
4.  Weight of epidemiology evidence regarding the association between formaldehyde exposure and leukemia ........ 563
4.1.  Overview of epidemiology investigations ..................................................................................................................... 563
4.2.  Endpoint-by-endpoint analysis..................................................................................................................................... 571
4.2.1.  All lymphohematopoietic cancers ............................................................................................................................. 571
4.2.2.  Cancer of lymphoid origin .......................................................................................................................................... 574
4.2.3.  Leukemia  ...................................................................................................................................................................... 574
REVIEW ARTICLE
Is exposure to formaldehyde in air causally associated with 
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Abstract
Recent scientific debate has focused on the potential for inhaled formaldehyde to cause lymphohematopoietic 
cancers, particularly leukemias, in humans. The concern stems from certain epidemiology studies reporting an 
association, although particulars of endpoints and dosimetry are inconsistent across studies and several other 
studies show no such effects. Animal studies generally report neither hematotoxicity nor leukemia associated with 
formaldehyde inhalation, and hematotoxicity studies in humans are inconsistent. Formaldehyde’s reactivity has been 
thought to preclude systemic exposure following inhalation, and its apparent inability to reach and affect the target 
tissues attacked by known leukemogens has, heretofore, led to skepticism regarding its potential to cause human 
lymphohematopoietic cancers. Recently, however, potential modes of action for formaldehyde leukemogenesis have 
been hypothesized, and it has been suggested that formaldehyde be identified as a known human leukemogen. 
In this article, we apply our hypothesis-based weight-of-evidence (HBWoE) approach to evaluate the large body 
of evidence regarding formaldehyde and leukemogenesis, attending to how human, animal, and mode-of-action 
results inform one another. We trace the logic of inference within and across all studies, and articulate how one 
could account for the suite of available observations under the various proposed hypotheses. Upon comparison of 
alternative proposals regarding what causal processes may have led to the array of observations as we see them, we 
conclude that the case for a causal association is weak and strains biological plausibility. Instead, apparent association 
between formaldehyde inhalation and leukemia in some human studies is better interpreted as due to chance or 
confounding.
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1.  Introduction and background
Formaldehyde is produced naturally by the human body. 
It is also a chemical intermediate used in the production 
of some plywood adhesives, fertilizer, paper, and urea-
formaldehyde resins (Agency for Toxic Substances and 
Disease Registry [ATSDR], 1999). It is found (as a preser-
vative or impurity) in many products around the home, 
such as antiseptics, medicines, and cosmetics/personal 
hygiene products (ATSDR, 1999). Formaldehyde is also 
used  for  embalming  and  preserving  biological  speci-
mens (United States Environmental Protection Agency 
[US EPA], 2010). Sources of exposure to formaldehyde 
include occupational exposure during use or production 
of materials containing formaldehyde; cigarette smoke; 
off-gassing from manufactured wood products in new 
mobile homes; and other new products found in homes 
(e.g., fiberglass, carpets, and paper products) (ATSDR, 
1999).
Studies have shown that exposure to high concentra-
tions of formaldehyde in air results in nasal cancer in 
rats. Some studies in humans exposed to lower concen-
trations of formaldehyde in air in the workplace found 
increased incidence of nasopharyngeal cancer, but other 
studies have not found an increased risk of these can-
cers  in  formaldehyde-exposed  workers  (ATSDR,  1999; 
Marsh and Youk, 2005; Marsh, 2007a, 2007b; Bachand 
et al., 2010; US EPA, 2010). More recently, there has been 
increased  concern  and  scientific  debate  regarding  the 
potential for exposure to formaldehyde in air to cause 
lymphohematopoietic  cancers  in  humans,  particularly 
leukemias (US EPA, 2010; Bachand et al., 2010; Beane 
Freeman  et  al.,  2009;  Hauptmann  et  al.,  2009;  Zhang 
et al., 2009, 2010a, 2010b; Pyatt et al., 2008; Golden et al., 
2006; Heck and Casanova, 2004).
The concern for formaldehyde-induced leukemogen-
esis  stems  from  a  few  epidemiology  studies  reporting 
an  association  between  formaldehyde  exposure  and 
increased mortality from leukemia (e.g., Beane Freeman 
et  al.,  2009;  Hauptmann  et  al.,  2009),  although  other 
studies show no such effects (e.g., Bachand et al., 2010; 
Pinkerton et al., 2004). The studies reporting associations 
have shortcomings, including poor disease classification 
and unverified estimates of exposure. Studies have been 
conducted  to  examine  the  potential  for  formaldehyde 
in air to induce hematotoxicity in animals and humans 
and leukemia in animals. The animal studies generally 
reported neither hematotoxicity (Monticello et al., 1989; 
Appelman  et  al.,  1988;  Holmstrom  et  al.,  1989;  Kerns 
et al., 1983; Kamata et al., 1997; Woutersen et al., 1987; 
Til et al., 1988, 1989; Johannsen et al., 1986) nor leukemia 
(Albert et al., 1982; Kerns et al., 1983; Sellakumar et al., 
1985; Kamata et al., 1997; Feron et al., 1988; Til et al., 1989; 
Tobe et al., 1989; Takahashi et al., 1986) associated with 
formaldehyde exposure. Although a few animal studies 
reported changes in one or more hematology parameters 
(Dean et al., 1984; Tobe et al., 1989; Vargova et al., 1993), 
two animal studies reported leukemias (Soffritti et al., 
1989, 2002), and a few human study findings were consis-
tent with hematotoxicity from exposure to formaldehyde 
(Tang et al., 2009; Zhang et al., 2010b), these studies were 
inconsistent with other study findings and/or plagued by 
possible confounding.
Despite the lack of substantial and consistent epide-
miological and toxicological evidence for formaldehyde 
leukemogenesis, US EPA has concluded that formalde-
hyde should be deemed a known human leukemogen 
(US  EPA,  2010),  citing  possible  modes  of  action  put 
forth by Zhang et al. (2009, 2010a). The three proposed 
modes of action involve formaldehyde: (1) migrating to 
and directly targeting bone marrow hematopoietic stem 
cells; (2) targeting nasal stem cells (nasal-associated lym-
phoid tissue, or NALT) which then are released from the 
nasal passage, circulate in the blood, and are eventually 
incorporated into bone marrow, leading to leukemia; or 
(3) targeting circulating hematopoietic stem cells, which 
then migrate back to bone marrow, eventually leading to 
leukemia. The proposed modes of action, however, find 
little support in the current literature; there is a large body 
of evidence indicating that inhaled formaldehyde (at rea-
sonably high exposure levels in humans, 2 ppm) does not 
move beyond the nasal respiratory mucosa to increase 
levels in the blood and does not cause DNA damage or 
cellular  transformation  (in  the  bone  marrow,  circulat-
ing hematopoietic stem cells, or the NALT) beyond the 
portal of entry (Lu et al., 2010, 2011; Moeller et al., 2011; 
Andersen et al., 2010). These results suggest strongly that 
if formaldehyde is not getting beyond the nasal respira-
tory mucosa (as indicated by its lack of genotoxicity and 
cellular transformation beyond the nasal epithelial cells), 
it is not likely to induce leukemogenesis (either via geno-
toxicity or another carcinogenic mode of action).
Acceptance of formaldehyde as a human leukemogen 
on the strength of observed associations of exposure and 
effect seen in the epidemiology studies requires accept-
ing the existence of underlying biological processes that 
embody the causal forces, whether or not these under-
lying causal processes are identified. This is true of any 
epidemiological association that is deemed causal, but 
what is notable about formaldehyde and leukemia is that 
current understanding both of leukemogenesis by other 
agents (entailing toxicity to the marrow and genotoxic 
attack on hematopoietic precursor cells found there) and 
of formaldehyde kinetics (which appear to preclude such 
effects distal to the respiratory tract) raises the issue of 
whether the phenomena observed in the human studies 
can be interpreted as causal and consistent with known 
biology. It is not simply that the underlying biological 
causal processes are unproven—or even hypothetical—
but rather, at least at first view, there seems to be no sci-
entifically plausible means for sufficient causal processes 
to operate based on what is believed to be true about 
formaldehyde and hematopoiesis.
In the present paper, we evaluate the scientific data 
relevant  to  the  potential  causal  association  between 
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humans using the structured hypothesis-based weight-
of-evidence (HBWoE) approach we have developed and 
applied elsewhere (Rhomberg et al., 2010). The HBWoE 
methodology is described below.
2.  Hypothesis-based weight-of-evidence 
(HBWoE) evaluation
2.1. Overview of approach
Before discussing the evidence regarding formaldehyde’s 
potential  leukemogenicity,  it  is  useful  to  address  our 
overall  approach  to  the  weight-of-evidence  question 
by outlining our method, explaining how it differs from 
other approaches, and setting out why we feel our chosen 
approach has value. Weed (2005) points out that the term 
“weight of evidence” is often used loosely; he calls on 
practitioners to articulate what they mean by the phrase 
and to specify their approach. Analyses of various techni-
cal approaches to weight of evidence have been offered by 
Krimsky (2005) and Linkov et al. (2009). Clearly, profes-
sional judgment is involved, but it is not enough simply 
to name the evidence at hand and then announce one’s 
conclusion. Our method aims to make the reasoning pro-
cess and bases for judgments explicit and transparent so 
that, even if other observers differ with our conclusions, 
debate can focus on the soundness of the inferences and 
their connections to study results, rather than devolve 
into ad hominem arguments about the identity and per-
spectives of the judges. That is, we seek to make expert 
judgment a public process by focusing on the logic of the 
process—not just the outcome. Ideally, rational evalua-
tion of objective evidence and scientific scrutiny of such 
evaluation  should  be  the  criterion  for  knowledge,  not 
simple authority of the interpreter.
For some, weight of evidence may connote a process 
for coming to a yes/no decision in the face of incomplete 
or  contradictory  evidence—to  agree  on  a  conclusion 
despite lack of definitive proof—but we seek a method, 
rather, that arrives at a useful and reasoned character-
ization of the relative scientific credence that should be 
placed in alternative interpretations of the data at hand 
in view of the arguments for and against each alterna-
tive. That is, we aim to communicate uncertainty about 
conclusions so as to enable productive discussion about 
subsequent decisions.
A good weight-of-evidence analysis should attend to 
all the relevant data, and not simply cite studies (or par-
ticular outcomes within studies) that tend to support or 
refute a conclusion. The frequent practice of reviewing 
literature by naming the positive or otherwise notable 
outcomes of the included studies, emphasizing findings 
by the studies’ authors, and leaving the negative results 
for other endpoints or measures of effect implicit can 
bias evaluations when studies are positive and negative 
for  different  endpoints.  The  analysis  should  entail  an 
endpoint-by-endpoint  comparative  approach,  on  the 
grounds that true causal effects should be specific (par-
ticular endpoints, not one or another of a set of arguably 
related endpoints) and repeatable (within the limits of 
study  uncertainty  and  power).  Although  study  quality 
and design strengths and shortcomings should be noted, 
we favor an approach that does not reject outright less-
than-ideal studies (the outcomes of which may be infor-
mative nonetheless) but, rather, tempers the conclusions 
drawn. What makes poorer studies less informative is a 
decreased ability to distinguish between the causative, 
face-value interpretation of outcomes and the alterna-
tive interpretation that the results are spurious because 
of intrusion of factors not adequately eliminated as pos-
sible influences. Thus, the rational and transparent way 
to down-weight poorer studies is to consider the impact 
of this ambiguity as one evaluates alternative interpreta-
tions of the data, using the patterns of concordance or 
lack thereof with other studies as part of the evaluation 
of the likelihood that the study in question has misled us 
or informed us.
We also seek an approach that integrates inferences 
across different and diverse kinds of data that can tie 
together inference based on epidemiology, animal test-
ing,  and  mode-of-action  and  pharmacokinetic  data. 
Too often, in our view, these different realms of inquiry 
are approached separately—each subset of data evalu-
ated  within  its  own  realm  and  according  to  its  own 
standards—and only then the conclusions are brought 
together for synthesis. This approach fails to take advan-
tage of the ways in which information from one realm 
can  and  should  affect  interpretation  of  data  within 
another. For instance, judgments about whether patterns 
of association seen in human studies represent a causal 
connection of chemical exposure and disease ought to 
be based not only on the concordance and repeatability 
of such patterns among human studies, they also should 
consider whether animal studies show signs of the opera-
tion of the underlying biological processes. Human data 
have the advantage of greater relevance to the immedi-
ate question at hand, but they suffer characteristically 
from imprecise measures of exposure and effect, and, 
being uncontrolled and observational, from the difficulty 
of  eliminating  possible  extraneous  influential  factors. 
Animal studies can be controlled more precisely and the 
underlying biology can be probed more thoroughly, but 
the relevance of these studies is indirect and only useful 
to the degree that the animals share underlying causative 
processes with humans. Since species-specific effects are 
known in both humans and particular species or strains 
of experimental animals, lack of concordance of effect 
across human and animal studies is not a definitive refu-
tation of the proposed causative process, but the reasons 
for and plausibility of such species differences or other 
non-concordant outcomes becomes part of the evalua-
tion of correspondence of hypotheses.
An  often-overlooked  aspect  of  weight-of-evidence 
evaluation is the importance of noting when causative 
explanations have been accommodated to account for 
results already in hand and when post hoc additions or 
modifications to hypotheses have been constructed to Formaldehyde as a leukemogen—Weight of evidence  559
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explain what might otherwise be contradictory findings. 
Such  modifications  of  explanatory  models  as  a  result 
of new data are valid parts of scientific discovery as we 
seek explanations and insights into possible underlying 
causes through the examination of the patterns of phe-
nomena, but one needs to distinguish such a creative, 
hypothesis-generating process from the subsequent test-
ing of those hypotheses with results that were not used in 
formulating the proposed model of causes. To the extent 
that hypotheses are supportable only with such added 
assumptions and interpretations, even if these additions 
are plausible and even if the data are then fully in accord 
with  the  hypothesized  explanations,  this  constitutes 
weaker support than if the tentative explanations pre-
ceded, and were only later confirmed by, the data.
We have developed an approach to the above questions 
that we term “hypothesis-based weight of evidence” (or 
HBWoE). It is hypothesis based in the sense that its criti-
cal aspect is to specify the hypothesized basis for using 
information at hand to infer the existence of the ability 
of an agent to cause human health impact. The “hypoth-
esis” referred to in the name “hypothesis-based weight 
of evidence” consists of the proposed basis for using the 
cited study results as evidence of human risk. That is, one 
names the study observations that are being proposed 
as giving insights into human risk and also names the 
proposed  basis  for  how  those  observations  could  be 
interpreted as informative about human risk potential. 
This hypothesized basis can be specific in its biological 
mode-of-action underpinnings, but it can also be more 
general. For instance, one might base the proposal that 
an agent is a human carcinogen on observations of its 
carcinogenicity  in  animal  studies  on  the  grounds  that 
rodents and humans share a good deal of common mam-
malian biology and the body of observations about how 
frequently positive animal tests are found for agents with 
direct human evidence for carcinogenicity. The strength 
of such an inference would be judged in view of our expe-
rience from other agents regarding how often common 
biology indeed seems to be operating in human and ani-
mal disease, the frequency of concordant and discordant 
results, and the consistency of animal tests observed for 
the particular chemical at hand.
The  hypothesized  basis  for  inference  about  human 
risk from particular data should be seen not just as an 
extrapolation, but as a generalization—it is a proposal 
about something in common regarding the causal pro-
cesses in the study situation and the human population 
of interest. As a generalization, it ought to apply to other 
situations as well—or at least have reasons why it does 
not—and one can evaluate the success of the hypothesis 
at being in accord with the whole suite of relevant obser-
vations at hand. If there are limits to the generalization—it 
applies to one species but not another, to males but not 
females, at this dose but not that dose—then the plau-
sibility of such exceptions in view of available evidence 
and broader knowledge becomes part of the evaluation 
of the hypothesis against available data. (Such inferences 
and evaluations are particularly susceptible to the kind of 
post hoc modification of hypotheses mentioned above, 
and  care  must  be  taken  to  account  for  after-the-fact 
adjustments of the hypothesis in evaluating its strength.)
2.1.1.  Hill Criteria and the concept of “accounts”
Whenever a causal hypothesis is proposed, there is always 
(at least implicitly) a counter-hypothesis that the com-
mon link does not exist, and the array of outcomes we see 
among the studies at hand have other explanations that 
do not bear the same implications about potential risk in 
human target populations. When evaluating hypotheses, 
we suggest that it is important to make these counter-
hypotheses explicit as well, including as much specific-
ity about the nature of these “other explanations” as can 
usefully be provided, so that the alternatives can also be 
evaluated  against  all  the  data.  In  the  end,  compelling 
hypotheses are ones that not only are in accord with and 
serve to explain patterns and concordances among the 
data, but also have few ad hoc adjustments to account 
for observations that do not fit; moreover, they provide 
markedly  more  plausible  explanations  of  the  array  of 
results on hand than can be provided by the counter-
hypotheses.  Evaluating  explicit  hypotheses  and  their 
alternatives  against  all  the  data  provides  transparency 
about  the  basis  for  expert  professional  judgment  and 
communicates how scientifically compelling alternative 
explanations,  with  different  consequences  for  human 
risk potential, ought to be deemed.
The question of evaluating causality in epidemiologi-
cal data is often approached by applying the so-called 
“Hill Criteria” developed by Sir Austen Bradford Hill (Hill, 
1965). A similar or “extended Hill-Criteria” approach has 
often been applied beyond the realm of epidemiology. In 
view of this established practice, the question may arise: 
What does HBWoE provide that is not already provided 
by the Hill Criteria? First, one should note that the Hill 
Criteria  were  developed  for  application  to  epidemiol-
ogy data, which by nature are more observational than 
experimental. The criteria relate to the patterns among 
observational studies that one ought to expect if a com-
mon causal effect were operating but, independently, do 
not demonstrate causation. At most, adherence of data 
to the criteria constrains the scope for alternative, non-
causal explanations. Epidemiology rarely has the ability 
to put causal explanations to the test (other than by eval-
uating consistency with further studies), and the kind 
of critical tests that can be constructed in experimental 
studies, with alternative influential factors controlled, is 
rarely available. Our goal of furthering the integration of 
epidemiological and toxicological inference is aided by 
an approach that gives experimentation, and the kind of 
critical tests that it can provide, a central role.
Second, as often applied, the Criteria become some-
thing of a checklist or a set of headings for citation of out-
comes favorable or opposed to a causal hypothesis, but 
each evaluation is often not done very rigorously or trans-
parently  and  suffers  from  the  criticism  we  mentioned 560  L. R. Rhomberg et al.
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above—simply citing the studies that fit and announcing 
a professional judgment conclusion. Hypothesis-based 
weight of evidence can be seen as a process for encour-
aging rigorous and transparent evaluation of the criteria, 
particularly  those  referring  to  consistency,  specificity, 
repeatability, and biological plausibility. In keeping with 
the theme of not simply making judgments, but rather 
showing the proposed basis for those judgments, HBWoE 
emphasizes not just the conclusions about each criterion, 
but also a transparent and articulated examination of its 
logical and evidentiary basis. To rigorously address the 
question of biological plausibility, one needs to follow a 
method similar to what we propose.
Finally,  as  Bradford  Hill  originally  intended,  his 
criteria  (which  he  called  “postulates”)  were  designed 
to articulate the basis for judgments and facilitate the 
integration of evaluations across criteria, not simply as 
a checklist for which, if enough features of the array of 
data seemed to fit, causality could be concluded. Hill 
saw the postulates as guides to thinking rather than as 
measures of evidence. In our reading of Hill’s original 
paper, his intent for the application is along precisely 
the lines we propose—the evaluation of a specific causal 
hypothesis against alternative non-causal explanations. 
Bradford Hill makes explicit the importance of consider-
ing alternative “accounts” of the observations at hand in 
stating:
None of my nine viewpoints can bring indisputable 
evidence for or against the cause-and-effect hypoth-
esis and none can be required as a sine qua non. What 
they can do, with greater or less strength, is to help us 
to make up our minds on the fundamental question—is 
there any other way of explaining the set of facts before 
us, is there any other answer equally, or more, likely 
than cause and effect? (Hill, 1965) [emphasis added]
The essence of the “accounts” (which we put forth in 
this context as a technical term) is that they constitute 
being explicit about Bradford Hill’s “ways of explaining 
the set of facts before us.” They are not conclusions or 
findings but, rather, provisional proposals for the reasons 
behind the set of observations at hand.
Hypothesis-based  weight  of  evidence  comes  down 
to  evaluation  of  alternative  accounts.  An  account  is  a 
set of proposed explanations and hypotheses that could 
be put forth to explain all of the observed data at hand. 
The array of all observations among all relevant studies 
comprises the fixed set of available facts; the challenge 
of scientific investigation is to discern what causes and 
processes  account  for  those  facts  having  come  out  as 
they did. Among the explanations that could be tenta-
tively proposed are causal underlying processes that, if 
true, would lead to observed patterns and apparent con-
nections within and among studies, but one could also 
entertain explanations that attribute particular outcomes 
to chance fluctuations, biases in measurement or report-
ing,  confounding  factors,  operation  of  case-specific 
influences of unknown nature, or other such reasons. In 
the end, all the facts have to be accounted for by some 
combination of these, since the study outcomes came 
out as they did for some reason, even if we do not have 
clear ideas of what those reasons are. Any one proposed 
set of such reasons constitutes an account—a tentative 
“story” as to why the facts are as they are.
Clearly,  there  could  be  an  infinite  set  of  different 
accounts, but, in practice, there will be a few major con-
tenders.  Since  the  purpose  of  the  weight-of-evidence 
evaluation  is  to  identify  underlying  causal  factors  of 
relevance  to  our  larger  question,  the  key  account  will 
be one that proposes such an underlying causal factor. 
Such an account is centered on the proposed ability of a 
chemical to cause and increase the frequency of appear-
ance of a particular toxic effect, put forward as a reason 
behind the existence of much of the apparent patterns 
and connections within and among studies. But there 
may be some facts on hand that are not readily attributed 
to such a factor, either ones that appear to contradict the 
general operation of the hypothesized cause or ones that, 
although not overtly contradicting, nonetheless are not 
explained by the key causal hypothesis. These facts need 
tentative  explanations  as  well,  from  which  subsidiary 
explanations also become part of the account.
There is always an important second account—one that 
denies the existence of the key causal factor and instead 
attributes the facts that appear to be explained by such a 
factor to other causes, either an alternative causal prin-
ciple or simply a set of case-specific reasons under which 
any appearance of patterns within and across studies is 
mere happenstance. When one doubts the outcomes of a 
poor-quality study, one is in effect entertaining the pos-
sibility that some array of other factors or reasons (beside 
the one the study aimed at characterizing) has accounted 
for the outcomes, and the study’s design does not allow 
one to attribute the outcomes confidently to the nomi-
nally tested influence.
When the “causal” account’s plausibility overwhelms 
the  alternative’s,  which  by  comparison  seems  to  lack 
non-arbitrary reasons to deny the apparent patterns of 
causation, then we can feel confident that we have char-
acterized a truly causal factor. But we undertake weight-
of-evidence evaluations precisely when the case is not 
so clear—when the causal account itself has many facts 
that require modification or assumed special conditions 
of the causal hypothesis, or when there are apparently 
refuting facts that must be explained away as potential 
counterexamples. In short, weight of evidence is applied 
when the data at hand have contradictions and limita-
tions such that even the optimal account requires ad hoc 
elements and assumptions to account for at least some 
of the problematic facts. The weight of evidence for the 
existence of the key causal factor consists of the com-
parative plausibility of the alternative accounts—the one 
that invokes it and the one that denies it. The credence we 
should give to an account and its implications for human 
health risk assessment depends on the degree to which it Formaldehyde as a leukemogen—Weight of evidence  561
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provides a more satisfactory and plausible accounting of 
the array of observations at hand than do any competing 
accounts. That is, we see the metaphor of “weight” of evi-
dence as being evaluated with a two-pan balance—the 
relative plausibility of competing accounts—rather than 
as a single scale showing how much evidence in accord 
with a conclusion can be accumulated. Our approach 
to revealing and characterizing the plausibility of each 
account  is  to  “unpack”  the  set  of  explanations  they 
invoke, noting how much each strains credulity in view 
of the data at hand and wider knowledge of the relevant 
science. The explanations in each account need not be 
proven—what is important is that one set out the follow-
ing questions:
What  is  being  proposed  as  causal  and  generaliz- •	
able phenomena (i.e., what constitutes the basis for 
applying observations of biological perturbations or 
realized risks in other contexts to project potential 
risks to humans as they are exposed)?
What is being proposed as the basis for deviations  •	
that lead to observations that do not fit the hypoth-
esized causal model (i.e., that would otherwise be 
counterexamples or refutations)?
What assumptions are made that are ad hoc (i.e., to  •	
explain particulars, but for which the evidence con-
sists of their plausibility and the observations they 
are adduced to explain)?
What further auxiliary assumptions have to be made,  •	
and how reasonable are they in view of our wider 
knowledge and understanding?
What is relegated to error, happenstance, or other  •	
causes not relevant to the question at hand?
For those events or processes proposed as critical for  •	
a given account, what other observable manifesta-
tions should they have? Are these other manifesta-
tions indeed found?
If either the operation or necessity of the proposed  •	
critical events for a given account were disproven, 
how else would one explain the array of outcomes?
2.2.  HBWoE methodology
Although HBWoE is intended to be flexible in its appli-
cation, the approach generally consists of the following 
steps, which are not intended to be a checklist and may 
involve an approach that is not necessarily in this order.
Systematically review all studies that are potentially  •	
relevant to the causal question at hand (i.e., epidemi-
ology, mode of action, pharmacokinetic, toxicology) 
and summarize the results without regard to whether 
they tend to support or undermine particular inter-
pretations. All potentially relevant data and modes of 
analysis, not only those featured or noted as signifi-
cant by the studies’ authors, should be included. The 
aim is to specify the set of relevant observations that 
can be brought to bear. Ask further questions about 
the  data  within  these  studies—specifically,  think 
about the quality of the individual studies (strengths 
and weaknesses of study design, potential for ambi-
guity of interpretation of outcomes). Note the inter-
pretation of data by the authors and how well those 
conclusions are supported by the reported observa-
tions. Note instances where evidence of associations 
depends on choosing the most significant among a set 
of parallel analyses of the same data (e.g., with differ-
ent category cut-offs or different dose measures) and 
note whether there is any a priori reason to favor one 
mode of analysis over others. Note instances where 
the interpretation of proposed causes may have been 
accommodated to account for patterns in the data 
after the fact (e.g., preferring one dose measure over 
another  because  it  provides  a  more  interpretable 
pattern to dose-response data). The aim is to provide 
the basis for a critical review of the available studies, 
rather than simply collecting the findings noted and 
conclusions drawn by study authors.
Within a realm of investigation (e.g., epidemiology,  •	
animal toxicology studies), examine the data for par-
ticular endpoints across studies. The aim is to evalu-
ate consistency, specificity of apparent effects, and 
repeatability of outcomes. Note instances of similar 
patterns across studies, species, sexes, strains, etc., 
and also instances of apparent discordance among 
these.  The  aim  is  to  provide  the  basis  for  judging 
the apparent limitations or exceptions to proposals 
about generally operating causal effects.
Identify and articulate lines of argument by which  •	
results from available studies could be used to infer 
the existence, nature, or magnitude of human risk. 
These  could  be  newly  proposed  or  they  could  be 
proposals  already  put  forth  within  the  scientific 
community  that  one  seeks  to  evaluate.  Each  line 
of argument should specify the data on which the 
inference  would  be  based  and  also  the  reasoning 
for why those data are informative about the human 
risk question. Typically, the reasoning would entail 
a generalization about causal forces such that some 
commonality is proposed between the causal forces 
seen in the study data and those that would be pre-
sumed to operate in the human target population. It 
is important to specify how widely the invoked com-
monality is proposed to apply (e.g., just to humans 
but not experimental animals, or just to one sex, or 
just to humans and a particular strain of animals). 
The proposed reasons for why the limits to general-
ization exist should also be specified, to the degree 
possible (so one can evaluate whether they have an 
evidentiary basis or are simply ad hoc). These lines of 
argument are the “hypotheses” of HBWoE, and they 
are articulated so that one can evaluate how well they 
are in agreement with all of the data, how well they 
would explain patterns in the data if they were true, 
what  other  observable  consequences  the  invoked 
causal principles should have, and whether in fact 
these consequences are observed.562  L. R. Rhomberg et al.
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Trace through the logic within each line of evidence.  •	
That is, think about how all of the relevant studies 
within each line of evidence support each other, con-
sidering  consistencies  and  inconsistencies  across 
studies. For example, one would do this for all of the 
epidemiology studies together (i.e., apply Bradford 
Hill Criteria), all of the mode-of-action and pharma-
cokinetic data together, and all of the toxicology data 
together. The aim is to establish how well the hypoth-
eses being examined comport with and help explain 
common  patterns  in  the  data,  what  data  seem  to 
constitute  exceptions  or  contrary  outcomes  to  the 
hypothesized causal principles, and what reasons for 
such exceptions might be proposed.
Trace  through  the  logic  regarding  all  lines  of  •	
evidence as a whole and how they inform inter-
pretation of each other. Specifically, how the epi-
demiology  studies  as  a  whole,  mode-of-action 
studies as a whole, and toxicology data as a whole 
(that we have articulated as part of Step 4) inform 
interpretation  of  one  another.  The  question  is 
whether explanations or hypothesized causal fac-
tors  proposed  in  one  realm  (e.g.,  epidemiology) 
have aspects that should be observable in others 
(e.g., mode-of-action studies), enabling evaluation 
of whether signs of those causal processes do or do 
not appear where expected.
Next, one needs to formulate alternative accounts.  •	
Each account comprises a set of proposals, hypoth-
eses,  assertions,  and  assumptions  that  together 
should provide a tentative story for why all of the 
relevant observations came out as they did. Each of 
the causal hypotheses identified in Step 5 would con-
stitute the core of an account, but the same account 
should also include the proposed reasons why facts 
that do not fit or are deemed to be outside the span 
of generalization should not be taken as disproofs 
because  their  non-concordance  is  explicable.  An 
account that denies a central causal hypothesis as 
an explanation for an apparent association needs to 
provide an alternative proposed explanation for the 
observed patterns.
Finally,  evaluate  alternative,  and  competing,  •	
accounts. Now that one has worked carefully through 
not only each study and each individual line of evi-
dence but, importantly, considered how each line of 
evidence informs the other, it is at this point that one 
asks how well each hypothesis is supported by the 
data and how many ad hoc assumptions are required 
to support each hypothesis. The rationale and reason-
ing for how the data support (or do not support) each 
account’s hypotheses, together with the plausibility 
of subsidiary explanations or assumptions in view of 
wider biological knowledge, constitute the basis for 
evaluating the scientific support each account gets 
from available data. The comparative support consti-
tutes the basis for judging the relative credence that 
alternative accounts should be given.
The goal in the end is to present the lines of reasoning  •	
for (not to prove or disprove) each account, based on 
the science and integration of the lines of evidence, 
so that the data will speak for themselves in support-
ing (or not supporting) the overarching hypotheses 
that have been put forth.
By  comparison  of  the  various  accounts,  one  may  •	
be left with a variety of outcomes or proposed next 
steps.  The  results  may  suggest  sharpening  a  pro-
posed hypothesis, or there may be obvious data gaps 
that can now be pursued more clearly so that each 
account can be defined more clearly, or one account 
may be more clearly supported by the data than other 
accounts. An advantage of the HBWoE approach is 
that it can help identify research that would be most 
able  to  inform  outstanding  questions  and  resolve 
ambiguous interpretations.
 In this article, we first describe an overview of the HBWoE 
evaluation  of  formaldehyde  and  leukemogenesis  by 
describing the various accounts that must be considered 
before concluding whether a possible causal association 
exists  between  formaldehyde  exposure  and  leukemo-
genesis. We then describe the details of our analysis for 
each of the lines of evidence (epidemiology, toxicology, 
pharmacokinetic,  and  mode  of  action)  that  form  the 
bases of these accounts, individually and in terms of how 
each inform each other.
3.  Overview of HBWoE as applied to 
formaldehyde and leukemogenesis
The  HBWoE  evaluation  for  human  leukemogenesis 
from inhaled formaldehyde comes down to evaluating 
the comparative degree to which each of the alternative 
accounts is supported by reference to scientific evidence. 
In short, one is faced with a contradiction between the 
apparent  (though  not  certainly  causal)  association  of 
leukemia with formaldehyde exposure in at least some 
human studies and the apparent implausibility of such a 
causal effect in view of current biological understanding. 
The apparent contradiction can be reconciled in one of 
two ways: (1) by accepting that human risks are actually 
increased and positing that the biological impossibility 
of such increases is somehow mistaken—that is, since 
the effect appears, it must have a possible causal expla-
nation; or (2) by concluding that doubts about possible 
mechanisms have merit, and the apparent association of 
formaldehyde and leukemia seen in some human stud-
ies does not in fact indicate a causal connection (and 
that those studies showing lack of effect are indeed the 
ones to be taken at face value)—that is, the appearance 
of some apparent associations is in fact accounted for 
by chance or by shortcomings in the ostensibly positive 
human studies, which, according to this view, should be 
deemed false-positive results.
In pursuit of the first account that suggests a causal 
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and  leukemia  because  their  effects  are  seen,  several 
candidate causal mechanisms have been hypothesized 
(Zhang  et  al.,  2009,  2010a).  As  these  mechanisms  are 
evaluated, it is important to consider their ad hoc nature; 
rather than being suggested a priori because of plausi-
bly relevant observed properties, they are constructed 
after the fact specifically to propose a remedy to the fatal 
shortcoming  of  impossibility.  Furthermore,  they  are 
constrained by the need to offer a possible causal con-
nection between leukemia and formaldehyde inhalation 
without  producing  observable  effects  that  contradict 
currently accepted knowledge and observations. This ad 
hoc nature does not make the hypothesized mechanisms 
false, but it does put a premium on finding some inde-
pendent, positive evidence of their operation and role 
rather than simply relying on their ability, if true, to fur-
nish the needed mechanisms or apparent consistencies 
with observations, since they were chosen in part as sup-
port of these observations and proposed mechanisms.
An alternative, and contrasting, account is that it is 
not possible for formaldehyde to move beyond the nasal 
respiratory mucosa to cause systemic DNA damage and 
cellular transformation (in the bone marrow, circulating 
hematopoietic stem cells, or the NALT), and therefore 
there is no biologically plausible mechanism for form-
aldehyde leukemogenesis. This account is supported by 
a large body of hematotoxicity studies (in animals and 
humans); toxicokinetic, genotoxocity, and mechanistic 
data in animals, humans, and in vitro; and a large body of 
null epidemiology findings. Under this account, the sig-
nificant number of null epidemiology findings are con-
sidered true results, and the few positive findings in the 
epidemiology studies (which have shortcomings, includ-
ing  poor  disease  classification  and  poor  estimates  of 
exposure), are likely attributable to confounding by other 
exposures or to chance. If this account is true, an associa-
tion between inhalation of formaldehyde and leukemia 
would be understood as not plausible for humans.
Our HBWoE evaluation compares these two accounts 
by  first  describing  what  is  known  and  what  has  been 
interpreted from the formaldehyde epidemiology, toxi-
cology, and mode-of-action data, pointing out questions 
that arise from within and across these studies and their 
interpretation, the answers to (or at least discussions of) 
which provide the bases for tracing the logic for each 
alternative hypothesis.
4.  Weight of epidemiology evidence 
regarding the association between 
formaldehyde exposure and leukemia
To  conduct  the  HBWoE  analysis  of  the  epidemiology 
data  regarding  the  association  between  formaldehyde 
exposure and leukemia, we first conducted a literature 
search,  using  PubMed  and  TOXLINE,  for  all  human 
studies measuring or estimating formaldehyde exposure 
and the incidence of or mortality from any lymphohe-
matopoietic cancer. Search terms included “leukemia,” 
“lymphoma,”  “Hodgkin,”  “non-Hodgkin,”  “hematologic 
neoplasm,”  “myeloma,”  “hematopoietic,”  “lymphatic,” 
“formaldehyde,”  “epidemiol*,”  “occupation*,”  “cohort*,” 
and “worker*.” We also relied on the reference lists of 
several review articles and meta-analyses (e.g., Bachand 
et al., 2010; Zhang et al., 2010a; Bosetti et al., 2008; Collins 
and Lineker, 2004). We critically reviewed each relevant 
study and focused particularly on two cohorts that have 
received  much  recent  attention:  the  National  Cancer 
Institute (NCI) industrial worker and embalmer cohorts. 
The former was analyzed in several studies using tradi-
tional  cohort  study  designs,  whereas  individuals  were 
drawn from the latter to conduct case-control analyses.
After providing a brief overview of the epidemiology 
literature below, we describe an endpoint-by-endpoint 
analysis of each lymphohematopoietic cancer and groups 
of cancers that have been investigated. This is followed 
by an HBWoE evaluation of the epidemiology evidence 
with respect to the hypothesis that formaldehyde causes 
leukemia.
4.1.  Overview of epidemiology investigations
Several  cohort  and  case-control  studies  have  been 
conducted  on  formaldehyde  exposure  and  lympho-
hematopoietic cancers (Tables 1 and 2). The first study 
published  was  of  pathologists  and  medical  laboratory 
technicians in the United Kingdom (UK) who were fol-
lowed  through  1973  (Harrington  and  Shannon,  1975). 
Since  that  time,  studies  of  embalmers,  undertakers, 
funeral directors, radiologists, pathologists, anatomists, 
leather tannery workers, iron foundry workers, plastics 
manufacturing workers, wood industry workers, garment 
workers, pest-control workers, and workers at formalde-
hyde production or usage plants have been conducted in 
the United States, the UK, France, Sweden, Italy, Denmark, 
Finland, and Canada. Cohort studies ranged in size from 
154 to 126,347 subjects with follow-up beginning as early 
as  1925  and  up  through  2004.  Among  the  eight  case-
control studies we identified, the largest included 1511 
cases, and follow-up periods among the studies ranged 
from 1940 to 2000 (Table 2). Formaldehyde exposure was 
rarely measured in any study and, when it was, concen-
tration information was not available for the entire period 
of employment. Owing to the limited concentration data, 
exposure was typically estimated based on job descrip-
tions. Formaldehyde risks were then calculated based on 
the date of hire/first exposure, minimum employment 
duration, duration of employment/exposure, time since 
first exposure, cumulative exposure, average exposure, 
average intensity of exposure, peak exposure, and num-
ber  of  peak  exposures.  Health  outcomes  were  coded 
according to the International Classification of Diseases 
(ICD)  7th,  8th,  or  9th  revision  (Table  3).  Because  the 
majority were coded using the 8th revision (ICD-8) and 
there are few differences between the 8th and 9th revi-
sions,  classifications  in  the  following  sections  and  the 
tables refer to the 8th revision unless otherwise noted. 
The health outcomes assessed included mortality from 564  L. R. Rhomberg et al.
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lymphohematopoietic cancer (ICD 200–209), cancer of 
lymphoid origin (ICD 200–204), leukemia (ICD 204–207), 
hematopoietic cancer of non-lymphoid origin (ICD 205, 
206, 208, 209), lymphatic leukemia (ICD 204), myeloid 
leukemia  (ICD  205),  other  unspecified  leukemia  (ICD 
207),  Hodgkin’s  lymphoma  (ICD  201),  non-Hodgkin’s 
lymphoma (ICD 200, 202), and multiple myeloma (ICD 
203). The majority of studies were subject to confound-
ing  by  several  co-exposures,  many  of  which  were  not 
accounted for in statistical analyses.
Several individuals and/or cohorts were analyzed in 
more than one study. Beane Freeman et al. (2009) con-
ducted the most recent study of the NCI industrial worker 
cohort,  with  follow-up  through  2004.  This  cohort  was 
first studied by Blair et al. (1986), who followed workers 
employed in 10 formaldehyde-producing or -using facili-
ties through 1979. Hauptmann et al. (2003) conducted a 
follow-up through 1994, although it was noted by Beane 
Freeman  et  al.  (2009)  that  1006  deaths  were  omitted 
unintentionally from this analyses (all results presented 
here are from a reanalysis by Beane Freeman et al. [2009], 
which included these deaths). To avoid counting infor-
mation on this cohort more than once, only data from the 
most recent publication by Beane Freeman et al. (2009) 
are shown in the tables, but results from the previous 
studies of this cohort are discussed in the text if they are 
not consistent with the latest analysis.
Coggon et al. (2003) evaluated a cohort of 14,014 UK 
workers  at  factories  where  formaldehyde  was  used  or 
produced that had been evaluated previously by Acheson 
et al. (1984) and Gardener et al. (1993). Acheson et al. 
(1984) evaluated mortality in 7680 men first employed 
before 1965 in one of six factories, with follow-up through 
1981. Gardener et al. (1993) extended the follow-up of 
Table 2.  Formaldehyde case control studies.
Reference
Study 
Population
Job/Exposure 
Category
Period of 
Employment
Period of 
Follow-up
Total 
Follow-up 
(person-
years)
Minimum 
Employment 
(years)
Mean Time-
Weighted 
Average 
Exposure (ppm)
Peak 
Exposure 
(ppm)
Average 
Intensity 
(ppm)
Gerin et al., 
1989
Canadian 
population in 
Montreal
Lifetime job 
histories 
obtained by 
interview and 
translated 
into level of 
exposureto 
formaldehyde
1979–1985 1979–1985         Low
Medium
High
Ott et al.,  
1989
US Union 
Carbide 
chemical 
manufacturing 
facilities
111 work areas, 
21 specific 
chemicals and 
52 chemical-
activity groups
1940–1978 1940–1978   ≥1 day      
Linos et al., 
1990
Iowa and 
Minnesota 
Funeral home 
workers
Funeral service 
and crematoria 
workers
NR NR
Partanen et al., 
1993
Finland Wood 
production 
workers
Wood workers 
(formaldehyde, 
solvents, wood 
dust)
1957–1982 1957–1982   ≥1      
Tatham et al., 
1997
Atlanta, 
Connecticut, 
Iowa, Kansas, 
Miami, San 
Francisco, 
Detroit, and 
Seattle workers
Exposed to 
formaldehyde 
or other 
chemicals
1984–1988 1984–1988   ≥1      
Blair et al.,  
2001
Iowa and 
Minnesota 
Industrial 
workers
15 different 
industrial and 
occupational 
job categories 
(non-farming)
1980–1983 1980–1983   ≥1      
Wang et al., 
200b
Connecticut 
women
Exposure 
to organic 
solvents and 
formaldehyde
1996–2000 1996–2000          
Hauptmann 
et al., 2009
US Embalmers Never 
Embalming
Ever 
Embalming
1932–1986 1960–1986 19,104   0
>0–0.10
>0.10–0.18
>0.18
0
>0–7.0
>7.0–9.3
>9.3
0
>0–1.4
>1.4–1.9
>1.9
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7660 of these workers through 1989, and began follow-
ing 6357 additional workers who began work after 1964. 
Coggon et al. (2003) then followed the majority of these 
workers  through  2000.  Because  results  are  consistent 
among the three analyses, only results from Coggon et al. 
(2003) are discussed here.
Hauptmann  et  al.  (2009)  conducted  a  case-control 
study  based  on  over  6000  embalmers  (NCI  embalm-
ers cohort) who died between 1960 and 1985 and were 
included in proportionate mortality ratio (PMR) studies 
by Hayes et al. (1990) and Walrath and Fraumeni (1983, 
1984). Walrath and Fraumeni (1983) studied embalm-
ers licensed in California, Walrath and Fraumeni (1984) 
studied  those  licensed  in  New  York,  and  Hayes  et  al. 
(1990)  assembled  data  on  US  embalmers  and  funeral 
directors who died between 1975 and 1985. In the tables, 
we present data from both Hauptmann et al. (2009) and 
Hayes et al. (1990) because they use different methodolo-
gies. Data from Walrath and Fraumeni (1983, 1984) are 
discussed in the text but not the tables, because study 
subjects are included in the Hayes et al. (1990) analysis 
and were analyzed in a similar fashion.
Table 2.  continued.
Reference
Cumulative 
Exposure 
(ppm)
Duration of 
Exposure or 
Length of 
Employment 
(years)
Number of 
Embalmings ICD Code
Cases 
(total)
Controls 
(total)
Possible Co-Exposures 
Discussed
Gerin et al., 
1989
  <10
≥10
  ICD-8, 200, 202
201
206
53
533  
Ott et al.,  
1989
  0
<5
≥5
  Non-Hodgkin’s
Multiple 
Myelpoma
Leukema
2
1
3
NR 52 chemical groups (e.g., 
epoxides, halogenated 
compounds, fused cyclics, 
nitriles, vinylics)
Linos et al., 
1990
Leukemia
Non-Hodgkin’s
578
622
1245 NR
Partanen 
et al., 1993
    ICD-7, 200–202
201
200, 202
204
5
1
4
2
152 Wood dust, pesticides, 
chlorophenols, phenol, 
terpenes, solvents (stains, 
lacquers, toluene, xylenes, 
benzene, styrene, butyl 
acetate, ethyl acetate, butanol, 
isopropanol, ethanol), aliphatic 
hydrocarbons (solvent 
naphtha, white spirits), 
ketones, glycol ethers, and 
engine exhaust
Tatham et al., 
1997
  <10
≥10
  ICD-8, 200, 202 1511 1659 Pesticides, herbicides, 
wood/saw dust, solvents, 
shoe/leather dust, meat 
packaging or processing, 
metal plating, cutting oils, 
chlorophenols, heterocyclic 
nitrogens, carbamates, 
organophosphates, phenoxy 
herbicides, chlorinated 
hydrocarbons, and pyrethroids
Blair et al.,  
2001
Low  
High
<10
≥10
  ICD-8, 204–207
205.0
205.1
204.0
204.1
64
14
8
0
30
137 Solvents, paints, metals, solder
Wang et al., 
200b
Never
Low
Medium–High
    ICD-9, 200–202 601 717 Organic solvents 
(benzene, chloroform, 
carbon tetrachloride, 
dichloromethane, methyl 
chloride, trichloroethylene)
Hauptmann 
et al., 2009
0
>0–4058
>4058–9253
>9253(ppm-h)
0
>0–20
>20–34
>34
0
>0–1422
>1422–3068
>3068
ICD-8, 200–209
200–204
205, 206, 208, 209
205
168
99
48
34
265 Isopropanol, ethylene 
glycol, methanol, phenol, 
glutaraldehyde, ionizing 
radiation, benzene, and 
cigarette smoking
Note:  NR = not reported; AML = acute myeloid leukemia; CML = chronic myeloid leukemia; ALL = acute lymphoid leukemia; CLL = chronic 
lymphoid leukemia.  See Table 3 for ICD codes.Formaldehyde as a leukemogen—Weight of evidence  571
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4.2.  Endpoint-by-endpoint analysis
In this section, we discuss each of the individual lympho-
hematopoietic cancer endpoints analyzed in the epide-
miology studies described above. Lymphohematopoietic 
cancers include a group of hematopoietic and lymphoid 
cell disorders that have distinct classifications based on 
morphologic, cytogenic, immunophenotypic, and molec-
ular characteristics (see Vardiman, 2010, for a review of 
the classifications). We consider various groupings of can-
cer types as analyzed by study authors, although results 
from these analyses must be considered carefully because 
each specific lymphohematopoietic cancer is a different 
disease.  Although  some  cancer  types  may  have  some 
common mechanisms (e.g., pharmacokinetics), in gen-
eral, lymphohematopoietic cancers each have a distinct 
etiology, so an association with one type is not necessarily 
indicative of risk of another (Schottenfeld and Fraumeni, 
2006). That is, if one study reports a statistically significant 
finding for one cancer type (A) but not another (B), and 
another study reports a statistically significant finding for 
cancer type B but not A, this is not consistent evidence of 
an association. In the same vein, an association between 
formaldehyde and a group of cancers does not necessarily 
provide evidence for all cancers in that group, as it may be 
driven by one cancer type with a distinct mode of action. 
Thus, it is crucial in a weight-of-evidence analysis to con-
sider each individual cancer type and the implications of 
analyses of cancer groups.
For each cancer or group of cancers, we evaluated the 
weight of each study based on several factors, including 
the study objectives and hypothesis; the study subjects; 
the  exposure  and  health  outcome  assessments;  the 
follow-up period; the consideration of bias, confounders, 
and effect modifiers; the statistical methods; the docu-
mentation and interpretation of results; and the external 
validity (i.e., the bearing on the larger question at hand, 
formaldehyde as a potential cause of human lympho-
hematopoietic  neoplasms).  For  each  cancer  or  group 
of cancers, we also assessed the consistency of findings 
(which included consideration of the type of exposure 
metric, e.g., peak vs. cumulative) and whether any expo-
sure-response relationships were evident.
4.2.1.  All lymphohematopoietic cancers
The association between formaldehyde exposure and all 
lymphohematopoietic cancers combined has been inves-
tigated in 12 studies (Table 4). Eleven cohort and one 
case-control study assessed whether study subjects had 
an increased risk over the general population. Of these, 
only one reported associations (Hayes et al., 1990). Hayes 
et  al.  (1990)  found  an  increased  proportion  of  deaths 
attributable  to  lymphohematopoietic  cancers  among 
embalmers in the NCI embalmers cohort (PMR = 1.39, 
95% confidence interval [CI]: 1.15–1.67).
Lymphohematopoietic cancer risks were also evalu-
ated  based  on  one  or  more  exposure  metrics  in  iron 
foundry  workers,  embalmers,  and  industrial  workers. 
Risks were not increased in formaldehyde-exposed and 
unexposed US iron foundry workers (Andjelkovich et al., 
1995), and risks reported in embalmers and industrial 
workers  were  not  consistent  across  exposure  metrics 
(Hauptmann et al., 2009; Beane Freeman et al., 2009).
Table 3.  International disease classification (ICD) codes.
ICD Code Revision 7 Revision 8 Revision 9
  (200–207) Neoplasms of lymphatic 
and hematopoietic tissues
(200–209) Neoplasms of lymphatic and 
hematopoietic tissue
(200–208) Malignant neoplasms of 
lymphatic and hematopoietic tissue
200 Lymphosarcoma and 
reticulosarcoma
Lymphosarcoma and reticulum-cell 
sarcoma
Lymphosarcoma and reticulosarcoma 
and other specified malignant tumors 
of lymphatic tissue
201 Hodgkin’s disease Hodgkin’s disease Hodgkin’s disease
202 Other forms of lymphoma 
(reticulosis)
Other neoplasms of lymphoid tissue Other malignant neoplasms of 
lymphoid and histiocytic tissue
203 Multiple myeloma Multiple myeloma Multiple myeloma and 
immunoproliferative neoplasms
204 Leukemia & aleukemia Lymphatic leukemia Lymphoid leukemia
204.0 Lymphatic leukemia Acute lymphocytic leukemia Acute lymphoid leukemia
204.1 Myeloid leukemia Chronic lymphocytic leukemia Chronic lymphoid leukemia
204.3 Acute leukemia — —
204.4 Other & unspecified leukemia — —
205 Mycosis fungoides Myeloid leukemia Myeloid leukemia
205.0 — Acute myeloid leukemia Acute myeloid leukemia
205.1 — Chronic myeloid leukemia Chronic myeloid leukemia
206 Lymphatic system Monocytic leukemia Monocytic leukemia
207 Hematopoietic system Other and unspecified leukemia Other specified leukemia
208 — Polycythemia vera Leukemia of unspecified cell type
209 — Myelofibrosis —
238.4 — — Polycythemia vera
289.83 — — Myelofibrosis
294 Polycythemia — —572  L. R. Rhomberg et al.
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Hauptmann  et  al.  (2009)  conducted  a  case-control 
study  of  168  embalmers  (21  with  leukemia)  from  the 
NCI  embalmers  cohort  (evaluated  by  Hayes  et  al., 
1990) and examined lymphohematopoietic cancer risks 
based on seven exposure metrics: exposed (ever/never 
embalmed), peak exposure, average intensity of exposure 
when embalming, 8-hour time-weighted average (TWA) 
exposure, cumulative exposure, exposure duration (years 
embalming),  and  number  of  embalmings.  Exposure 
estimates were developed from a previous exposure-as-
sessment experiment by Stewart et al. (1992). The inves-
tigators conducted trend tests for each exposure metric 
including and excluding unexposed individuals. There 
were  no  statistically  significant  associations  between 
formaldehyde exposure and lymphohematopoietic can-
cer based on any exposure metric.
Beane Freeman et al. (2009) conducted the most recent 
study of the NCI industrial worker cohort, with follow-up 
through  2004.  They  examined  lymphohematopoietic 
risks based on exposure metrics including exposed (yes/
no),  peak  exposure,  number  of  peak  exposures  ≥4.0 
ppm,  duration  of  exposure,  average  intensity  of  expo-
sure,  cumulative  exposure,  years  since  first  exposure, 
and years since first exposure ≥4 ppm. Beane Freeman 
et al. (2009) stated that there was no evidence that risks 
increased with cumulative number of peaks ≥4.0 ppm or 
for duration of exposure for any lymphohematopoietic 
cancer evaluated, but they did not present results. An 
association was observed with the presence of at least 
one career peak exposure ≥4.0 ppm (risk ratio [RR] = 1.37, 
95% CI: 1.03–1.81, ptrend = .02 based on exposed subjects 
only and ptrend = .04 based on all study subjects), but not 
number  of  peak  exposures  ≥4.0  ppm.  Risks  were  also 
increased with increasing peak intensity with follow-up 
to 1981 (ptrend = 0.00987 based on exposed subjects only 
and ptrend = 0.0485 based on all study subjects), but not 
with follow-up from 1981-1994 or 1995-2004. Risks were 
lower in those with no exposure vs. those with their first 
exposure to ≥ 4 ppm formaldehyde 0-25 years earlier (RR 
= 0.57, 95% CI: 0.36-0.88). This was consistent with results 
of  Hauptmann  et  al.  (2003),  who  followed  this  cohort 
through 1994. In their reanalysis of this cohort through 
1994, Beane Freeman et al. (2009) found that, of the six 
exposure metrics, associations were only observed for 
peak exposure ≥0.04 ppm (RR = 1.48, 95% CI: 1.04–2.12, 
ptrend = .02 including or excluding unexposed subjects).
4.2.2.  Cancer of lymphoid origin
Risks  from  cancers  of  lymphoid  origin  were  examined 
in four cohorts (Table 5). Both Dell and Teta (1995) and 
Chiazze et al. (1997) defined cancers of lymphoid origin 
as those in ICD-7 200–205 categories. Whereas Chiazze 
et al. (1997) did not report increased risks, Dell and Teta 
(1995) reported increased risks among plastics manufac-
turers (standardized mortality rate [SMR] = 1.69, 95% CI: 
1.07–2.53). No significant associations were found in the 
NCI embalmers cohort based on any of the seven expo-
sure metrics evaluated (Hauptmann et al., 2009). Analyses 
of peak exposure, average intensity, cumulative exposure, 
cumulative number of peaks ≥4.0 ppm, or duration of 
employment also did not indicate any associations in the 
NCI industrial cohort (Beane Freeman et al., 2009).
4.2.3.  Leukemia
A large number of investigations have focused on the 
association  between  formaldehyde  and  leukemia 
(Tables 6, 7, 8, and 9). The types of leukemia investi-
gated vary among studies, and this section focuses on 
analyses of all leukemia and aleukemias (leukemias in 
which the circulating white blood cells are normal or 
decreased in number) combined (ICD-7 204) and lym-
phatic, myeloid, monocytic, other, and unspecified leu-
kemias combined (ICD-8 204–207 and ICD-9 204–208), 
whereas later sections discuss assessments of specific 
types of leukemia. Risk estimates for leukemia among 
28  analyses  that  did  not  assess  exposure-response 
were generally null (Table 6, table 6C). Only two cohort 
studies,  conducted  by  Walrath  and  Fraumeni  (1984) 
and Dell and Teta (1995), reported increased propor-
tions or risks (PMR = 1.5, p <.05 and SMR = 2.65, 95% CI: 
1.15–5.24, respectively).
There  were  no  increased  risks  of  leukemia  in  any 
formaldehyde exposure group among the three studies 
that assessed exposure-response and, with one excep-
tion, no exposure-response associations were reported. 
Stern et al. (1987) found no association with duration of 
employment as a leather tannery worker and Pinkerton 
et al. (2004) found risks in garment workers were not 
related with duration of exposure, time since first expo-
sure, or year of first exposure (Table 6). Beane Freeman 
et al. (2009) examined associations with formaldehyde 
Table 4b.  Other cohorts.
Reference Obs Estimate 95% CI
         
Wong et al., 1983 6 SMR 1.36 0.50–2.95
         
Levine et al., 1984 8 SMR 1.24 —
         
Hayes et al., 1990 115 PMR 1.39 1.15–1.67
         
Hall et al., 1991 9 (M) SMR 1.42 0.65–2.69
         
Hall et al., 1991 1 (F) SMR 1.75 0.04–9.77
         
Matanoski et al., 1991 57 SMR 1.25 0.95–1.62
         
Bertazzi et al., 1986, 
1989
3 SMR 1.73 0.36–5.06
         
Stellman et al., 1998* 28 RR 1.22 0.84–1.77
         
Marsh et al., 2001 199 SMR 0.90 0.78–1.04
         
Pinkerton et al., 2004* 59 SMR 0.97 0.74–1.26
*ICD-8 200–208.Formaldehyde as a leukemogen—Weight of evidence  575
© 2011 Informa Healthcare USA, Inc. 
in the NCI industrial worker cohort by peak exposure, 
average  intensity,  cumulative  exposure,  cumulative 
number  of  peaks  ≥4.0  ppm  (data  not  reported),  and 
duration of exposure (data not reported), years since 
first exposure, and years since first exposure ≥4 ppm, 
including and excluding a referent group with no expo-
sure. They found no trends except for peak exposure 
when all exposure groups were included (ptrend = .02) but 
not when the referent group was excluded (ptrend = .12). In 
this cohort, risks were lower in those with no exposure vs. 
those with their first exposure to ≥4 ppm formaldehyde 
0-25 years earlier (RR = 0.34, 95% CI: 0.18-0.67) and also 
in those whose first exposure to ≥4 ppm formaldehyde 
was 25-42 years earlier vs. 0-25 years earlier (RR = 0.37, 
95% CI: 0.16-0.83). The RR estimates in the NCI indus-
trial worker cohort are similar to those reported in the 
previous follow-up of this cohort to 1994 (e.g., for peak 
exposure ≥4.0 ppm, RRthrough 1994 = 1.60, 95% CI: 0.90–2.82 
vs. RRthrough 2004 = 1.42, 95% CI: 0.92–2.18) (Beane Freeman 
et al., 2009; Hauptman et al., 2003). In this cohort, risks 
Table 5b.  Other cohorts.
Reference Obs Estimate 95% CI
Dell and Teta, 1995* 23 SMR 1.69 1.07–2.53
Chiazze et al., 1997* 5 SMR 0.46 0.15–1.08
Note: *ICD-7 200–205.
Table 5a.  Association between formaldehyde and cancers of lymphoid origin (ICD 200–204).
Measures
Hauptmann et al., 2009 Beane Freeman et al., 2009
Embalmers case-control NCI cohort (1934-2004)
Category Obs Estimate 95% CI Category Obs Estimate 95% CI
Unexposed/Exposed Never embalming 18 OR 1.00 —          
Ever embalming 81 OR 1.10 0.50-2.10          
Peak Exposure 0 ppm 18 OR 1.00 — 0 ppm 26 RR 1.17 0.72–1.89
>0–7.0 ppm 29 OR 1.20 0.60–2.70 >0–<2.0 ppm 73 RR 1.00 —
>7.0–9.3 ppm 37 OR 1.50 0.70–3.20 2.0–<4.0 ppm 56 RR 1.27 0.89–1.82
>9.3 ppm 15 OR 0.60 0.20–1.30 ≥4.0 ppm 74 RR 1.35 0.97–1.89
ptrend = .111 (exposed) ptrend = .06 (exposed)
ptrend = .523 (exposed and unexposed) ptrend = .10 (exposed and unexposed)
Average Intensity 0 ppm 18 OR 1.00 — 0 ppm 26 RR 1.08 0.68–1.71
>0–1.4 ppm 34 OR 1.40 0.60–2.90 >0–<0.5 ppm 116 RR 1.00 —
>1.4–1.9 ppm 26 OR 1.00 0.50–2.20 0.5–<1.0 ppm 49 RR 1.36 0.97–1.9
>1.9 ppm 21 OR 0.90 0.40–1.90 ≥1.0 ppm 38 RR 1.05 0.72–1.53
ptrend = .287 (exposed) ptrend > .5 (exposed)
ptrend = .598 (exposed and unexposed) ptrend > .5 (exposed and unexposed) 
Cumulative Exposure 0 ppm-h 18 OR 1.00 — 0 ppm-yr 26 RR 0.94 0.59–1.49
>0–4058 ppm-h 23 OR 0.90 0.40–2.00 >0–<1.5 ppm-yr123 RR 1.00 —
>4058–9253 ppm-h 33 OR 1.30 0.60–2.80 >1.5–<5.5 
ppm-yr
30 RR 0.65 0.44–0.98
>9253 ppm-h 25 OR 1.00 0.40–2.00 ≥5.5 ppm-yr 50 RR 1.06 0.75–1.49
ptrend = .912 (exposed) ptrend > .5 (exposed)
ptrend = .965 (exposed and unexposed) ptrend > .5 (exposed and unexposed)
Cumulative number of 
peaks ≥4.0 ppm 
        No association. Results not shown.
Duration of Exposure/
Employment
0 yrs 18 OR 1.00 — No association. Results not shown.
>0–20 yrs 16 OR 0.70 0.30–1.60
>20–34 yrs 32 OR 1.20 0.60–2.60          
>34 yrs 33 OR 1.20 0.60–2.50          
ptrend = .360 (exposed)          
ptrend = .449 (exposed and unexposed)          
Number of Embalmings 0 18 OR 1.00 —          
>0–1422 17 OR 0.70 0.30–1.60          
>1422–3068 37 OR 1.50 0.70–3.00          
>3068 27 OR 1.00 0.50–2.20          
ptrend = .963 (exposed)          
ptrend = .865 (exposed and unexposed)          
8-Hour Time-Weighted 
Average Intensity
0 18 OR 1.00 —          
>0–0.10 32 OR 1.20 0.60–2.60          
>0.10–0.18 25 OR 1.00 0.50–2.10          
>0.18 24 OR 1.00 0.50–2.10          
ptrend = .766 (exposed)          
ptrend = .605 (exposed and unexposed)          576  L. R. Rhomberg et al.
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were  lower  in  those  with  no  exposure  vs.  those  with 
their first exposure to ≥4 ppm formaldehyde 0-25 years 
earlier (RR = 0.34, 95% CI: 0.18-0.67) and also in those 
whose first exposure to ≥4 ppm formaldehyde was 25-42 
years earlier vs. 0-25 years earlier (RR = 0.37, 95% CI: 
0.16-0.83).
4.2.4.  Lymphatic leukemia
Results from analyses of lymphatic leukemia (ICD 204) 
are similar to those reported for all leukemias combined 
(Tables 6 and 7). Among the four studies that assessed 
lymphatic leukemia, all risk estimates are null (Table 7, 
table 7A). Blair et al. (2001) and Pinkerton et al. (2004) 
reported no association between formaldehyde exposure 
and mortality from lymphatic leukemia. There were no 
exposure-response relationships for any of the six expo-
sure metrics evaluated by Beane Freeman et al. (2009) in 
the NCI industrial cohort. This result was also observed 
in this cohort with follow-up only through 1994 (Beane 
Freeman et al., 2009; Hauptmann et al., 2003).
4.2.5.  Hematopoietic cancer of non-lymphoid origin
Associations  between  formaldehyde  exposure  and 
hematopoietic  cancers  of  non-lymphoid  origin  were 
investigated  in  several  studies  (Table  8).  In  an  early 
analysis of the NCI embalmers cohort, Hayes et al. (1990) 
found the PMR from polycythaemia vera or myelofibrosis 
was not higher than expected, but it was from monocytic 
leukemia, other (i.e., not lymphatic, myeloid, or mono-
cytic), and unspecified leukemias combined (PMR = 2.28, 
95% CI: 1.29–3.52). Pinkerton et al. (2004) found no asso-
ciation with monocytic leukemia or leukemia of other or 
unspecified type among garment workers (SMR = 0.92, 
95% CI: 0.34–2.00).
Risks  of  myeloid  leukemia  (ICD  205),  monocytic 
leukemia (ICD 206), ploycthaemia vera (ICD 208), and 
myelofibrosis (ICD 209) combined were examined in 
recent studies of the NCI industrial worker and embalmer 
cohorts (Hauptmann et al., 2009; Beane Freeman et al., 
2009;  Table  8).  Beane  Freeman  et  al.  (2009)  did  not 
report any excess risks in the industrial worker cohort 
Table 6b.  Other cohorts.
Reference ICD code Obs Estimate 95% CI
Harrington and Shannon, 1975 
(pathologists)
204–207 1 SMR 0.63 0.02–3.48
Harrington and Shannon, 1975 
(technicians)
204–207 1 SMR 0.45 0.01–2.53
Walrath and Fraumeni, 1983 204–207 12 PMR† 1.40 na
Wong et al., 1983 204–207 2 SMR† 1.18 0.13–4.26
Levine et al., 1984 204–207 4 SMR‡ 1.60 0.44–4.10
Walrath and Fraumeni, 1984 204–207 12 PMR† 1.50 p < .05
Logue et al., 1986 (radiologists) 204¶ na SMR 1.55 na
Logue et al., 1986 (pathologists) 204¶ na SMR 1.06 na
Stroup et al., 1986 204–207 10 SMR 1.50 0.70–2.70
Robinson et al., 1987 204¶ 1 SMR¶ 0.59 0.01–3.28
Stern et al., 1987 (Plant A) 204¶ 4 SMR† 0.70 0.19–1.80
Stern et al., 1987 (Plant B) 204¶ 6 SMR† 0.75 0.28–1.64
Stern et al., 1987 (Finishing Department) 204¶ 7 SMR† 1.25 0.50–2.58
Ott et al., 1989* Non-lymphocytic 2 OR 2.6 na
Ott et al., 1989* Lymphocytic 1 OR 2.60 na
Linos et al., 1990* na 4 OR 2.10 0.40–10.00
Hall et al., 1991 204–207 4 SMR 2.63 0.41–3.89
Matanoski et al., 1991 na 31 SMR 1.35 0.92–1.92
Partanen et al., 1993 204¶ 2 OR 1.40 0.25–7.91
Andjelkovich et al., 1995 204–207 2 SMR† 0.43 0.05–1.57
Dell and Teta, 1995 204¶ 8 SMR† 2.65 1.15–5.24
Hansen and Olsen, 1995 204¶ 39 SPIR 0.80 0.60–1.60
Chiazze et al., 1997 204¶ 1 SMR 0.24 0.006–1.36
Stellman et al., 1998 na 12 RR 0.96 0.54–1.71
Blair et al., 2001* na 64 OR‡ 0.98 0.70–1.36
Coggon et al., 2003 204–208 31 SMR 0.91 0.62–1.29
Ambroise et al., 2005 204–208 1 SMR 4.42 0.11–24.64
Note:
na = not available.
*Case-control study.
†SMR or PMR values divided by 100.
‡Risk estimate not provided in original citation, value calculated by Bachand et al. (2010).
¶ICD-7.Formaldehyde as a leukemogen—Weight of evidence  579
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based on analyses by peak exposure, average intensity, 
cumulative  exposure,  cumulative  number  of  peaks 
≥4.0 ppm, or duration of exposure (Table 8). They also 
found no exposure-response associations among analy-
ses including or excluding the unexposed population. 
This is consistent with previous analyses of this cohort 
(Hauptmann et al., 2003; Blair et al., 1986).
Hautpmann  et  al.  (2009)  found  that  risk  estimates 
from analyses using subjects who never embalmed as 
a referent category were highly unstable because of the 
small number of cases in this category (n = 4, odds ratio 
[OR] = 3.0, 95% CI: 1.0–9.5 for ever vs. never embalmed). 
Still, among six exposure metrics, there were no exposure-
response associations reported when unexposed refer-
ents (i.e., 0 embalmings) were included or excluded with 
one exception—there was a trend reported with duration 
of exposure when the unexposed group was excluded 
(ptrend = .046) but not when it was included (ptrend = .348). 
Because of the issues with the aforementioned analyses, 
Hauptmann et al. (2009) also conducted analyses using 
those who performed <500 embalmings as a referent cat-
egory. Results from these analyses, which they suggest are 
more reliable, are presented in Table 8. The majority of 
risk estimates were null, except for the highest exposure 
group for cumulative exposure (>34 years, OR = 2.60, 95% 
CI: 1.0–6.4) and number of embalmings (>3068 embalm-
ings,  OR = 2.3,  95%  CI:  1.00–5.70).  Hauptmann  et  al. 
(2009) also reported that among those who embalmed 
for more than 20 years, a significant increased risk of 
non-lymphoid cancers was observed (OR = 3.5, 95% CI: 
1.1–10.9). The p values reported for the trend tests by 
Hauptman et al. (2009) are incorrect, as they are the same 
as those reported for the tests which used 0 embalmers 
(vs. <500) as the referent category; therefore, they are not 
reported here.
4.2.6.  Myeloid leukemia
Myeloid  leukemia  was  assessed  in  three  case-control 
studies and four cohort studies, some of which also ana-
lyzed acute and/or chronic subtypes (Table 9). Results 
varied  among  the  four  studies  that  compared  risks  in 
exposed vs. unexposed individuals. Stroup et al. (1986) 
reported an excess in myeloid leukemia in US anatomists 
(SMR = 8.8, 95% CI: not reported). Similarly, Linos et al. 
(1990)  reported  an  excess  of  acute  myeloid  leukemia 
in  funeral  home  workers,  although  this  was  based  on 
three exposed cases (OR = 6.7, 95% CI: 1.2–36.2). Hayes 
et al. (1990) reported a significant excess proportion of 
myeloid leukemia deaths overall in the NCI embalmers 
cohort  (PMR = 1.57,  95%  CI:  1.01–2.34),  but  found  no 
associations in analyses by subtype (PMRacute = 1.52, 95% 
CI: 0.85–2.52; PMRchronic = 1.84, 95% CI: 0.79–3.62). Blair 
et al. (2001) conducted a case-control study of several 
industrial and occupational job categories in US workers 
and found no associations between intensity of formalde-
hyde exposure and acute or chronic myeloid leukemia.
Pinkerton et al. (2004) assessed myeloid leukemia in a 
cohort of US garment workers and found no association 
with formaldehyde exposure overall (SMR 1.44, 95% CI: 
0.80–2.37) or when examined by subtype (SMRacute = 1.34, 
95%  CI:  0.61–2.54;  SMRchronic = 1.39,  95%  CI:  0.38–3.56). 
There were also no trends with duration of exposure or 
time  since  first  exposure  (p > .05),  although  risks  were 
increased in workers with 20 or more years since first 
exposure (SMR = 1.91, 95% CI: not reported). In contrast, 
there were no increased risks in workers exposed for 10 
or more years with 20 or more years since first exposure 
overall  (SMR = 2.43,  95%  CI:  0.98–5.01)  or  in  analyses 
limited to acute myeloid leukemia (SMR = 2.51, 95% CI: 
0.81–5.85).
In an analysis of the NCI industrial worker cohort with 
follow-up  through  2004,  Beane  Freeman  et  al.  (2009) 
assessed whether myeloid leukemia risk was associated 
with formaldehyde estimated as peak exposure, average 
intensity,  cumulative  exposure,  cumulative  number  of 
peaks ≥4.0 ppm (data not reported), duration of expo-
sure (data not reported), years since first exposure, and 
years since first exposure ≥4 ppm. These investigators 
reported no associations between any exposure metric 
and myeloid leukemia, including peak exposure (RR = 
1.78, 95% CI: 0.87-3.64, ptrend = 0.13 for exposed groups), 
except for lower risks in those with no exposure vs. those 
with their first exposure to ≥ 4 ppm formaldehyde 0-25 
years earlier (RR = 0.30, 95%  CI: 0.11-0.81) and higher 
risks with increasing peak intensity with follow-up from 
1981-1994  (ptrend  =  0.0353  based  on  exposed  subjects 
only and ptrend = 0.210 based on all study subjects), but 
not with follow-up to 1981 or 1995-2004 (Table 9). These 
null results were consistent with analyses of this cohort 
through 1994 based on every exposure metric except peak 
exposure, for which risks were increased (RR = 2.79, 95% 
CI: 1.08–7.21, ptrend = .02 for exposed groups, ptrend = .0087 
for all groups) (Beane Freeman et al., 2009; Hauptmann 
et al., 2003). There were no associations based on any 
other metric in analyses.
Hauptmann  et  al.  (2009)  conducted  a  case-control 
study of professional embalmers, including cases from 
previous  studies  (Walrath  and  Fraumeni,  1983,  1984; 
Hayes et al., 1990), and assessed myeloid leukemia risk 
based on seven formaldehyde exposure metrics (Table 9). 
Having ever embalmed was associated with myeloid leu-
kemia (OR = 11.2, 95% CI: 1.3–95.6, ptrend = .027), but there 
was only one case who never embalmed, making this risk 
estimate highly unreliable. Because of this, Hauptmann 
et al. (2009) combined unexposed individuals and those 
with  <500  embalmings  as  a  referent  group  to  provide 
Table 8b.  Other cohorts.
Reference Code Obs Estimate 95% CI
Pinkerton 
et al., 2004
206–208 6 SMR 0.92 0.34–2.00
Hayes et al., 
1990
206, 207 20 PMR 2.28 1.39–3.52
Hayes et al., 
1990
208 3 PMR 3.90 0.80–
11.38
Hayes et al., 
1990
209 4 PMR 2.62 0.42–3.91582  L. R. Rhomberg et al.
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more conservative and reliable risk estimates; these are 
discussed here and shown in Table 9. An increased risk 
for myeloid leukemia was not reported for any exposed 
group except those with more than 34 years of employ-
ment  (OR = 3.9,  95%  CI:  1.2–12.5),  more  than  3068 
embalmings  (OR = 3.0,  95%  CI:  1.0–9.2),  or  more  than 
9253 ppm-hours of cumulative formaldehyde exposure 
(OR = 3.1, 95% CI: 1.0–9.6). Hauptmann et al. (2009) con-
ducted similar analyses for acute myeloid leukemia and 
found no associations in any dose group. Reported p val-
ues for trend tests for total and acute myeloid leukemia 
appear to be those based on analyses using 0 embalm-
ings (vs. <500 embalmings) as a referent category and are 
not presented here.
Although there are some isolated findings of statisti-
cally  significant  associations  between  formaldehyde 
exposure  and  myeloid  leukemia,  these  have  not  been 
found consistently either within or among studies and 
are far outnumbered by null findings in the more robust 
studies.
4.2.7.  Other unspecified leukemia
Most cohort and case-control studies examined other 
(i.e., not lymphatic, myeloid, or monocytic) or unspeci-
fied leukemias (ICD 207) grouped with other lymphohe-
matopoietic cancer types. The ICD 207 category alone 
was only examined in the NCI industrial worker cohort 
(Table 10). Beane Freeman et al. (2009) reported no asso-
ciations between formaldehyde exposure and other or 
unspecified leukemia based on peak exposure, average 
intensity, cumulative exposure, cumulative number of 
peaks ≥4.0 ppm (data not reported), or duration of expo-
sure  (data  not  reported).  These  results  are  consistent 
with previous evaluations of the NCI industrial worker 
cohort (Hauptmann et al., 2003; Blair et al., 1986). Hayes 
et al. (1990) examined monocytic (ICD 206) and other 
unspecified leukemia (ICD 207) combined in embalm-
ers  and  reported  an  increased  proportion  of  deaths 
(PMR = 2.28, 95% CI: 1.29–3.52). This disease category 
was not evaluated in the follow-up by Hauptman et al. 
(2009).
4.2.8.  Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, and 
multiple myeloma
Cohort and case-control study results for Hodgkin’s and 
non-Hodgkin’s  lymphoma  and  multiple  myeloma  are 
presented in Tables 11 to 13. Eleven assessments of form-
aldehyde-exposed vs. unexposed workers did not show 
associations between exposure and Hodgkin’s lymphoma 
(Table 10). In the one study that evaluated iron foundry 
workers vs. the general population, risks were also not 
increased (Andjelkovich et al., 1995). When exposure-re-
sponse relationships were evaluated in the NCI industrial 
worker cohort, associations were reported for peak expo-
sure (ptrend = .01 for exposed groups) and average intensity 
(ptrend = .05  for  exposed  groups)  but  not  for  cumulative 
exposure, cumulative number of peaks ≥4.0 ppm (data 
not reported), or duration of exposure (data not reported) 
(Beane Freeman et al., 2009). This is consistent with the 
earlier examination of the NCI industrial worker cohort, 
for which exposure-response relationships for peak expo-
sure (ptrend = .04) and average intensity (ptrend = .03), but not 
other exposure metrics, were reported (Beane Freeman 
et al., 2009; Hauptmann et al., 2003).
None of the 13 epidemiology investigations reported 
associations between formaldehyde exposure and non-
Hodgkin’s lymphoma for any exposure metric evaluated 
(Table 12). There were also no exposure-response asso-
ciations observed (Table 12).
Multiple  myeloma  was  not  associated  with  form-
aldehyde  exposure  in  any  of  the  eight  groups  studied 
(Table 13). In the NCI industrial worker cohort, multiple 
myeloma risk was higher in individuals with no expo-
sure  based  on  all  measures  evaluated  (Table  13).  The 
only  association  with  formaldehyde  reported  was  for 
peak exposure ≥4.0 ppm (RR = 2.04, 95% CI: 1.01–4.12); 
however, the trend was not significant (p > .05) and there 
was no association with the number of peak exposures 
≥4.0 ppm. This finding was consistent with results from 
earlier follow-ups of this cohort (Beane Freeman et al., 
2009; Hauptmann et al., 2003).
4.3.  HBWoE evaluation of epidemiology studies
We conducted an HBWoE evaluation of the epidemiol-
ogy data with regard to an association between formal-
dehyde exposure and leukemia. Based on review of the 
data discussed in the previous section, we address the 
following questions:
What  are  the  implications  of  studies  of  individual  1. 
lymphohematopoietic  cancers  and  several  group-
ings of these cancer types (e.g., all cancers of lym-
phoid origin, all of non-lymphoid origin) regarding 
leukemia risks from formaldehyde exposure?
Were results from the epidemiology data consistent  2. 
for  different  types  of  exposure  metrics  (e.g.,  peak 
exposure,  number  of  peak  exposures  ≥4.0  ppm, 
cumulative  exposure)?  Were  results  dependent  on 
the  robustness  of  exposure  measurements,  par-
ticularly for the NCI industrial worker and embalmer 
cohorts?
Were co-exposures considered in the interpretation  3. 
of the study results?
Were  there  consistent  exposure-response  associa- 4. 
tions within and across studies?
Were there potential statistical limitations among the  5. 
epidemiology studies?
How should latency be considered when interpret- 6. 
ing study results? Is it possible that risks decline over 
time owing to a relatively short induction-incubation 
period (as proposed by Beane Freeman et al., 2009)?
 As a whole, considering these questions allows for an 
assessment of the extent to which the epidemiology data 
support either a causal association between formalde-
hyde exposure and leukemia or an alternative hypothe-
sis. Importantly, one needs to consider the epidemiology Formaldehyde as a leukemogen—Weight of evidence  583
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data in the context of the hematotoxicity and mode-of-
action data (discussed later), as each of the three lines of 
evidence inform interpretation of the other; specifically, 
a claim of causation cannot be solely based on one or the 
other but has to be reflected consistently across the epi-
demiology, mode-of-action, and hematoxicity data.
4.3.1.  Cancer outcome assessments likely led to disease 
misclassification
There are several ways in which cancer outcomes were 
defined and assessed in the formaldehyde epidemiology 
studies, several of which may have led to disease misclas-
sification and/or misleading results.
With  few  exceptions,  most  studies  assessed  cancer 
mortality,  and  several  of  the  larger  studies  relied  on 
death  certificates  to  determine  cause  of  death  (e.g., 
Beane  Freeman  et  al.,  2009;  Hauptmann  et  al.,  2003, 
2009; Hayes et al., 1990; Pinkerton et al., 2004; Stroup 
et al., 1986; Walrath and Fraumeni, 1983, 1984). Death 
certificates  do  not  always  identify  leukemia  subtype, 
and leukemia diagnosis was considered unreliable prior 
to 1992 (Collins and Lineker, 2004; Bachand et al., 2010; 
Miller et al., 1992; Percy et al., 1981, 1990, both as cited by 
Collins and Lineker, 2004). Thus, relying on death certifi-
cates may have led to disease misclassification.
In addition, diagnoses of lymphohematopoietic can-
cers has evolved in recent decades, and historic records 
may  be  inaccurate  (Bachand  et  al.,  2010;  Collins  and 
Lineker, 2004; Miller et al., 1992; Percy et al., 1990, as cited 
by Collins and Lineker, 2004; Scott and Chiu, 2006). For 
example, past classifications of lymphomas do not make 
distinctions between different cell types (Scott and Chiu, 
2006). This means that, within studies that investigated 
subjects  over  many  decades,  individuals  assigned  the 
same cancer actually may not have had the same cancer.
There is also an issue with assessing cancers in cat-
egories.  Each  different  kind  of  lymphohematopoietic 
cancer is a distinct disease with a unique etiology, set 
of risk factors, and, presumably, mechanism of action. 
Consequently,  grouping  cancer  types  together  is  not 
informative regarding risks for a particular cancer type. 
Any observed increased risks could be driven by risks for 
one cancer type (e.g., if the majority of cancers in a group 
were the same type, or one cancer type had very large 
risks associated with it); a lack of risks could be indicative 
of no risks among all lymphohematopoietic cancers or 
that  combining  cancer  types  masks  true  associations 
with one particular cancer type. For example, in the NCI 
industrial worker cohort, the two cancers that contribute 
to  the  association  between  peak  formaldehyde  expo-
sure and all lymphohematopoietic cancers are multiple 
myeloma and Hodgkin’s disease (Beane Freeman et al., 
2009). These cancers are not associated with formalde-
hyde exposure in other studies.
In sum, disease misclassification likely led to uncer-
tain risk estimates. In addition, studies that purport to 
show associations with a group of cancers that include 
leukemia do not provide sufficient evidence that risk, if it 
exists, is for leukemia and not another white cell cancer.
4.3.2.  Exposure assessments likely affected by exposure 
measurement error or misclassification
Because of the difficulty in obtaining exposure data for 
individuals  in  cohort  and  case-control  studies,  inves-
tigators  typically  estimated  exposure  from  few,  if  any, 
measurements  of  formaldehyde  concentrations.  For 
example,  Andjelkovich  et  al.  (1995)  assigned  formal-
dehyde exposures to each iron foundry worker by job 
category based on midpoints of ranges from actual sam-
pling data. Pinkerton et al. (2004) conducted analyses 
based on 1 year of measured data from the 1980s and 
applied it to the entire follow-up period in garment work-
ers  (1955–1998).  Exposure  estimates  in  formaldehyde 
workers in the NCI cohort were developed by assigning 
job  categories  from  work  histories  abstracted  in  1980 
and an expert assessment of job and tasks using current 
and past measurement data (Stewart et al., 1986; Blair 
et al., 1986). Although this was considered to be a well-
conducted exposure assessment for the time, validation 
of the exposure matrix was not possible, and exposures 
to formaldehyde and other potential confounders after 
1980  were  assumed  to  be  minimal  (Beane  Freeman 
et al., 2009; Blair et al., 1986, 1990; Stewart et al., 1986). 
Peak exposure categories (none, >0 to <0.5 ppm, 0.5 to 
<2.0 ppm, 2.0 to <4.0 ppm, or ≥4.0 ppm) were estimated 
and defined as short-term exposures (generally less than 
15 minutes) exceeding the 8-hour time-weighted aver-
age (TWA8) category (Blair et al., 1986; Beane Freeman 
et al., 2009). In the NCI embalmers cohort (Hauptmann 
et al., 2009), questionnaire data were linked to data from 
an exposure experiment (Stewart et al., 1992). No mea-
surements of peak exposure were available, and average 
formaldehyde  intensity,  peak,  time-weighted  average, 
and cumulative exposure were estimated using a predic-
tive  model.  Comparison  of  modeled  average  intensity 
to  measurements  from  independent  embalmings  sug-
gested the model overestimated exposure by 35%, and 
peak  exposures  could  not  be  validated  (Hauptmann 
et al., 2009).
Despite  the  paucity  of  exposure  information,  in 
two of the largest cohorts evaluated (the NCI indus-
trial worker and embalmer cohorts), several exposure 
metrics were estimated (e.g., peak exposure, average 
Table 9b.  Other cohorts.
Reference Obs Estimate 95% CI
Stroup et al., 1986 5 SMR 8.8 —
Hayes et al., 1990 24 PMR‡ 1.57 1.01–2.34
Linos et al., 1990 
(acute)
3 OR 6.70 1.20–
36.20
*Results from analyses using those who never embalmed as 
the referent group (with one myeloid leukemia case) were 
highly unstable. Results presented here are from analyses using 
individuals with <500 embalmings as the referent group. (See 
Table 4 in Hauptman et al., 2009).
†95% CI does not include 1.0.
‡PMR divided by 100.586  L. R. Rhomberg et al.
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exposure,  cumulative  exposure,  exposure  duration). 
Owing to the importance that peak exposures play in 
the interpretation of the NCI studies, it is important to 
note that peaks were not actually measured, but only 
inferred  from  job  descriptions.  Detailed  analyses  of 
exposure metrics used for the NCI industrial worker 
cohort were conducted by Blair et al. (1990) and Stewart 
et al. (1986). They reported that measures of duration 
(employment  and  exposure)  and  average  exposure 
and  level  of  exposure  were  highly  correlated  (r = .8). 
Peak exposures had low to moderate correlations with 
employment duration (r = .2), exposure duration (r = .3), 
cumulative exposure (r = .3), average exposure (r = .5), 
and level of exposure (r = .7). Average exposure showed 
little correlation with duration of employment (r = −.1) 
and duration of exposure (r = .0). Based on these cor-
relations, it is unclear why lymphohematopoietic and 
leukemia  mortality  rates  were  associated  with  peak 
exposure but not with the number of peak exposures 
≥4.0 ppm, cumulative exposure, or exposure duration 
(Beane Freeman et al., 2009). Even if higher exposure 
intensities are of more consequence as a result of form-
aldehyde’s mode of action, those experiencing higher 
air  concentrations  over  time  with  any  repeatability 
would have a higher number of peak exposures ≥4.0 
ppm and higher cumulative and average exposures, so 
these measures ought to show an association as well. 
This  is  not  the  case,  indicating  the  association  with 
peak exposure is not likely to be causal (other issues 
with this statistic are discussed below).
The lack of precise exposure data likely led to exposure 
measurement  error  and/or  exposure  misclassification 
in these epidemiology studies. This could have biased 
results either towards or away from the null (Jurek et al., 
2005). Based on the null associations with other exposure 
metrics, in the case of peak exposure, it appears to be the 
latter.
4.3.3.  Exposures to other chemicals in the workplace may 
have confounded results
None of the studies adequately addressed co-exposures 
to other agents. For example, embalmers were exposed 
to infectious agents and other chemicals in embalming 
fluid,  such  as  methanol,  propylene  glycol,  industrial 
methylated spirit, phenol, and glycerol (Coleman and 
Kogan, 1998; Bachand et al., 2010; Bosetti et al., 2008; 
Collins  et  al.,  2004).  Industrial  workers  were  likely 
exposed to other chemicals as well (e.g., antioxidants, 
asbestos,  benzene,  carbon  black,  dyes  and  pigments, 
hexamethylenetetramine,  melamine,  phenol,  plasti-
cizers,  urea,  and  wood  dust)  (Beane  Freeman  et  al., 
2009). Although benzene is the only known leukemogen 
among  these  agents,  it  is  possible  that  any  observed 
risks, if found to be real, may have been attributable to 
exposures to other agents.
4.3.4.  Exposure-response associations within and among 
studies are not consistent
If formaldehyde is in fact a causal factor for leukemia, 
one would expect leukemia risk to increase with form-
aldehyde exposure both within and among studies. As 
described below, few studies actually assessed exposure-
response (Pinkerton et al., 2004; Stern et al., 1987; Beane 
Freeman et al., 2009; Hauptmann et al., 2009); among 
those, consistent associations were not reported. Among 
studies, leukemia risks appeared to be higher in profes-
sionals  with  lower  average  formaldehyde  exposures 
(mean TWA8 concentrations <0.5 to 1 ppm in profes-
sional  settings  [e.g.,  workplaces  of  histopathologists, 
embalmers, anatomists]; IARC, 2006), yet more highly 
exposed industrial workers (mean TWA8 concentrations 
<1 to >10 ppm in industrial settings [e.g., formaldehyde 
manufacturing]; IARC, 2006) showed lesser effects, add-
ing to the weight of evidence suggesting formaldehyde is 
not a causal factor.
In analyses of formaldehyde and risks of all leukemias 
combined, Pinkerton et al. (2004) found no exposure-
response  associations  with  duration  of  exposure,  time 
since first exposure, or year of first exposure in garment 
workers.  Stern  et  al.  (1987)  also  found  no  trend  with 
duration of exposure. There were some statistically sig-
nificant trends reported in the NCI industrial cohort but, 
Table 10a.  Association between formaldehyde and other 
unspecified leukemia (ICD-8 207).
Measures
Beane Freeman et al., 2009
NCI Cohort (1934-2004)
Category Obs Estimate 95% CI
Peak 
Exposure
0 ppm 2 RR 0.61 0.13–2.85
>0–<2.0 ppm 13 RR 1.00 —
2.0–<4.0 ppm 8 RR 0.86 0.35–2.12
≥4.0 ppm 13 RR 1.15 0.53–2.53
ptrend > .5 (exposed)  
ptrend = .5 (exposed and unexposed) 
Average 
Intensity
0 ppm 2 RR 0.58 0.13–2.62
>0–<0.5 ppm 21 RR 1.00 —
0.5–<1.0 ppm 7 RR 0.98 0.42–2.33
≥1.0 ppm 6 RR 0.84 0.33–2.12
ptrend > .5 (exposed)  
ptrend > .5 (exposed and unexposed) 
Cumulative 
Exposure
0 ppm-yr 2 RR 0.77 0.16–3.59
>0–<1.5 ppm-yr 15 RR 1.00 —
>1.5–<5.5 ppm-yr 10 RR 1.65 0.73–3.73
≥5.5 ppm-yr 9 RR 1.44 0.61–3.36
ptrend = .15 (exposed)  
ptrend = .13 (exposed and unexposed) 
Cumulative 
number of 
peaks ≥4.0 
ppm
No association. Results not shown. 
         
         
Duration of 
Employment
No association. Results not shown.
Table 10b.  Other cohorts.
Reference Code Obs Estimate 95% CI
Hayes et al., 1990 206, 207 20 PMR 2.28 1.39–3.52Formaldehyde as a leukemogen—Weight of evidence  587
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as described below, these findings were not robust or 
indicative of causation.
In the NCI industrial worker cohort, study subjects 
were divided into “low” (>0 to <2.0 ppm), “medium” (2.0 
to <4.0), and “high” (≥4.0) exposure categories for the 
inferred lifetime peak level, and analyses were conducted 
by comparing risks in the medium- and high-exposure 
categories  to  those  in  the  low-exposure  category.  As 
shown in Figure 1, these analyses showed no statistically 
significant associations and no exposure-response rela-
tionship with leukemia. If, however, a “zero” category was 
added, comprised of workers from the facilities that were 
presumably unexposed, the exposure-response trend for 
leukemia vs. “peak” became statistically significant, as 
was the contrast between the high vs. the zero (but not 
vs. the low) category.
Even though the “low” group included people down 
to zero as the lifetime “peak” exposure, the leukemia risk 
for the “zero” group was markedly lower. People classi-
fied as “zero” must have had systematically different job 
descriptions than those in the “low” category (for which 
peak exposure could be as low as zero and still admit 
them  into  the  “low”  group),  so  the  comparability  of 
these groups is in question. Moreover, the “zero” group 
has leukemia risks that are notably smaller than the gen-
eral population. Indeed, when analyses were done on an 
SMR  basis,  risks,  although  not  statistically   significant, 
were  much  lower  than  those  for  the  US  population   
(SMRall  leukemia = 0.48,  95%  CI:  0.23–1.01; 
SMRlymphatic    leukemia = 0.26,  95%  CI:  0.04–1.82; 
SMRmyeloid    leukemia = 0.65,  95%  CI:  0.25–1.74)  (Beane 
Table 11a.  Association between formaldehyde and Hodgkin’s lymphoma (ICD 201).
Measures
Beane Freeman et al., 2009 Andjelkovich et al., 1995
NCI cohort (1934–2004) Iron foundry workers
Category Obs Estimate 95% CI Category Obs Estimate 95% CI
Unexposed/Exposed Unexposed 2 SMR 0.70 0.17–2.80 Unexposed 0 SMR 0.00 0.00–4.12
Exposed 25 SMR 1.42 0.96–2.10 Exposed 1 SMR 0.72 0.01–4.00
                   
                   
Peak Exposure 0 ppm 2 RR 0.67 0.12–3.60          
>0–<2.0 ppm 6 RR 1.00 —          
2.0–<4.0 ppm 8 RR 3.30 1.04–10.50          
≥4.0 ppm 11 RR 3.96 1.31–12.02          
ptrend = .01 (exposed)          
ptrend = .004 (exposed and unexposed)           
Average Intensity 0 ppm 2 RR 0.53 0.11–2.66          
>0–<0.5 ppm 10 RR 1.00 —-          
0.5–<1.0 ppm 9 RR 3.62 1.41–9.31          
≥1.0 ppm 6 RR 2.48 0.84–7.32          
ptrend = .05 (exposed)            
ptrend = .03 (exposed and unexposed)           
Cumulative Exposure 0 ppm-yr 2 RR 0.42 0.09–2.05          
>0–<1.5 ppm-yr 14 RR 1.00 —          
>1.5–<5.5 ppm-yr 7 RR 1.71 0.66–4.38          
≥5.5 ppm-yr 4 RR 1.30 0.4–4.19          
ptrend = .08 (exposed)            
ptrend = .06 (exposed and unexposed)           
Cumulative number of 
peaks ≥4.0 ppm
No association. Results not shown.          
                   
                   
Duration of Employment No association. Results not shown.          
Table 11b.  Other cohorts.
Reference Obs Estimate 95% CI
Wong et al., 1983 2 SMR 2.40 0.27–8.66
         
Robinson et al., 1987 2 SMR 3.33 0.59–10.49
         
Gerin et al., 1989 8 OR 0.50 0.20–1.40
         
Hayes et al., 1990 3 PMR 0.72 0.15–2.10
         
Hall et al., 1991 1 SMR 1.31 0.03–7.33
         
Matanoski et al., 1991 2 SMR 0.36 0.04–1.31
         
Hansen and Olsen, 
1995
12 SPIR 1.00 0.50–1.70
         
Coggon et al., 2003 6 SMR 0.70 0.26–1.53
         
Pinkerton et al., 2004 2 SMR 0.55 0.07–1.98
         
Hauptmann et al., 2009 8 OR 0.50 0.10–2.60588  L. R. Rhomberg et al.
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Freeman et al., 2009). In contrast, among the all of the 
exposed  groups,  the  SMR  estimates  are  more  consis-
tent  with  US  expected  levels  (SMRall  leukemia = 1.02,  95% 
CI: 0.85–1.22; SMRlymphatic leukemia = 1.15, 95% CI: 0.83–1.59; 
SMRmyeloid    leukemia = 0.90;  95%  CI:  0.67–1.21)  (Beane 
Freeman et al., 2009).
In short, it appears that the reported significant rela-
tion  of  “peak”  formaldehyde  exposure  and  leukemia 
risk depended entirely on a lower-than-usual leukemia 
rate in the “zero” group rather than any effects among 
exposed people. “Peaks” were inferred possibilities rather 
than actual exposures, and they did not account for the 
duration of time spent in the highest peak-exposure cat-
egory or the relevant latent period between the date of 
first highest peak exposure and death (Marsh and Youk, 
2004). Individuals with high peak exposures early but not 
later in their career and those with low peak exposures 
for the majority of their career but high peaks near the 
end were likely in the same exposure category. Similarly, 
those with one peak exposure were likely classified in the 
same category as those with several peak exposures. In 
both of these scenarios, individuals with very different 
exposures were grouped in similar categories. In con-
trast,  when  grouping  workers  by  the  inferred  number 
of  peaks  ≥4.0,  or  by  cumulative  or  average  exposure, 
individuals with similar exposures were more likely to 
be grouped together. Based on these latter metrics, form-
aldehyde  exposure  was  not  associated  with  leukemia. 
Thus, the finding of a significant effect for leukemia in the 
industrial cohort with peak exposure (Beane Freeman 
et al., 2009), which relies on picking apparently positive 
results  among  several  similar  analyses  demonstrating 
inconsistent results, is not a substantive or compelling 
finding.
It  is  notable  that  in  analyses  limited  to  myeloid 
leukemia,  a  different  pattern  emerges.  Neither  Beane 
Freeman et al. (2009) nor Pinkerton et al. (2004) found 
any  consistent  exposure-response  associations  among 
the NCI industrial worker cohort and garment workers, 
respectively, regardless of the exposure metric, whereas 
Hauptmann et al. (2009) reported trends in embalmers 
based on peak exposure and duration of exposure, but 
only  when  the  referent  categories  (<500  embalmings) 
Table 13a.  Association between formaldehyde and multiple 
myeloma (ICD 203).
Measures
Beane Freeman et al., 2009
NCI cohort (1934-2004)
Category Obs Estimate 95% CI
Unexposed/
eEposed
Unexposed 11 SMR 1.78 0.99–3.22
Exposed 48 SMR 0.94 0.71–1.25
         
         
Peak 
Exposure
0 ppm 11 RR 2.74 1.18–6.37
>0–<2.0 ppm 14 RR 1.00 —
2.0–<4.0 ppm 13 RR 1.65 0.76–3.61
≥4.0 ppm 21 RR 2.04 1.01–4.12
ptrend = .08 (exposed)  
ptrend > .5 (exposed and unexposed) 
Average 
Intensity
0 ppm 11 RR 2.18 1.01–4.70
>0–<0.5 ppm 25 RR 1.00 —
0.5–<1.0 ppm 11 RR 1.40 0.68–2.86
≥1.0 ppm 12 RR 1.49 0.73–3.04
ptrend > .5 (exposed)  
ptrend > .5 (exposed and unexposed) 
Cumulative 
Exposure
0 ppm-yr 11 RR 1.79 0.83–3.89
>0–<1.5 
ppm-yr
28 RR 1.00 —
>1.5–<5.5 
ppm-yr
5 RR 0.46 0.18–1.20
≥5.5 ppm-yr 15 RR 1.28 0.67–2.44
ptrend > .5 (exposed)  
ptrend > .5 (exposed and unexposed)
Cumulative 
number of 
peaks ≥4.0 
ppm
No association. Results not shown.
         
         
Duration of 
Employment
No association. Results not shown.
Table 12b.  Other cohorts.
Reference Obs Estimate 95% CI
Edling et al., 1987 2 SPIR * 2.00 0.50–7.20
         
Ott et al., 1989† 2 OR 2.00 —
         
Hayes et al., 1990 34 PMR 1.26 0.87–1.76
         
Linos et al., 1990† 6 OR 3.2 0.80–13.40
         
Partanen et al., 
1993†
4 OR 4.24 0.68–26.60
         
Hansen and Olsen, 
1995
32 SPIR 0.90 0.60–1.20
         
Tatham et al., 1997† 93 OR 1.20 0.86–1.50
         
Stellman et al., 1998 11 RR 0.92 0.50–1.68
         
Coggon et al., 2003 31 SMR 0.98 0.67–1.39
         
Hauptmann et al., 
2009
NR OR 0.90 0.40–2.10
Notes *Standardized proportionate incidence ratio.
†Case-control study.
 Table 13b.  Other cohorts.
Reference Obs Estimate 95% CI
Edling et al., 1987 2 SPIR * 4.00 0.50–14.40
Ott et al., 1989† 1 OR 1.00 —
Hayes et al., 1990 20 PMR 1.37 0.84–2.12
Dell and Teta, 1995 5 SMR 2.62 0.85–6.11
Stellman et al., 1998 4 RR 0.74 0.27–2.02
Coggon et al., 2003 15 SMR 0.86 0.48–1.41
Hauptmann et al., 2009 NR OR 1.40 0.50–5.60
Notes: *Standardized proportionate incidence ratio.
†Case-control study. 590  L. R. Rhomberg et al.
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were included in the analyses. No trends were observed 
when the referent category was excluded or when expo-
sure was defined as average intensity, cumulative expo-
sure, number of embalmings, or 8-hour TWA intensity. 
Again,  this  lack  of  consistency  suggests  that  observed 
trends are not likely indicative of causation.
Regarding  other  lymphohematopoietic  cancer  types 
or groups, Beane Freeman et al. (2009) observed a trend 
only  with  peak  exposure  and  all  lymphohematopoietic 
cancers combined in the NCI industrial cohort. No other 
trends with all lymphohematopoietic cancers combined 
were observed in this cohort or the NCI embalmers cohort 
(Hauptmann  et  al.,  2009).  No  trends  were  observed  in 
either cohort for cancers of lymphoid origin and, for can-
cers of non-lymphoid origin, trends were only observed for 
duration of exposure in the NCI embalmers cohort when 
unexposed individuals were excluded (which left two indi-
viduals in the lowest category). There were no trends in the 
NCI industrial workers cohort with lymphatic leukemia, 
and no trends at all for non-Hodgkin’s lymphoma or multi-
ple myeloma. Beane Freeman et al. (2009) observed a trend 
with  peak  exposure  and  average  intensity  for  Hodgkin’s 
lymphoma but not with cumulative exposure, cumulative 
number of peaks ≥4.0 ppm, or duration of employment.
Regarding  exposure-response  among  studies, 
professionals—such  as  embalmers,  pathologists,  and 
anatomists—have much lower formaldehyde exposures 
than  industrial  workers.  Yet  Blair  et  al.  (1990)  found 
small excess leukemia risks among professionals but not 
industrial workers; several meta-analyses have reported 
similar findings (Bosetti et al., 2008; Collins and Lineker, 
2004). Some possible explanations have been put forth to 
explain these findings, including infectious agents, other 
chemicals in embalming fluid, occupational and lifestyle 
factors, observer bias, and a higher degree of scrutiny 
and medical attention owing to perceived risks (Coleman 
and  Kogan,  1998;  Bachand  et  al.,  2010;  Bosetti  et  al., 
2008; Collins et al., 2004). Zhang et al. (2010a) suggest 
that effects in industrial workers may not be observed 
because analyses were conducted based on combined 
exposure categories, but this does not explain why effects 
are observed in professionals and not in industrial work-
ers (who have higher exposures), and results from the few 
large studies that examined exposure-response associa-
tions do not support the hypothesis that formaldehyde is 
causally associated with leukemia.
Overall, although some statistically significant trends 
have been noted, these trends were not found consis-
tently within or among studies. The lack of consistent 
exposure-response associations within or among studies 
indicates that the few associations noted between form-
aldehyde and leukemia are not causal.
4.3.5. Statistical limitations may have led to spurious 
associations
When the same set of data is analyzed in multiple par-
allel  ways  using  different  models,  groupings,  or  sum-
mary measures, the meaning of statistical tests becomes 
distorted  by  the  multiple-comparisons  problem.  That 
is, if enough alternatives are tried, some might be “sig-
nificant” by chance alone (since, at a criterion of p = .05, 
even when there is no effect, 5% of comparisons are ruled 
“significant”).
Data from several studies, including those of the NCI 
industrial worker and embalmer cohorts, were analyzed 
many different parallel ways (e.g., average or cumulative 
or peak exposure; pairwise comparisons or trends; using 
internal or external controls; with or without a “unex-
posed” group in the trend test; individual tumor types or 
various measures of combined tumors). Unless a correc-
tion for multiple comparisons is made, finding marginal 
significance in one or a few such comparisons is not sur-
prising even when there is no true effect. For example, 
in the NCI industrial worker cohort, associations were 
reported with peak exposures, but there was no a priori 
reason to focus on peak exposures. Furthermore, asso-
ciations were not found for other, more accurate indica-
tors of exposure, such as the number of peak exposures 
≥4.0 ppm, cumulative exposure, and average exposure. If 
there is no a priori reason to choose a superior exposure 
metric, one should not select a model based solely on 
statistical performance because choosing the metric with 
the strongest association with outcome could lead to bias 
(Kriebel et al., 2007). Instead, one should choose a model 
based on which is most consistent with the hypothesized 
mechanism of action. In the case of formaldehyde, peak 
exposure is clearly an inferior metric (discussed above), 
and  this  provides  an  even  stronger  argument  for  not 
choosing a model based on the strongest statistical asso-
ciation. The result for peaks can at most be a hypothe-
sis-generating observation to be tested on future data. 
Otherwise, it is post hoc and arbitrary.
4.3.6.  The latency argument proposed by Beane Freeman 
et al. (2009) appears to be a post hoc explanation for the 
observed effects
Epidemiology studies are often limited in that they are 
not conducted over long enough periods of time for can-
cer from particular exposures to develop, in which case 
causal associations cannot be detected. In the case of leu-
kemia, Beane Freeman et al. (2009) suggest just the oppo-
site, stating that risks for myeloid leukemia may decline 
over time owing to a relatively short induction-incubation 
period. In other words, they suggest that, after a latent 
period during which risks are not increased, increased 
risks for leukemia will be observed within a certain time 
period and plateau afterwards. Because of this, they sug-
gest that risks may diminish or not be observed if a study 
has too long a follow-up period. This appears to be a post 
hoc explanation for the diminished risks associated with 
peak  exposure  observed  in  the  NCI  industrial  worker 
cohort with follow-up through 2004 vs. 1994 (in workers 
who died 16–25 years after the first exposure). It does not 
explain how risks were only observed with peak exposure, 
and not with other exposure metrics (particularly cumula-
tive number of peaks ≥4.0 ppm), or how this trend was not Formaldehyde as a leukemogen—Weight of evidence  591
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observed in the NCI embalmers cohort (Hauptmann et al., 
2003; Walrath and Fraumeni, 1984) or garment workers 
cohort (Pinkerton et al., 2004), in which risks were only 
observed with exposures ≥20 years. Also, Beane Freeman 
et al. (2009) did not test this hypothesis even though they 
had the data to do so. For all of these reasons, a shorter 
latency is not a scientifically valid explanation for the lack 
of observed risks by Beane Freeman et al. (2009).
4.3.7.  Recent formaldehyde meta-analyses do not support an 
association between formaldehyde exposure and leukemia
A number of recent meta-analyses have been conducted 
on the body of epidemiology studies concerning form-
aldehyde  and  leukemia  (Bachand  et  al.,  2009;  Zhang 
et al., 2009; Bosetti et al., 2008; Collins and Lineker, 2004; 
Schwilk et al., 2010). Only the most recent of these analy-
ses (Bachand et al., 2009; Schwilk et al., 2010) include the 
most recent update to the NCI industrial worker cohort; 
the others rely on the Hauptmann et al. (2003) analysis, in 
which 1006 deaths were omitted unintentionally. Of the 
five meta-analyses, three reported no overall association 
between  formaldehyde  and  leukemia  (Bachand  et  al., 
2009; Bosetti et al., 2008; Collins and Lineker, 2004), and 
methodological limitations of the other two meta-anal-
yses (Zhang et al., 2009; Schwilk et al., 2010), which are 
almost the same except for the addition of two studies in 
the latter, make it challenging to interpret their summary 
risk estimates (REs).
Bachand et al. (2009) found that, among cohort stud-
ies, REs for exposed vs. unexposed ranged from 0.43 to 
1.60  for  leukemia—none  were  statistically  significant 
(i.e., no 95% CI excluded 1.0)—and the summary risk 
estimate  indicated  no  association  (RE = 1.05,  95%  CI: 
0.91–1.20). Data from only two case-control studies were 
analyzed, neither of which reported increased risks (Blair 
et al. [2001]: RE = 0.98, 95% CI: 0.70–1.36; Partanen et al. 
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Figure 1.  Relative risks of leukemia in the NCI industrial worker cohort compared to study subjects in the low-exposure category for (a) 
peak, (b) average, and (c) cumulative formaldehyde exposure. The “no exposure” category is comprised of workers from facilities that were 
presumably unexposed. The only statistically significant trends were for peak exposure when the “no exposure” workers were included in 
the analyses; all other trend tests including or excluding the “no exposure” workers were null. (See colour version of this figure online at 
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[1993]: RE = 1.40, 95% CI: 0.25–7.91). No associations were 
observed when analyses were stratified by leukemia type 
(myeloid, lymphatic/lymphocytic, or other/unspecified), 
job type (professional/technical or industrial), or region 
(USA/Canada or Europe).
Bosetti  et  al.  (2008)  calculated  REs  for  lymphohe-
matopoietic  cancers  and  leukemia  among  profession-
als and industrial workers evaluated in cohort studies 
published through February 2007. Risks of lymphohe-
matopoietic cancers among professionals were increased 
(RE = 1.31, 95% CI: 1.16–1.48), but they were decreased 
among industrial workers (RE = 0.85, 95% CI: 0.74–0.96). 
Similarly, leukemia risks were elevated among profes-
sionals (RE = 1.39, 95% CI: 1.15–1.68), but not industrial 
workers (RE = 0.90, 95% CI: 0.75–1.07). Based on analy-
ses of 18 studies published through December 1, 2003, 
Collins and Lineker (2004) found similar results. They 
reported that leukemia risks were not increased among 
industrial workers (RE = 0.9, 95% CI: 0.8–1.0) or patholo-
gists and anatomists (RE = 1.4, 95% CI: 1.0–1.9), but were 
increased among embalmers (RE = 1.6, 95% CI: 1.2–2.0), 
who had among the lowest exposures.
In  contrast  to  the  three  meta-analyses  discussed 
above,  Zhang  et  al.  (2009)  found  a  significant  effect 
across  industries  (RE = 1.54,  95%  CI:  1.18–2.00).  This 
can  be  explained  by  the  unusual  means  of  selecting 
and  combining  studies:  they  used  different  measures 
of exposure, selecting only one from each study even 
if several were examined, resulting in selection of peak 
exposure for studies where available, then average expo-
sure and cumulative exposure for others, and, finally, 
exposure duration if none of the other metrics were ana-
lyzed. Zhang et al. (2009) claim this is because average 
and cumulative exposure may be less accurate measures 
of true exposure if workers with very high exposure also 
have long intervening periods with little or no exposure, 
but they have not considered whether these metrics are 
relevant for assessing risk. Moreover, if several catego-
ries or levels of exposure were examined, Zhang et al. 
(2009)  took  data  from  only  the  highest  among  them. 
What constituted a “high” category also varied consid-
erably  among  studies,  depending  on  how  each  study 
established gradations of exposure. As a consequence, 
the comparisons across studies are very heterogeneous, 
and it is not clear whether a comparable question was 
being examined in each case. Furthermore, by not using 
the entire range of exposure estimates (i.e., by examining 
risks in the high-exposure group vs. the low-exposure 
group only), exposure-response could not be assessed, 
which likely generated misleading results, since a lack of 
exposure-response can indicate a lack of a causal asso-
ciation. Finally, Zhang et al. (2009) did not use the most 
recent NCI industrial worker cohort data, instead relying 
on data from the Hauptmann et al. (2003) study, which 
didn’t account for over 1000 deaths in the cohort and 
only reported increased risks of myeloid leukemia based 
on internal comparisons that depended on the reference 
category and category cut points.
Schwilk et al. (2010) updated the Zhang et al. (2009) 
analysis by including the most recent NCI industrial 
worker  and  embalmer  cohort  studies  (Hauptmann 
et al., 2009; Beane Freeman et al., 2009) and reported 
increased  risks  of  leukemia  (RR = 1.53,  95%  CI: 
1.11–2.21)  and  myeloid  leukemia  (RR = 2.47,  95%  CI: 
1.42–2.47).  Because  Schwilk  et  al.  (2010)  use  similar 
methods  as  Zhang  et  al.  (2009),  their  study  suffers 
from the same limitations. In addition, Schwilk et al. 
(2010)  use  one-sided  p  values,  which  increased  the 
likelihood of false-positive results. They also reported 
several  exposure-response  relationships  in  six  stud-
ies and concluded an exposure-response association 
exists, but they did not discuss these associations for all 
exposure metrics from each study. As we have shown, 
had they done this, it would be evident that there are 
no consistent exposure-response associations between 
formaldehyde exposure and leukemia. Because of all 
these limitations, the results of the Zhang et al. (2009) 
and Schwilk et al. (2010) analyses should be interpreted 
with caution, especially in view of the substantial het-
erogeneity  and  their  lack  of  concordance  with  other 
meta-analyses.
Overall,  results  from  the  meta-analyses  of  form-
aldehyde and leukemia are consistent with a lack of 
association and the results of our weight-of-evidence 
evaluation.
4.4.  Summary
As a whole, the available formaldehyde epidemiology 
studies do not support a causal association between 
formaldehyde  exposure  and  leukemia.  As  demon-
strated  in  the  endpoint-by-endpoint  analysis  and 
Tables 4 to 13, there is no lymphohematopoietic cancer 
or group of lymphohematopoietic cancers for which 
associations  with  formaldehyde  were  found  consis-
tently within or across studies. Although some statisti-
cally significant associations were reported, these were 
outnumbered by null findings in the more robust stud-
ies using related exposure metrics, and there were no 
consistent exposure-response relationships observed. 
Limitations in exposure and cancer outcome assess-
ments as well as statistical analyses also likely affected 
calculations of risk.
If formaldehyde were truly a causal factor for leuke-
mia, consistent observations of effect should have been 
observed,  with  increased  risks  found  with  increased 
exposures. Because this is not the case, it is most likely 
that any observed effects were a result of confounders, 
limitations  in  statistical  methods  (e.g.,  multiple  com-
parisons),  disease  misclassification,  and/or  exposure 
misclassification/measurement error.
This question can be further explored by consider-
ing  information  on  toxicology  and  mode-of-action 
studies. It is a precept of the HBWoE approach that one 
considers  the  cross-discipline  integration  of  hypoth-
esized  effects.  To  the  degree  that  consideration  of 
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of inhaled formaldehyde to interact with and perturb 
hematopoiesis, this increases the relative plausibility 
of a conclusion that those associations seen in purely 
epidemiologic investigations are not in fact causal but 
are the result of chance, co-exposures, or confound-
ing, compared to an analysis that relies solely on the 
observed patterns seen among the epidemiology stud-
ies themselves. Moreover, if the dependence of effect on 
peak formaldehyde exposures that has been suggested 
in some epidemiology studies is indeed important in 
understanding  the  patterns  among  human  studies, 
this dependence ought to be reflected in information 
about  dosimetry  and  hypothesized  modes  of  action. 
Conversely, if hypothesized modes of action, if operat-
ing, would not be expected to produce a dependence 
on peak exposures, then the role of peaks in explaining 
positive and null results among human studies is weak-
ened. These issues will be discussed further below.
5.  Weight of evidence regarding 
hematotoxicity from formaldehyde exposure
In the following analysis, we examine a potential asso-
ciation between formaldehyde exposure and leukemia 
in animals and hematotoxicity as reflected by changes in 
peripheral blood hematology in both humans and ani-
mals. We conducted a literature search, using PubMed, 
for all human studies measuring or estimating formal-
dehyde exposure and the changes in peripheral blood 
hematology, in addition to all short- and long-term animal 
studies that investigated either potential formaldehyde-
associated  leukemogenicity  or  hematology  changes  in 
peripheral blood. Search terms included “hematology,” 
“hematotoxicity,” “leukemia,” “lymphoma,” “lymphohe-
matopoietic,”  “formaldehyde,”  “rat,”  “mouse,”  “rodent,” 
“human,”  and  “occupational.”  We  also  relied  on  refer-
ences within the papers that we found in the PubMed 
search  and  on  non-peer-reviewed  analyses  of  animal 
studies, which are part of the current debate on potential 
formaldehyde leukemogenicity.
Hematotoxicity may be defined as an insult that can 
be identified in blood and blood components. This tox-
icity is reflected in the production or loss of blood com-
ponents, including red blood cells (RBCs, erythrocytes), 
white  blood  cells  (WBCs,  leukocytes),  platelets,  and 
hemoglobin (Hb) (found in RBCs), responsible for car-
rying  oxygen.  Hematopoietic  progenitor  cells  (HPCs) 
in bone marrow give rise to RBCs and WBC subtypes—
neutrophils, lymphocytes (B and T types), monocytes, 
eosinophils,  basophils,  and  megakaryocytes,  from 
which platelets are derived (Cotran et al., 1999). There 
are three main types of myeloid progenitor cells that 
undergo several stages of differentiation to give rise to 
the blood cells (e.g., granulocyte-macrophage colony-
forming unit [CFU-GM] gives rise to granulocytes and 
macrophages) (Cotran et al., 1999). Blood-forming cells 
normally leave the bone marrow only when fully dif-
ferentiated, but a small number of progenitor cells can 
leave the bone marrow and circulate in blood (Aster 
and Kumar, 1999).
A decline in peripheral blood of one or more WBC 
type counts can result in leukopenia, that of RBCs, ane-
mia, and when all cell types in peripheral blood decline, 
pancytopenia. When the oxygen-carrying capacity of 
RBCs is compromised, new RBCs can be manufactured 
at a faster-than-usual rate, which may result in larger 
mean  RBC  size  (mean  corpuscular  volume,  MCV). 
Numerous factors can influence changes in blood com-
ponents. These include, but are not limited to, certain 
infections,  nutrient  imbalance,  xenobiotic  insults  to 
either blood components directly or to the bone mar-
row progenitor cells, alcohol intake, smoking, exces-
sive bleeding, menstruation, and certain medications 
(Mayo Clinic, 2008). Leukemogenesis may be viewed as 
a multistage process that involves interruption of the 
normal cellular differentiation process in the bone mar-
row and accumulation of the undifferentiated cells in 
bone marrow, a condition that crowds and suppresses 
the remaining normal hematopoietic progenitor cells. 
This suppression of normal hematopoiesis can result 
in anemia, leukopenia, and pancytopenia. Eventually, 
the undifferentiated, and abnormally functional, cells 
in bone marrow spill into peripheral blood and become 
the predominant cells there (Irons and Stillman, 1996; 
Aster and Kumar, 1999). As discussed in Section 5.3.3 
below,  most  known  leukemogens  can  cause  pancy-
topenia (a decline in all cell types in peripheral blood) 
that is secondary to bone marrow toxicity. In addition 
to pancytopenia, bone marrow toxicity has been asso-
ciated with decreased counts or viability of circulating 
blood cells, including progenitor cells (Dempster and 
Snyder, 1991; Toft et al., 1982, both as cited in ATSDR 
2007).
5.1.  Formaldehyde hematotoxicity in animals
5.1.1.  Hematology
Several  animal  studies  have  assessed  the  hematotoxic 
potential of formaldehyde via both oral and inhalation 
routes. As shown in Table 14, these studies ranged from 
subacute to chronic in duration (4 weeks to 24 months) 
and used a wide range of exposure concentrations; the 
highest  was  5000  ppm  in  drinking  water  (Tobe  et  al., 
1989) and 20 ppm in air (Woutersen et al., 1987).
As  shown  in  Table  14,  the  results  from  the  inhala-
tion studies generally show that formaldehyde does not 
induce changes in standard hematology parameters in 
peripheral blood. One study (Dean et al., 1984) showed a 
significant (p < .05) decrease in monocytes, but not other 
leukocytes, in the blood of B6C3F1 mice after 3 weeks 
of exposure to 15 ppm formaldehyde, but no exposure-
related changes in either bone marrow cellularity or CFU 
progenitor cell counts. In contrast, a longer-term study 
by Kerns et al. (1983) in the same mouse strain found no 
changes in hematology.
The  results  of  the  ingestion  exposure  studies  are 
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formaldehyde. For example, the studies by Appelman 
et  al.  (1988),  Johannsen  et  al.  (1986),  and  Til  et  al. 
(1988, 1989) did not find any changes in hematology 
with exposure. Tobe et al. (1989) reported statistically 
significant lowered RBC counts and Hb concentrations, 
but  these  changes  were  not  exposure-concentration 
dependent.  The  results  by  Tobe  et  al.  (1989)  were 
contradicted  by  Vargova  et  al.  (1993),  who  reported 
increased hematocrit (Hct) and Hb concentrations and 
RBC counts in blood. Furthermore, statistically signifi-
cant changes in WBC counts following oral exposure to 
formaldehyde were found by Vargova et al. (1993) as 
increased monocyte counts and decreased lymphocyte 
counts only following exposure to very high doses (as 
high as 80 mg/kg for 4 weeks, equivalent to ~800 ppm 
in drinking water).
5.1.2. Leukemia
We  reviewed  eight  animal  studies  investigating  the 
tumorigenic potential of formaldehyde by inhalation 
(Kerns et al., 1983; Kamata et al., 1997; Albert et al., 
1982;  Feron  et  al.,  1988)  and  ingestion  (Tobe  et  al., 
1989;  Til  et  al.,  1989;  Takahashi  et  al.,  1986;  Soffritti 
et al., 1989, 2002). We also considered two unpublished 
and non-peer-reviewed analyses (DeVoney et al., 2010, 
poster abstract only; Woutersen, 2007) of data from the 
Battelle Columbus Laboratories (1981) study that was 
later published by Kerns et al. (1983). Animal inhala-
tion studies generally showed significantly increased 
rates of nasal tumors (Kerns et al., 1983; Kamata et al., 
1997; Sellakumar et al., 1985) but, as shown in Table 15, 
not of leukemias or lymphomas, when these endpoints 
were  investigated.  Ingestion  studies  showed  neither 
increased rates of nasal nor hematopoietic malignan-
cies in rats. We have limited our review to analyzing 
potential formaldehyde-associated changes in leuke-
mia and lymphoma rates in the exposed animals. Table 
15 describes the animal species, exposure characteris-
tics, and hematopoietic malignancy outcomes of the 
studies discussed in this section.
Battelle  Columbus  Laboratories  (1981)  exposed 
Fischer  344  rats  and  B6C3F1  mice  via  inhalation  to 
formaldehyde for 2 years. As shown in Table 15, tumor 
incidence  data  from  Battelle  Columbus  Laboratories 
(1981) were analyzed by Kerns et al. (1983), DeVoney 
et al. (2010 poster abstract), and Woutersen (2007) but 
with different outcomes. Whereas DeVoney et al. (2010 
poster abstract) reported elevated lymphoma incidence 
in female B6C3F1 mice and elevated leukemia incidence 
in female Fischer 344 rats, Woutersen’s analysis found 
increased  lymphoma  incidence  only  in  female  mice, 
immediately after exposure, although this trend showed 
no statistically significant association for formaldehyde 
when the 3-month period following exposure was con-
sidered (Woutersen, 2007). Kerns et al. (1983) reported 
no formaldehyde-associated elevated rates of leukemia 
or lymphoma in this study in either rats or mice. It is 
noteworthy that the leukemias found in Fischer 344 rats 
by Battelle Columbus Laboratories (1981) likely included 
mononuclear cell leukemias (MCLs), which are usually 
observed  in  ~50%  and  ~28%  of  unexposed  male  and 
female  Fischer  344  rats,  respectively  (Haseman  et  al., 
1998). This high background incidence of MCLs in rats 
brings into question the outcomes and resulting conclu-
sions  of  these  non-peer-reviewed  results  by  DeVoney 
et al. (2006 poster, 2010 poster abstract). Furthermore, as 
discussed by Ishmael and Dugard (2006), any MCL coun-
terpart in humans is rare, MCLs are more likely elevated 
by chemical exposure in Fischer rats but not in Osborne 
Mendel or Sprague Dawley rats, and MCL incidence can 
be reduced by type of chemical delivery vehicle, such 
as corn oil, all which suggest that any positive findings 
involving MCL incidence in animals may not be relevant 
in humans.
Four studies, all of which used rats, assessed the tum-
origenicity of formaldehyde from drinking water. The 
exposure concentrations were as high as 5000 ppm in 
water. Exposure durations were either 2 years (Soffritti 
et al., 1989, 2002; Til et al., 1989; Tobe et al., 1989) or 32 
weeks preceded by 8 weeks of treatment with a tumor 
initiator,  N-methyl-N’-nitrosoguanidine  (Takahashi 
et al., 1986). Of these studies, only Soffritti et al. (1989, 
2002)  reported  statistically  significantly  increased 
hematopoietic  malignancies  (i.e.,  lymphomas  and 
leukemias).
Soffritti  et  al.  (1989)  performed  two  experiments. 
In the first experiment, the authors exposed male and 
female Sprague Dawley rats to 0, 10, 50, 100, 500, 1000, 
or 1500 ppm of formaldehyde in drinking water for 2 
years.  The  authors  reported  an  increase  in  leukemia 
incidence at concentrations above 50 ppm (specifically, 
lymphoblastic leukemias and lymphosarcomas, immu-
noblastic  lymphosarcomas,  and  “other  leukemias,” 
although  the  anatomic  location  of  these  neoplasms 
was not indicated). The increase, particularly in immu-
noblastic lymphosarcomas, was not exposure related, 
however. Moreover, the lack of statistical analysis of the 
data in this report does not allow a full assessment of 
cause and effect. In the second experiment, the authors 
exposed male and female Sprague-Dawley breeder rats 
and their male and female offspring to regular drinking 
water and drinking water containing 2500 ppm form-
aldehyde.  The  authors  reported  increased  leukemia 
rates  (specifically  immunoblastic  lymphosarcomas 
and “other leukemias”) for each of the male and female 
breeder  groups  and  the  male  offspring  group,  but 
there was no incidence in the female offspring group. 
The lack of statistical analysis for this experiment also 
precludes proper data assessment. In their subsequent 
report of this same study, Soffritti et al. (2002) presented 
the results from only the first experiment mentioned 
above, but these results differed from the earlier report 
by Soffritti et al. (1989). The authors neither explained 
why they included only one experiment in this report 
nor  addressed  the  differences  in  reported  outcomes 
between reports.Formaldehyde as a leukemogen—Weight of evidence  595
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5.2.  Formaldehyde hematotoxicity in humans
There  are  limited,  mostly  occupational,  studies  in 
humans of the hematotoxic effects of exposure to form-
aldehyde. Tang et al. (2009) recently abstracted data from 
eight studies conducted in China that assessed WBC and 
platelet counts and Hb concentration in subjects occupa-
tionally exposed to formaldehyde (Yang et al., 2007; Kuo 
et al., 1997; Cheng et al., 2004; Xu et al., 2007; Qian et al., 
1988; Feng et al., 1996; Tang et al., 2003; Tong et al., 2007, 
all as cited by Tang et al., 2009). The findings by Kuo et al. 
(1997), the only study of hematological effects cited by 
Tang et al. (2009) available in English, are associated with 
several uncertainties that weaken the conclusions drawn 
by Tang et al. (2009) about these effects. Many questions 
arise about the outcomes and exposure-related uncer-
tainties in the findings of the other, untranslated, studies 
cited by Tang et al. (2009) (Section 5.3.2 provides further 
discussion of this point). We found four other studies 
that assessed hematological parameters associated with 
formaldehyde exposure (Ye et al., 2005; Lyapina et al., 
2004; Srivastava et al., 1992; Zhang et al., 2010b). Table 16 
describes the exposure characteristics and hematology 
outcomes, as available, of the studies discussed in this 
section.
In the China-based hematotoxicity studies reported 
in Tang et al. (2009), the leukocyte counts in the exposed 
subjects were generally lower than in the control sub-
jects, but differences were statistically significant in only 
four (Yang et al., 2007; Cheng et al., 2004; Qian et al., 
1988; Tong et al., 2007, all as cited by Tang et al., 2009) of 
the eight studies. Feng et al. (1996, as cited by Tang et al., 
2009), Xu et al. (2007, as cited by Tang et al., 2009), and 
Tang et al. (2003, as cited by Tang et al., 2009) did not find 
statistically  significant  differences  in  leukocyte  counts 
related to formaldehyde exposure. Several studies found 
an inverse correlation between duration of exposure to 
formaldehyde and leukocyte counts (Tong et al., 2007; 
Yang et al., 2007; Tang et al., 2003; Kuo et al., 1997, all as 
cited by Tang et al., 2009), but the relationship was only 
reported as statistically significant in the study by Kuo 
et al. (1997, as cited by Tang et al., 2009).
Ye et al. (2005) assessed lymphocyte subset counts in 
peripheral blood in student controls (living in dorms), 
factory workers (8.6 years mean duration of exposure), 
and ballroom waiters (12 week exposure duration), all 
non-smokers.  The  formaldehyde  concentration  was 
0.8 ppm in the factory, 0.09 ppm in the ballroom, and 
0.009 ppm in the dorms. As shown in Table 16, differ-
ences in percentage of lymphocyte subset counts among 
groups were limited to statistically significantly increased 
B lymphocytes, and decreased CD3 (total T cells) and 
CD8  (T-cytotoxic),  but  not  CD4  (T-helper-inducer),  T 
lymphocytes, in the workers as compared with the stu-
dents. The change in CD3 cells (~5% decrease) appeared 
to  be  driven  by  CD8  cells  (~25%  decrease).  It  is  not 
apparent why CD3 and CD8 cells decrease, but not CD4. 
Since total T cells were decreased, however, it is possible 
that there was no need for the helper T cells (CD4) and 
therefore no change was observed relative to controls. 
Nevertheless, this is an interesting finding by Ye et al. 
(2005)  and  warrants  further  investigation  of  lympho-
cyte subset dynamics. Further, since this study shows 
statistically  significant  changes  in  both  B-  and  T-cell 
populations, it is likely that any effect attributed to form-
aldehyde exposure is immune and acquired and did not 
originate from an insult to the bone marrow. It would 
be interesting to know the counts in peripheral blood of 
RBCs and WBCs, other than lymphocytes, to shed light 
on potential bone marrow involvement, but these data 
were not available for this study.
Lyapina et al. (2004) found no significant differences 
in standard hematology tests of workers applying form-
aldehyde-carbamide  glue  when  compared  with  those 
from subjects with no known appreciable formaldehyde 
exposure  (formaldehyde  levels  not  reported  for  either 
group).  The  authors  reported  a  statistically  significant 
inverse relationship, however, between the duration of 
occupational exposure to formaldehyde and RBC count, 
but there was no relationship with WBC count. Similarly, 
Srivastava  et  al.  (1992)  found  decreased  Hb  concen-
trations in the blood of three of six workers who were 
involved in producing and preparing melamine-formal-
dehyde resin. However, it is not readily apparent whether 
the differences in RBC count and hemoglobin are related 
to  formaldehyde  exposure  since  this  study  included  a 
limited number of subjects. In addition, this study found 
increased total lymphocytes (>3200 per mm3 of blood) in 
three of six workers. The authors of this study indicated 
that the subjects were exposed to relatively high levels of 
formaldehyde at different times during the day.
Recently, Zhang et al. (2010b) investigated the asso-
ciations  between  formaldehyde  exposure  and  various 
hematology parameters in subjects working with formal-
dehyde-melamine resin in two factories in China (median, 
1.28  ppm  formaldehyde)  as  compared  with  volunteer 
subjects from three other factories with lower formalde-
hyde levels (median, 0.026 ppm). Formaldehyde can dis-
sociate from the melamine resin, become airborne, and 
be inhaled by the factory workers. The workers were pos-
sibly also exposed to formaldehyde dermally, and sub-
ject to potential formaldehyde-induced skin reactions, if 
they touched the resin with their bare skin. The authors 
assessed personal workplace exposures to formaldehyde 
in air on 3 days for a full shift (>6 hour/shift) and to other 
volatile organic compounds (VOCs), including benzene, 
on two or three occasions within a 3-week period. The 
authors matched exposed and control subjects by age 
and sex; however, there were considerably different rates 
of current alcohol drinkers (yes/no answer) and recent 
respiratory infections (yes/no answer) in the exposed as 
compared with the control subjects (26% vs. 41% and 40% 
vs. 29%, respectively). Alcohol intake and recent respira-
tory infections can influence WBC counts. As shown in 
Table 16, Zhang et al. (2010b) report statistically signifi-
cant lower counts of total WBCs, lymphocytes, granulo-
cytes, platelets, and RBCs in addition to a higher MCV, 596  L. R. Rhomberg et al.
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but not monocytes or Hb concentration in exposed sub-
jects relative to controls. In addition, the authors found 
no statistically significant difference in the growth of cir-
culating CFU-GM hematopoietic progenitor cells ex vivo 
between exposed and control subjects.
In the following section, we weigh the evidence from 
human  and  animal  studies  discussed  in  Sections  5.1 
and 5.2 to assess the likelihood of a hematotoxic role for 
formaldehyde.
5.3. HBWoE evaluation of formaldehyde 
hematotoxicity studies
Based on the available data summarized above, some 
have hypothesized that formaldehyde may cause hema-
totoxicity and leukemia in humans. We ask the following 
questions with regard to this hypothesis:
Do animal studies suggest formaldehyde exposure is  1. 
causally associated with hematotoxicity and leukemia?
What do the human studies tell us about potential  2. 
formaldehyde  hematotoxicity  in  humans?  Are  the 
results  of  human  studies  consistent  with  those  of 
animal studies?
What is known about the hematotoxicity of known  3. 
leukemogens  (e.g.,  benzene)  from  animal  and 
human  studies  and  how  does  that  compare  to 
formaldehyde?
Are there alternative explanations for decreased WBC  4. 
and RBC counts?
 As a whole, considering these questions allows for an 
assessment of the extent to which the hematotoxicity and 
animal leukemia data support either a causal association 
between  formaldehyde  exposure  and  leukemia  or  an 
alternative hypothesis. Importantly, one needs to con-
sider the hematotoxicity and animal leukemia data in the 
context of the epidemiology and mode-of-action data, as 
each of the three lines of evidence inform interpretation 
of each other.
Table 14.  Formaldehyde animal hematotoxicity studies.
Study Species Sex
Exposure Outcomes
Concentration Duration RBC, Hct, Hb WBC
Inhalation studies
Monticello et al., 1989 Monkey, 
rhesus
Male 0, 6 ppm 6 h/d, 5 d/wk, 6 wk NS NS
Appelman et al., 1988 Rat, Wistar Male 0, 0.1, 1, 10 ppm 6 h/d, 5 d/wk, 13 or 
52 wk
NS NS
Holmstrom et al., 1989 Rat, Sprague-
Dawley
Female 0, 12.6 ppm 6 h/d, 5 d/wk, 22 mo NS NS
Kerns et al., 1983 Rat, 
Fischer 344
Female, Male 0, 2.0, 5.6, 14.3 ppm 6 h/d, 5 d/wk, 24 mo 
with follow-up till 
30 mo
NS NS
As above Mouse, 
B6C3F1
Female, Male As above As above NS NS
Dean et al., 1984 Mouse, 
B6C3F1
Female 0, 15 ppm 6 h/d, 5 d/wk, 3 wk NS ↓ monocytes 
Other cell types NS
Kamata et al., 1997 Rat, 
Fischer 344
Male 0, 0.3, 2, 15 ppm 6 h/d, 5 d/wk, 28 mo NS NS
Woutersen et al., 1987 Rat, Wistar Female, Male 0, 1, 10, 20 ppm 6 h/d, 5 d/wk, 13 wk NS NS
Ingestion Studies
Vargova et al., 1993 Rat, Wistar Male 0, 20, 40, and 
80 mg/kg bw/d
5 d/wk, 4 wk; gastric 
intubation
↑ at 40, 
80 mg/kg/d
↑ monocytes 
↓ lymphocytes
Til et al., 1989 Rat, Wistar Female 0, 1.8, 21, 109 mg/
kg bw/d
Daily, 24 mo, 
drinking water
NS NS
As above Rat, Wistar Male 0, 1.2, 15 or 82 mg/
kg bw/d
Daily, 24 mo, 
drinking water
NS NS
Til et al., 1988 Rat, Wistar Female, Male 5, 25 and 125 mg/
kg bw/d
Daily, 4 wk NS NS
Johannsen et al., 1986 Rat, 
Sprague-
Dawley
Female, Male 0, 50, 100, 150 mg/
kg/d
Daily, 3 mo NS NS
As above Dog, Beagle Female, Male 0, 50, 75, 100 mg/
kg/d
Daily, 3 mo NS NS
Tobe et al., 1989 Rat, Wistar Female, Male 0, 200, 1000, 5000 
ppm (0, 10, 50, 
300 mg/kg bw/d)
Daily, 24 mo, 
drinking water
↓, not 
concentration 
dependent
Assessed, NR
Note. WBC = white blood cell count in peripheral blood; RBC = red blood cell count in peripheral blood; Hct = hematocrit; 
Hb = hemoglobin concentration in blood; NS = not statistically significant; ↓ = statistically significant decrease; ↑ = statistically significant 
increase; mg/kg bw/d = milligram per kilogram body weight per day; ppm = parts per million; wk = week(s); mo = month(s).Formaldehyde as a leukemogen—Weight of evidence  597
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5.3.1.  Key animal studies do not provide strong evidence 
of an association between formaldehyde exposure and 
hematotoxicity and leukemia
5.3.1.1. Hematology  Known leukemogens, such as ben-
zene, can cause bone marrow toxicity, which affects the 
ability of bone marrow cells to produce blood-forming 
cells  (ATSDR,  2007).  As  discussed  in  the  introduction 
to this section, this toxicity can be manifested in bone 
marrow  suppression  and  pancytopenia,  a  generalized 
decrease  of  blood  cellular  components.  This  insult  to 
bone marrow may progress to a malignancy that shows a 
predominance in production of one or more cell types in 
bone marrow that spill into peripheral blood.
We examined the available formaldehyde animal stud-
ies for signs of hematotoxicity as reflected in peripheral 
blood. Of 12 studies we reviewed, 9 reported no change 
in hematology parameters (see Table 14). These studies, 
which ranged from exposures lasting a few weeks to lon-
ger than 2 years, spanned a range of concentrations and 
durations that would be sufficient to show any changes 
in hematology.
Three studies reported a change in one or more hema-
tology parameter: Dean et al. (1984) by inhalation, and 
Tobe et al. (1989) and Vargova et al. (1993) by oral expo-
sure. However, these outcomes were mixed. For example, 
Dean et al. (1984) reported a decrease in monocytes but 
no other hematology parameter, whereas Vargova et al. 
(1993) reported an increase in monocytes but a decrease 
in lymphocyte counts. Vargova et al. (1993) also found 
increased  Hct,  Hb  concentration,  and  RBC  counts  in 
blood, in contrast to results from Tobe et al. (1989), which 
indicated decreased Hb concentrations and RBC counts. 
It is noteworthy that the changes in the aforementioned 
studies resulted from very high exposures, particularly in 
oral exposure studies, ranging from 40 to 300 mg/kg body 
weight/day  (approximately  800–5000  ppm  in  drinking 
water), as noted in Table 14.
Overall, the hematological ingestion and inhalation 
studies of formaldehyde we reviewed are inconsistent and 
eclipsed by overwhelming evidence from the same and 
other species of animals that show no change in hematol-
ogy parameters. When found, the statistically significant 
changes are likely not related to formaldehyde exposure, 
particularly because they arise among many other statis-
tically insignificant associations. Further, if bone marrow 
toxicity had occurred, it is likely that declines in more 
than one blood cell type would have been observed, such 
as is established for benzene (discussed in Section 5.3.3), 
and that was not reported by the authors of any of the 
studies we reviewed.
5.3.1.2.  Leukemia  We  also  analyzed  the  outcomes  of 
animal  studies  that  examined  the  carcinogenicity  of 
formaldehyde  by  inhalation  or  ingestion.  The  major-
ity of these studies, listed in Table 15 and discussed in 
Section 5.1, found no excess hematopoietic malignan-
cies  associated  with  formaldehyde  exposure  (Albert 
et al., 1982; Kerns et al., 1983; Sellakumar et al., 1985; 
Kamata et al., 1997; Feron et al., 1988; Til et al., 1989; 
Tobe et al., 1989; Takahashi et al., 1986). However, the 
studies by Soffritti et al. (1989, 2002), the unpublished 
data from the DeVoney et al. (2010 poster abstract), and 
Woutersen’s (2007 presentation) analyses of data from 
Battelle Columbus Laboratories (1981) found increased 
incidence of hematopoietic malignances from formalde-
hyde ingestion and inhalation, respectively.
Soffritti et al. (1989) performed two carcinogenicity 
experiments by ingestion and reported statistically sig-
nificantly increased hematopoietic malignancies in two 
reports (Soffritti et al., 1989, 2002) described in Section 
5.1 and Table 15, the results of which are inconsistent 
and have been criticized by both ATSDR (1999) and the 
European Food Safety Authority (EFSA, 2006) as unreli-
able.  The  lack  of  confidence  in  the  results  by  Soffritti 
et al. (1989, 2002) stems, in part, from concerns about 
the  rodent  colony  where  the  experiments  occurred. 
Feron et al. (1990) suggested that the elevated leukemia 
incidence might have been “unrelated to formaldehyde 
ingestion,” because of the wide range of incidence rates 
of hematopoietic malignancies in control animals from 
the same colony—as high as 19%. Moreover, a possible 
infection of the rat colony by Mycoplasma pulmonis (an 
organism  that  preferentially  colonizes  the  respiratory 
tract in rats and secretes substances that can promote 
mitogenesis in lymphocytes) also has been presented as 
a potential confounder for hematolymphopoietic malig-
nancies reported by Soffritti et al. (1989, 2002).
Other studies examining formaldehyde carcinogenic-
ity via the oral route did not indicate an increased inci-
dence of hematopoietic malignancies relative to control 
exposures.  The  longer-term  carcinogenicity  studies  by 
both Til et al. (1989) and Tobe et al. (1989) showed no 
increase in these malignancies after 2 years of exposure 
and  follow-up,  consistent  with  Takahashi  et  al.  (1986) 
who only followed animals for 40 weeks.
As  reported  in  conference  posters,  DeVoney  et  al. 
(2006 poster, 2010 poster abstract) reevaluated data from 
Battelle  Columbus  Laboratories  (1981)  and  reported 
increased lymphoma incidence rates for female B6C3F1 
mice exposed to ~15 ppm by inhalation (28% vs. 18% 
in  exposed  vs.  control  mice,  respectively).  According 
to Haseman et al. (1998), the background rate for lym-
phoma  in  these  female  mice,  based  on  1092  control 
mice used in National Toxicology Program (NTP) stud-
ies, is 19.9%, with a range of 6% to 44% in all studies 
examined.  Therefore,  the  rates  reported  by  DeVoney 
et al. (2006 poster, 2010 poster abstract) fall within back-
ground tumor rates for the rodent species use in Battelle 
Columbus Laboratories (1981) and do not provide suf-
ficient  evidence  for  formaldehyde  leukemogenicity. 
These non-peer-reviewed results by DeVoney et al. (2006 
poster, 2010 poster abstract) are contrasted by another 
evaluation of Battelle Columbus Laboratories (1981) data 
by Woutersen (2007) (as presented at the Formaldehyde 
International  Science  Conference),  who  found  a  sta-
tistically  significant  increased  trend  in  lymphoma  for 600  L. R. Rhomberg et al.
  Critical Reviews in Toxicology
only female mice among the rodent species and sexes 
examined.  Moreover,  there  was  no  statistically  signifi-
cant association with formaldehyde when post-exposure 
follow-up data (3-month period) was considered. When 
considering  the  three  distinct  analyses  of  the  Battelle 
Columbus  Laboratories  (1981)  carcinogenicity  data, 
in addition to the high background tumor rates in the 
rodent species examined, it becomes less likely that the 
Table 16.  Human hematotoxicity studies.
Study Exposure (ppm)
Number 
of persons 
(exposed, 
control)
% change in WBC count 
between groups or % of 
subjects with decreased 
hematology parameters
Peripheral blood changes
Other findings Total WBC Platelets Hb
Yang et al., 
2007*
0.018–0.036 239, 200 WBCs: 14% (E) vs. 4% (C) 
Platelets: 11% (E) vs. 1% (C) 
RBCs: 32% (E) vs. 21.5% (C)
↓↓ ↓↓ ↓↓  
Kuo et al., 
1997
ND–0.054 
(personal 
samples) 
0.006–
0.237(area 
samples)
50, 71 NA ↓ NS NS Statistically significant 
(−0.33, p < .05) inverse 
relationship between 
FA and WBC counts, but 
not 11 other hematology 
parameters
Cheng et al., 
2004*
0.2–0.76 72, 150 WBCs: 14% in E vs. 5% in C ↓ NA NA  
Lyapina et al., 
2004
0.52–1.049 
(mean, 0.71)
29, 21 NA NS NS NR Statistically significant 
inverse relationship 
between duration of 
exposure to formaldehyde 
and RBC counts and Hct
Xu et al., 
2007*
0.36–5.56 10, 10 −11.4 NS NS NS  
Ye et al., 2005 0.8 (8-h TWA), 
1.38 (max) in 
workers; vs. 
0.009 (mean), 
0.012 (max) in 
controls
36, 6 NA NA NA NA Workers vs. students 
in dorms. Statistically 
significantly increased B 
lymphocytes. Statistically 
significantly decreased 
CD3 and CD8 but not 
CD4 T lymphocytes in 
peripheral blood
As above 0.09 (5-h TWA), 
0.24 (max); vs. 
0.009 (mean), 
0.012 (max) in 
controls
18, 6 NA NA NA NA Waiters vs. students in 
dorms. No change in B or 
T lymphocytes counts in 
peripheral blood
Zhang et al., 
2010b
0.63–2.51 
(mean, 1.28)
43, 51 −13.5 ↓↓ ↓ NS Decreased RBC; increased 
MCV (statistically 
significant)
Qian et al., 
1988*
2.44 (estimated) 55, 41 −13.3 ↓↓↓ NA NA Increase in 
immunoglobulins (Ig) IgM 
and IgA, and eosinophils 
(no statistical significance 
reported)
Feng et al., 
1996*
0.57–15.61 104, 68 NA NS NA NS  
Srivastava 
et al., 1992
NR 6, 0 Increased blood 
lymphocyte counts in 3 of  
6 subjects
NA NA Decrease Decreased Hb in 4 of 6 
subjects
Tang et al., 
2003*
NR 110, 120 −17.1 NS NA NA Decreased WBC count 
with increasing work years 
(no statistical significance 
reported)
Tong et al., 
2007*
NR 65, 70 −18 ↓↓↓ ↓↓↓ NS WBC and platelet counts 
decreased with increasing 
work years (no statistical 
significance reported)
Note. E = exposed group; C = control group; NR = not reported; NS = not statistically significant; NA = not applicable/available; WBC = white 
blood cell count in peripheral blood; RBC = red blood cell count in peripheral blood; Hct = hematocrit; Hb = hemoglobin content of RBCs; 
↓ = statistically significant decrease (p < .05); ↓↓ = statistically significant decrease (p < .01); ↓↓↓ = statistically significant decrease (p < .001).
* As cited in Tang et al. (2009). These studies are in Chinese and are not available on PubMed.Formaldehyde as a leukemogen—Weight of evidence  601
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reported inconsistent increased lymphoma incidence is 
related to formaldehyde exposure.
The rates presented by DeVoney et al. (2006 poster, 
2010 poster abstract) for hematopoietic malignancies in 
female Fischer 344 rats demonstrate no dose-response 
for  leukemia;  the  authors  found  25%,  23%,  and  24% 
leukemia incidence in rats exposed to 2, 6, and 15 ppm 
formaldehyde vs. 15% in control rats. Similarly, the leu-
kemia rates in both exposed and control rats were either 
below or within the range of leukemia incidence in the 
controls  used  in  NTP  studies,  which  Haseman  et  al. 
(1998) lists as 37% (range, 24% to 54%) for leukemia in 
female Fischer 344 rats. Noteworthy is that the leukemias 
found in Fischer 344 rats likely included MCLs, which 
are usually observed in ~50% and ~28% of unexposed 
male and female Fischer 344 rats, respectively (Haseman 
et al., 1998). This high background incidence of MCLs 
in rats brings into question the validity of the unpub-
lished results by DeVoney et al. (2006 poster; 2010 poster 
abstract). Further, as discussed in Section 5.1.2, above, 
MCLs are not observed in humans, and findings involv-
ing MCL incidence in animals may not be relevant in 
humans.
The  results  by  Soffritti  et  al.  (1989,  2002)  and  the 
unpublished  reanalysis  by  DeVoney  et  al.  (2006 
poster; 2010 poster abstract) of the Battelle Columbus 
Laboratories  (1981)  data  do  not  provide  appreciable 
support for formaldehyde-induced leukemia in rodents. 
These  results  are  unlikely  to  indicate  formaldehyde 
leukemogenicity,  particularly  when  weighed  against 
the relatively high background rates of hematopoietic 
malignancies in the mouse and rat species used in these 
studies and the overwhelmingly negative results from 
nine  other  carcinogenicity  studies  in  rats  and  mice. 
Finally, it is not surprising that most studies show no 
change in leukemia incidence with formaldehyde expo-
sure since most studies, short- and long-term, showed 
no change in hematology parameters, which are impor-
tant  precursors  in  the  chain  of  events  for  chemically 
induced leukemia.
5.3.2.  Key human studies do not provide strong evidence 
of an association between formaldehyde exposure and 
hematotoxicity
The  studies  that  associate  hematology  parameters  in 
humans  with  formaldehyde  exposure  are  generally 
cross-sectional in nature. Cross-sectional environmental 
toxicology studies frequently involve concurrent obser-
vation of a biological endpoint and exposure to an envi-
ronmental agent at a single point in time or over a short 
time duration. Except for a few studies, no information 
was available on either the methods of exposure assess-
ment  of  formaldehyde  or  the  assessment  of  potential 
confounding effects from known hematotoxicants such 
as benzene. For some studies, formaldehyde exposure 
information was absent altogether (see Table 16).
We  investigated  whether  a  possible  exposure-re-
sponse  pattern  existed  between  the  reported  airborne 
formaldehyde  concentrations  and  the  reported  hema-
tology  responses  in  the  studies  that  we  reviewed.  The 
results of studies based in China and cited by Tang et al. 
(2009) do not show an exposure-response relationship 
between  formaldehyde  concentrations  and  hematol-
ogy parameters. For example, the study by Feng et al. 
(1996, as cited by Tang et al., 2009) reportedly showed 
no association between very high formaldehyde expo-
sures  (range,  0.57–15.61  ppm)  and  either  changes  in 
WBC counts or Hb concentrations in peripheral blood. 
Xu et al. (2007, as cited by Tang et al., 2009) also found 
no significant differences in Hb concentrations or WBC 
and platelet counts in association with relatively elevated 
formaldehyde exposures ranging from 0.36 ppm to 5.56 
ppm. In contrast, Qian et al. (1998, as cited by Tang et al., 
2009) estimated formaldehyde exposure to be 2.44 ppm, 
and found a statistically significant association between 
this concentration and a lower WBC count. In addition, 
some studies with lower formaldehyde exposures were 
statistically significantly associated with decreased WBC 
counts and other hematology parameters. For example, 
Cheng et al. (2004, as cited by Tang et al., 2009) found 
decreased WBC counts in individuals exposed to form-
aldehyde concentrations ranging from 0.2 ppm to 0.76 
ppm, whereas Yang et al. (2007, as cited by Tang et al., 
2009) found similar associations at lower concentrations 
not exceeding 0.036 ppm. When examining the hema-
tology outcomes of the studies we reviewed (shown in 
Table 16), we found no consistent exposure-dependent 
pattern in either qualitative or quantitative changes.
Moreover,  using  the  data  presented  by  Tang  et  al. 
(2009), we determined the percent change or difference 
in  total  WBC  counts  between  exposure  groups  when 
these counts were available; as shown in Table 16, WBC 
counts were between 11% and 19% lower in exposed vs. 
control subjects. However, when examining the studies 
altogether, we did not find dose dependency in the WBC, 
platelet, or Hb associations with formaldehyde exposure 
measurements.
Some of the Chinese occupational studies that reported 
significantly lower WBC concentrations in exposed sub-
jects also reported formaldehyde concentrations in air 
that were lower than those expected outside of work. For 
example, the air concentration ranges reported by Zhang 
et al. (2010b) (median, 0.026 ppm), by Yang et al. (2007, as 
cited by Tang et al., 2009) (0.018–0.036 ppm), and by Kuo 
et al. (1997) (ND–0.054 ppm) overlap with concentrations 
reported in indoor public places in several Chinese cities 
(0.12 ppm [range, 0.02–0.31 ppm] as reported by Tang 
et al. [2009] from the Chinese Ministry of Health). These 
data suggest that results based on workplace exposure to 
formaldehyde may be confounded by non-occupational 
exposures, which can be as high or even higher than the 
occupational exposures. Appreciable non-occupational 
sources of formaldehyde exposure exist, particularly in 
China, where most of the human formaldehyde hematol-
ogy studies have been conducted. Formaldehyde con-
centrations in indoor air of homes have been measured 602  L. R. Rhomberg et al.
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up to 0.5 ppm in China (mean, 0.19 ppm) and certain 
dietary items have been found to contain several hun-
dreds or even thousands of milligrams of formaldehyde 
per  kilogram  (as  reviewed  by  Tang  et  al.,  2009).  The 
authors’ lack of accounting for non-occupational sources 
of formaldehyde exposure adds to the uncertainties in 
the study outcomes and diminishes their credibility for a 
hematotoxic role for formaldehyde.
There  are  many  uncertainties  about  the  Chinese 
hematology  studies  as  reported  by  Tang  et  al.  (2009). 
For example, Tang et al. (2009) suggest that Kuo et al. 
(1997) shows a statistically significant inverse relation-
ship  between  formaldehyde  concentrations  and  WBC 
counts. Although Kuo et al. (1997), the only study among 
those  cited  by  Tang  et  al.  (2009)  available  in  English, 
indeed shows such an association (−.33, p < .05), it does 
not  show  a  significant  relationship  between  exposure 
measurements  and  11  other  hematology  parameters, 
including RBC and individual WBC-type counts. Further, 
the authors collected peripheral blood on two occasions 
1 year apart and found associations only with the second 
but not the first blood sample. Subjects in the Kuo et al. 
(1997) study were employed for an average of 3 years at 
the study locations; if the association between formal-
dehyde exposure and this lone hematology parameter is 
real, then it should have been consistent in both blood 
samples collected. When considering the uncertainties 
associated with this readily obtainable study (Kuo et al., 
1997), many questions arise about the full outcomes and 
exposure-related uncertainties in the findings of the other 
studies cited by Tang et al. (2009) (which are unavailable 
in English).
The  most  recent  study  to  assess  hematotoxicity  in 
humans exposed to formaldehyde is Zhang et al. (2010b). 
The study provides some associations between formal-
dehyde exposure and changes in hematology, but also 
demonstrates  serious  weaknesses  in  the  study  design. 
The hematology findings by Zhang et al. (2010b) do not 
consistently  support  a  hematotoxic  role  for  formalde-
hyde.  For  example,  the  authors  found  statistically  sig-
nificant lower WBC, RBC, and platelet counts in exposed 
vs. control factory workers, yet they found no statistically 
significant difference between exposed and control sub-
jects in relation to colony formation of myeloid progeni-
tor cells (CFU-GM), which give rise to granulocytes and 
macrophages, cultured from blood. If it were possible for 
formaldehyde to cause direct or indirect toxicity to bone 
marrow, a decreased ability of CFU-GM to grow in cul-
ture would likely be observed, but this did not occur.
It  is  not  clear  from  the  Zhang  et  al.  (2010b)  data 
whether all subjects with decreased WBC counts also 
had  decreased  RBC  counts  and  vice  versa.  If  bone 
marrow toxicity was indeed in progress in the subjects 
exposed  to  higher  levels  of  formaldehyde,  then  both 
WBC and RBC counts would be lower in the same indi-
viduals. In addition, because the WBC and RBC counts 
were  pooled,  it  is  impossible  to  determine  if  outli-
ers in either group might have influenced the results, 
since subject-specific hematology parameters are not 
reported. Therefore, one cannot make definitive con-
clusions concerning these data.
We investigated the consistency between the animal 
and human study outcomes. As we discuss, animal stud-
ies generally show no evidence of formaldehyde-induced 
hematotoxicity. Human studies, on the other hand, show 
inconsistent associations between formaldehyde expo-
sure measurements and hematologic parameters. Even 
when  hematology  changes,  such  as  depressed  WBC 
counts in the blood, are associated with formaldehyde, 
these associations are not exposure related, and do not 
agree with the findings from animal studies. This lack 
of  concordance  between  human  and  animal  studies 
does not provide evidence to support an argument for 
formaldehyde-induced hematotoxicity, unlike benzene 
and other leukemogens that show concordance between 
animal and human data (as discussed in Section 5.3.3). 
However, the limited number of human studies avail-
able, and the inconsistencies among them, warrants the 
need for well-controlled human studies with respect to 
exposure assessment and subject-matching between the 
exposed and control groups.
The available human hematotoxicity studies are cross-
sectional in nature. In cross-sectional studies, both expo-
sure and outcome are evaluated at the same time. A major 
weakness  of  cross-sectional  environmental  toxicology 
studies is that a chemical measurement at one point of 
time may not be indicative of earlier exposures that may 
have caused the biological outcome. Also, inappropriate 
subject-group matching (e.g., for smoking, drinking, age, 
sex) may result in findings of differences in biological 
outcomes associated with the agent in question when 
there are in fact none. In particular, Zhang et al. (2010b) 
only matched subjects by age and sex; however, there 
was  a  considerably  higher  rate  of  recent  respiratory 
infections  (yes/no  answer)  in  the  exposed  vs.  control 
subjects (40% vs. 29%, respectively). Zhang et al. (2010b) 
report  that  subjects  were  screened  by  physicians  and 
trained questionnaire administrators. However, no list-
ing of medications or medical conditions is available for 
the subjects in this study. We discuss possible confound-
ers in the subsequent sections, particularly from dermal 
exposure to formaldehyde and respiratory infections that 
can possibly modulate the associations in the studies we 
reviewed for human formaldehyde hematotoxicity.
5.3.3.  If formaldehyde causes leukemia in humans, it is likely 
due to a mechanism that is different from that observed with 
known leukemogens
Hematotoxicity has been demonstrated in both animals 
and  humans  exposed  to  leukemogens  (i.e.,  benzene, 
chemotherapeutic  alkylating  agents,  and  x-ray  and 
gamma radiation). This hematotoxicity can be illustrated 
with  benzene.  Benzene  has  been  frequently  found  to 
cause pancytopenia in animals (e.g., Aksoy et al., 1972; 
Farris et al., 1997, both as cited in ATSDR, 2007) and 
humans (e.g., Kipen et al., 1989; Schnatter et al., 2010; Formaldehyde as a leukemogen—Weight of evidence  603
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ATSDR, 2007). Moreover, numerous studies have shown 
that exposure to benzene can cause leukemia and other 
hematopoietic  malignancies  in  animals  by  inhalation 
and oral routes in several rodent species of both sexes 
(Snyder et al., 1984; Cronkite et al., 1984, 1985, 1989; all 
as cited in ATSDR, 2007). Many epidemiology studies 
have also shown robust associations between exposure 
to benzene and increased risk of leukemia (e.g., Rinsky 
et al., 1987, 2002; Yin et al., 1996; Infante et al., 1977; 
ATSDR, 2007). The mechanism for benzene hematotox-
icity and leukemogenicity is dependent on its metabo-
lism to reactive intermediates and is well established as 
having the ability to affect bone marrow cells directly 
(ATSDR, 2007).
Other  leukemogens  have  cytotoxic  and  genotoxic 
properties similar to benzene. These agents can affect 
all cells, particularly rapidly dividing cells such as bone 
marrow. For example, cyclophosphamide, a chemother-
apeutic  alkylating  agent,  has  produced  hematopoietic 
malignancies in exposed animals (Schmahl and Habs, 
1979) as well as leukopenia in humans (Bower et al., 2004; 
Tjan-Heijnen et al., 2001) and animals (Wang et al., 2002; 
Nohynek et al., 1997). X-ray and gamma-radiation also 
have been repeatedly shown to cause leukemia and bone 
marrow toxicity in animals and humans (IARC, 2000).
As discussed in the preceding section, the available 
human studies lack the appropriate exposure and sub-
ject information and the consistent outcomes to make 
a  convincing  case  for  formaldehyde  leukemogenicity. 
Upon reviewing the available studies of formaldehyde 
hematology effects, we found no consistent evidence of 
hematotoxicity in humans. Moreover, the animal studies 
using mice, rats, dogs, and monkeys, often of both sexes, 
overwhelmingly  reported  no  evidence  of  changes  in 
hematology parameters, as shown in Table 14. Therefore, 
if formaldehyde causes leukemia in humans, it must be 
by a mechanism that is different from that observed with 
known leukemogens and is likely specific to humans and 
not common to rodents. Table 17 illustrates the diver-
gence  of  formaldehyde  from  known  leukemogens  in 
terms of hematotoxicity indicators.
5.3.4.  There are alternative explanations for the 
pancytopenia reported by Zhang et al. (2010b) and the 
leukopenia reported by other studies
As reviewed above, animal studies generally do not show 
a hematotoxic effect of formaldehyde. However, several 
human studies report that formaldehyde is associated 
with lowered WBC and RBC counts in peripheral blood 
(see Table 16). Our review of available human studies 
of formaldehyde hematotoxicity finds that these studies 
do not sufficiently explain some of the formaldehyde-
associated  depression  in  RBC  and  WBC  counts  in 
“exposed” vs. “control” subjects. When we consider the 
uncertainties in these associations and the absence of a 
clear dose-response in the available studies, we find that 
there are many potential confounders to a possible form-
aldehyde-associated decline in WBC and RBC counts in 
blood. Some of these confounders include inappropriate 
matching by exposure due to consideration of only air-
borne measurements of formaldehyde (and not dermal 
or  oral),  no  reported  assessment  of  non-occupational 
exposures to formaldehyde, differences among groups in 
alcohol intake and respiratory infections, and the possi-
ble effect of formaldehyde on hematology parameters in 
peripheral blood (via dermal irritation and sensitization, 
as discussed in Section 5.3.4.1) in addition to other issues 
such as nutrient imbalance and certain medications, all 
of  which  may  have  a  significant  effect  on  hematology 
parameters.  Further,  unlike  established  leukemogens 
such as benzene (as discussed in Section 5.3.3), form-
aldehyde  has  not  been  associated  with  bone  marrow 
toxicity  or  aplastic  anemia  in  occupationally  exposed 
subjects.
5.3.4.1. Subjects exposed to formaldehyde share common 
immunology markers with subjects having dermatitis or 
other inflammatory conditions  As reviewed by Deane 
and Hickey (2009), epidermal inflammation in atopic der-
matitis, psoriasis, and allergic contact dermatitis involves 
the movement of leukocytes from peripheral blood to 
skin. Singbartl and Ley (2004) also describe the process 
of leukocyte recruitment to inflamed tissues in the case 
of acute renal failure as occurring in a cascade-like fash-
ion that encompasses capture, rolling, activation, firm 
adhesion, and tissue translocation of leukocytes. These 
mechanisms may contribute to a decrease in blood cells 
from peripheral blood in subjects with certain inflamma-
tory conditions in the skin or other organs.
The ability of liquid formaldehyde to cause dermatitis, 
skin irritation, and immune modulation in occupational 
and  non-occupational  settings  is  well  documented. 
For example, Nethercott and Holness (1988, as cited in 
ATSDR 1999) showed an 11% prevalence of contact skin 
dermatitis (3% positive formaldehyde skin-patch tests) in 
embalmers working at funeral homes vs. 0% in controls. 
Similar results have been reported for nurses exposed to 
formaldehyde disinfectant (Rudzki et al., 1989, as cited 
in ATSDR 1999). Further, in a review of formaldehyde 
in  cosmetic  products,  de  Groot  and  Maibach  (2010) 
find that formaldehyde applied to skin has been shown 
to  induce  dermatitis  from  short-term  use.  Finally,  in 
a review of skin sensitivity to formaldehyde in various 
populations, de Groot et al. (2009) found a 4.1% preva-
lence in one study of Chinese subjects and up to 9.2% 
in studies from the United States. If occupational dermal 
exposure to formaldehyde results in skin irritation and 
dermatitis, which influence changes in concentrations 
in peripheral blood of leukocytes and other hematology 
parameters, these changes may explain the heterogene-
ity in response with different exposure concentrations in 
the human studies summarized in Table 16. It is note-
worthy that bone marrow is dynamic in that cell loss is 
compensated by cell production, and this characteristic 
should be the subject of further study in the case of der-
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There are similarities between the observed effects in 
peripheral  blood  of  some  formaldehyde-exposed  sub-
jects (via inhalation and possibly dermally, as discussed 
above) and in subjects with dermatitis conditions. For 
example, Yoshino et al. (2000) found evidence that the 
degree of clinical dermatitis was associated (positively 
or negatively) with peripheral mononuclear WBC counts 
and  that  the  proliferation  of  peripheral  mononuclear 
cells may be suppressed in severe atopic dermatitis cases; 
the authors suggest that this is related to the high rate of 
T-cell  apoptosis  in  severe  atopic  dermatitis.  Similarly, 
Forte et al. (2009) found that a reduction in chemotactic 
response and phagocytic activity by neutrophilic and/
or mononuclear phagocytes in the majority of patients 
with atopic dermatitis ranged from moderate to severe. 
Further, Lebre et al. (2008) found that myeloid dendritic 
cells  and  plasmacytoid  dendritic  cells  from  patients 
with  atopic  dermatitis  showed  defective  interleukin 
(IL)-12, tumor necrosis factor (TNF)-α, and interferon 
(IFN)-α  production;  the  authors  suggest  that  these 
immune indicators may contribute to the maintenance 
of an allergic state in these patients. Dermatitis condi-
tions  have  been  associated  with  increased  eosinophil 
counts  (290  vs.  153.3  cells/mm3,  p < .05)  in  the  blood 
of patients with atopic dermatitis vs. healthy subjects, 
respectively (Jenerowicz et al., 2007). From the periph-
eral blood eosinophil count and eosinophil percent of 
blood cells, we calculated a lower mean WBC count in 
subjects   having dermatitis vs. healthy subjects (4581 vs. 
4746 WBCs/mm3, respectively; 30 subjects per group), 
but it was not possible to assess whether these counts 
were statistically significantly different from each other, 
since the raw data were not provided for the individual 
subjects in this study. Since hematology changes can be 
associated with allergic reactions in general, and derma-
titis in particular, and because formaldehyde can cause 
dermatitis and dermal sensitivity, an assessment of skin 
reactions to formaldehyde is necessary when investigat-
ing formaldehyde-induced hematology effects.
If  skin  reactions  are  indeed  present  in  the  study 
subjects,  they  may  confound  the  hematology  findings 
reported by many of the aforementioned studies. Dermal 
exposure to formaldehyde and its effects on clinical and 
subclinical skin sensitivity reactions are not reported in 
the human studies we reviewed. However, it is possible 
that the subjects in the studies by Zhang et al. (2010b), 
Lyapina et al. (2004), Srivastava et al. (1992), and in the 
studies cited by Tang et al. (2009) were exposed dermally 
to formaldehyde. In addition, the status of sensitization 
or  inflammation  in  exposed  vs.  control  individuals  in 
these studies is largely unknown. Further, Farage (2008) 
reported that skin reactions may not be easily diagnosed 
by visual inspection and may require more sophisticated 
technology that is not widely available. Therefore, even if 
subjects with higher air exposures to formaldehyde had 
some form of skin reaction to formaldehyde, the possibil-
ity exists that this condition would not be detected by a 
clinician.
5.3.4.2.  A  recent  respiratory  infection  can  result  in 
hematological changes—Subjects with exposure to form-
aldehyde in the study by Zhang et al. (2010b) were more 
likely than control subjects to have had recent respira-
tory tract infections  Several studies suggest that respi-
ratory infections can be associated with leukopenia, or 
decreased WBC counts in peripheral blood, in humans. 
Cummins et al. (1998) found a 5% decrease (p = .02) in 
total leukocyte counts in blood and a 9% decline (p = .001) 
in lymphocyte counts in 70 elderly subjects 4 weeks after 
they received an influenza vaccine. These results are sup-
ported by those from three cases of pediatric influenza 
infections that were associated with declines in periph-
eral blood WBC counts (Rice and Resar, 1998). Further, 
a study by Shen et al. (2008) showed that not only do 
infections modify hematology parameters, but also that 
the type of infection could be important. For example, 
children with influenza B infection had a significantly 
lower  total  WBC  count  than  those  with  influenza  A 
infection.  Influenza  infection  has  also  been  shown  to 
cause or exacerbate bone marrow suppression in mice 
(Lavrov and Semenkov, 1991; Hyland et al., 2005). Shen 
et al. (2008) found that leukopenia is not an uncommon 
occurrence in influenza infections and that this decline 
in WBC counts is possibly related to B-lymphocyte apop-
tosis in bone marrow.
The higher rate of recent respiratory infections in the 
exposed vs. control groups of the study by Zhang et al. 
(2010b) could have resulted in confounding of hematol-
ogy parameters. Alternatively, it may be argued that the 
higher rate of recent respiratory infections in the exposed 
workers is due to lower WBC counts or that respiratory tract 
infections could either increase or decrease WBC counts 
in peripheral blood (Mayo Clinic, 2008) and may, there-
fore, be unrelated to the findings in this study. However, 
all  reported  WBC  counts  for    formaldehyde-exposed 
subjects and their controls are above 4900 cells/mm3 of 
blood (e.g., Tang et al., 2009; Zhang et al., 2010b), which 
are  higher  than  the  Mayo  Clinic’s  benchmark  of  3500 
cells/mm3 for leukopenia (Mayo Clinic, 2008). Therefore, 
it is less likely that the lower WBC count is the cause of 
the  recent  infections  in  the  exposed  subjects.  Better-
matched exposure and control groups in future studies 
may eliminate this potential confounder.
5.3.4.3.  Other  unmeasured  potential  confounders  As 
discussed in the preceding subsections, several condi-
tions may be associated with decreased WBC and RBC 
counts in peripheral blood. In a study of adult Japanese 
male office workers, Nakanishi et al. (2003) found that 
WBC counts increased with increasing body mass index 
and smoking, but decreased with alcohol intake, nutri-
tional balance, and hours worked per day. Here we focus 
on two possible confounders of hematology parameters 
that may be associated with oral or inhalation exposure 
to formaldehyde: (1) the effects of formaldehyde on the 
hypothalamic/pituitary/adrenal (HPA) axis involvement 
in WBC count modulation; (2) the effect, on the kidneys, Formaldehyde as a leukemogen—Weight of evidence  605
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of possible exposure to melamine from formaldehyde-
melamine resins (which were the source of formaldehyde 
exposures in the study by Zhang et al., 2010b); kidneys 
are important in producing erythropoietin, the hormone 
responsible for inducing RBC production.
There is evidence to suggest that formaldehyde expo-
sure can modulate WBC counts in peripheral blood via 
an  endocrine  pathway.  Brondeau  et  al.  (1990)  found 
that  exposure  to  airborne  irritants  (including  formal-
dehyde) caused leukopenia at irritant levels (≥43 ppm 
for formaldehyde, in an exposure-dependent manner) 
over  a  4-hour  exposure,  and  that  this  effect  was  pre-
vented  by  removal  of  the  adrenal  gland,  suggesting  a 
possible role for this gland in apparent hematological 
effects. Sari et al. (2004) also found that relatively low 
concentrations (0.08, 0.4, and 2.0 ppm) of formaldehyde 
increased  hypothalamus/pituitary/adrenal  (HPA)  axis 
activity by increasing the numbers of both hypothala-
mus corticotropin releasing hormone-immunoreactive 
neurons  and  pituitary  adrenocorticotropin  hormone 
(ACTH)-immunoreactive cells in mice. These neuronal 
changes  were  paralleled  by  increased  mRNA  expres-
sion of pituitary ACTH, which functions in regulating 
adrenal gland function. It is also well established that 
the adrenal glands produce glucocorticoids, mainly cor-
tisol, a steroid that can suppress the immune response 
(Cotran et al., 1999). Although more research is needed 
to investigate the potential effect of formaldehyde on 
WBC counts via an endocrine pathway, particularly at 
occupationally relevant concentrations, there is sugges-
tive evidence that it occurs. This HPA pathway should be 
considered when evaluating hematology data associated 
with formaldehyde exposure.
The  recent  discovery  that  melamine  can  cause  or 
contribute to renal toxicity may have implications for the 
consumption of melamine when it is either present as 
an adulterant in food or inhaled during its manufacture 
or processing. In patients who have kidney disease it is 
likely that production of erythropoietin, the hormone 
responsible for inducing RBC production, is depressed. 
As a result, the bone marrow makes fewer RBCs and 
therefore patients with kidney disease often have to take 
erythropoietin supplements (NIH, 2008). This notion of 
melamine-induced changes in RBC counts and hemo-
globin  concentration  finds  support  from  Srivastava 
et al. (1992) who reported declines in hemoglobin con-
centration  and  elevations  in  lymphocyte  counts,  but 
not other hematology indicators, in workers with con-
siderable  exposure  to  formaldehyde-melamine  resin. 
Moreover, Dobson et al. (2008) found that melamine 
or  melamine  cyanuric  acid  ingestion  in  rats  caused 
renal toxicity. Further, acute renal failure has also been 
reported in human infants in Beijing, China, who were 
exposed to melamine via a popular Chinese brand of 
milk formula, “Sanlu” (Sun et al., 2010). The role for 
melamine in renal toxicity and how it might be related to 
changes in RBC counts and Hb concentration in blood 
is  important,  particularly  when  analyzing  the  results 
of the study by Zhang et al. (2010b). Consideration of 
melamine exposure in the Zhang et al. (2010b) study 
participants is important, since the study participants 
were potentially exposed by inhalation and ingestion to 
formaldehyde-melamine resins at work, and they were 
possibly exposed to melamine from food items made or 
contaminated with melamine-adulterated milk powder 
outside work.
Finally, there are several other potential confounders 
of hematology parameters in occupational studies. For 
example, alcohol consumption, which is a potential con-
founder in the study by Zhang et al. (2010b), can modu-
late immune function (Szabo and Mandrekar, 2009). Also, 
nutritional deficiencies in folic acid and cyanocobalamin 
(vitamin B12) have been associated with megaloblastic 
anemia, which manifests with faulty RBCs that are larger 
than  normal  (increased  MCV)  (Morris  et  al.,  2007). 
Further, certain herbal supplements, such as Echinacea, 
have been associated with depressed WBC counts after 
chronic ingestion (Kemp and Franco, 2002). It is thus 
possible that WBC and RBC counts in peripheral blood 
are  modulated  by  formaldehyde  exposure  in  mecha-
nisms involving extramedullary systems (i.e., outside the 
bone marrow); this would contribute to confounding in 
epidemiology studies that result in observed differences 
between exposed and controls.
Future  studies  investigating  a  possible  association 
between exposure to formaldehyde and hematotoxicity 
should consider a number of confounders, including, but 
not limited to, the ones discussed here.
5.4.  Summary
As a whole, the available studies of formaldehyde hema-
totoxicity in both animals and humans provide little evi-
dence to support the account that formaldehyde exposure 
is causally associated with leukemia. The animal studies 
generally reported neither hematotoxicity nor leukemia 
associated  with  formaldehyde  inhalation  or  ingestion. 
The  two  studies,  one  of  which  is  not  peer-reviewed, 
that reported some evidence of formaldehyde-induced 
leukemia are not convincing of such an association due 
to (1) inconsistent and potentially flawed data that has 
been dismissed by both EFSA and ATSDR (as discussed 
in  Section  5.3.1.2)  (Soffritti  et  al.,  1989,  2002);  (2)  the 
high background tumor rate in the animal models used 
(DeVoney et al., 2006 poster, 2010 poster abstract); (3) the 
Table 17.  Comparison of formaldehyde hematotoxicity to known leukemogens.
  Benzene Cyclophosphamide Radiation Formaldehyde
Pancytopenia in animals Yes Yes Yes No
Hematopoietic malignancies in animals Yes Yes Yes No
Pancytopenia in humans Yes Yes Yes More research needed606  L. R. Rhomberg et al.
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lack of corroboration from numerous other studies that 
examined the same endpoints in animals.
A few human studies, as cited by secondary sources, 
may  be  consistent  with  hematotoxicity,  but  they  are 
inconsistent with other study findings and plagued by 
possible  confounding.  As  discussed  in  Section  5.3.2, 
the  studies  suggestive  of  hematotoxicity  are  reported 
by Tang et al. (2009) and Zhang et al. (2010b). However, 
because the only study of hematological effects cited by 
Tang et al. (2009) available in English (Kuo et al., 1997) 
is associated with several uncertainties, the conclusions 
drawn by Tang et al. (2009) are weakened. Until the other 
studies cited by Tang et al. (2009) are translated, many 
questions exist about the outcomes and exposure-related 
uncertainties in the findings. Many medical and lifestyle 
factors can contribute to changes in hematology, par-
ticularly declines in WBC and RBC counts. The study by 
Zhang et al. (2010b) provides some evidence to support 
an association between formaldehyde and hematotoxic-
ity; however, as discussed in Sections 5.3.2 and 5.3.4, this 
study’s outcomes are mixed and may suffer from poten-
tial  confounding  of  results  by  recent  respiratory  tract 
infections and leukopenia resulting from possible der-
matitis. When considering the many possible known and 
unknown confounders in the studies we reviewed, such 
as  dermatitis,  respiratory  infection,  alcohol  consump-
tion, non-occupational sources of formaldehyde, etc., it 
is impossible to rule out confounding. In addition, many 
of the human studies are cross-sectional and therefore 
cannot adequately show cause and effect. Moreover, the 
available data from human studies do not provide suf-
ficient proof for formaldehyde-induced hematotoxicity 
particularly when animal studies provide strong evidence 
against  it.  If  formaldehyde  is  hematotoxic  in  humans, 
this toxicity would likely be via a mechanism not feasible 
in rodents, rhesus monkeys, or beagle dogs, since formal-
dehyde exposure does not cause hematotoxicity in these 
animals, therefore bringing into the question of biologi-
cal plausibility of formaldehyde-induced hematotoxicity 
in humans.
Finally,  the  question  of  potential  formaldehyde-
induced  hematoxicity  can  be  explored  by  considering 
information on epidemiology and mode-of-action stud-
ies. As part of the HBWoE approach, one considers the 
cross-discipline integration of hypothesized effects. As 
discussed herein, the epidemiology and mode-of-action 
data cast doubt on the ability of inhaled formaldehyde 
to interact with and perturb hematopoiesis, which com-
plicates further the plausibility of a conclusion of causal 
association based on the observations in the hematotox-
icity and animal leukemia studies.
6.  Weight of evidence regarding a 
plausible mode of action for formaldehyde 
leukemogenesis
In the following analysis, we examine the data relevant 
to  the  modes  of  action  that  have  been  proposed  for 
formaldehyde  leukemogenesis.  We  focused  on  studies 
that  examined  formaldehyde  metabolism  and  distri-
bution,  and  genotoxicity  in  animals,  humans,  and  in 
vitro. We conducted literature searches, using PubMed 
and  several  search  terms  in  combination  with  “form-
aldehyde”:  “genom*,”  “chromosom*,”  “micronuclei,” 
“cytogenetic,”  “DNA  damage,”  “genotox*,”  “mutagen*,” 
“metabol*,”  “toxicokinetic,”  and  “pharmacokinetic.” 
We also relied on recent key review articles and agency 
reports (IARC, 2006; US EPA, 2010; Heck and Casanova, 
2004; Pyatt et al., 2008; Golden et al., 2006), as well as 
references within those reports and papers found in the 
PubMed search. 
As discussed, the epidemiology data do not support 
a  causal  association  between  formaldehyde  exposure 
and leukemia. In addition, the available studies of form-
aldehyde hematotoxicity in both animals and humans 
provide  little  evidence  for  formaldehyde-associated 
leukemia. The animal studies generally reported neither 
hematotoxicity nor leukemia associated with formalde-
hyde exposure, and although a few human study findings 
are  consistent  with  hematotoxicity,  they  are  inconsis-
tent with other study findings and plagued by possible 
confounding.
Despite these findings, three modes of action for form-
aldehyde  leukemogenesis  have  been  hypothesized  by 
Zhang (2009, 2010a) and are also discussed in US EPA’s 
recent  draft  toxicological  profile  for  formaldehyde  (US 
EPA, 2010). The proposed modes of action are as follows:
Formaldehyde targeting bone marrow hematopoietic  1. 
stem  cells—formaldehyde  complexes  as  a  hydrate 
[CH2(OH)2]  that  could  potentially  reach  the  bone 
marrow, where it could directly induce DNA dam-
age and chromosomal aberrations in hematopoietic 
stem or progenitor cells, leading to leukemia.
Formaldehyde  targeting  nasal  stem  cells  (nasal- 2. 
associated  lymphoid  tissue,  or  NALT)—nasal  stem 
cells are damaged by formaldehyde, released from 
the  nasal  passage,  circulate  in  the  blood,  and  are 
eventually incorporated into bone marrow leading to 
leukemia.
Formaldehyde  targeting  circulating  hematopoietic  3. 
stem cells—stem cells circulate from marrow to nasal 
tissue where they are transformed by formaldehyde 
(pre-mutagenic lesions), and then migrate back to 
bone marrow, eventually leading to leukemia.
 Here we first describe what is known about formalde-
hyde metabolism, biological distribution, and genotox-
icity. We then provide a weight-of-evidence analysis of 
the formaldehyde data with regard to the three proposed 
modes of action.
6.1.  Formaldehyde toxicokinetics
The toxicokinetics of formaldehyde has been extensively 
studied and is summarized in recent reviews and agency 
toxicological  profiles  (ATSDR,  1999;  ATSDR,  2010; Formaldehyde as a leukemogen—Weight of evidence  607
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Heck and Casanova, 2004; IARC, 2006; US EPA, 2010). 
Formaldehyde is a normal by-product of several meta-
bolic pathways in mammals, and is naturally present in 
tissues, cells, and biological fluids. Under physiological 
conditions, it exists in equilibrium, predominantly in its 
hydrated form methanediol [CH2(OH)2], with less than 
0.1% as free formaldehyde. Formaldehyde is water solu-
ble and highly reactive; therefore, it is readily absorbed 
and  metabolized  in  biological  systems.  It  is  primarily 
metabolized  by  glutathione-dependent  formaldehyde 
dehydrogenase (FALDH) and aldehyde dehydrogenases 
(ALDHs). Formaldehyde enters the “one-carbon” pool 
and is readily incorporated into macromolecules in the 
body. In rats exposed to [14C]formaldehyde via inhalation 
(0.63 or 13 ppm), the exhaled fraction was independent 
of exposure concentration, with 40% of the 14C incorpo-
rated into macromolecules and 40% exhaled as  14CO2, 
and the remainder was excreted in the feces and urine, 
and incorporation into macromolecules in the blood was 
via the one-carbon pool and not through DNA or protein 
adducts (Heck et al., 1983, as cited in Heck and Casanova, 
2004). Salthammer et al. (2010) discusses a median con-
centration of 4.3 ppb formaldehyde in human breath that 
is likely due to endogenous sources.
The  concentration  of  endogenous  formaldehyde  in 
human blood is approximately 0.1 mM and, as discussed 
in Heck and Casanova (2004), this concentration is not 
increased in humans who inhale 2 ppm formaldehyde 
for 40 minutes or in monkeys inhaling 6 ppm for 4 weeks. 
The  inability  of  exogenous  formaldehyde  to  increase 
blood  concentrations  of  formaldehyde  was  confirmed 
in  an  analysis  by  Franks  (2005)  using  a  sophisticated 
mathematical model. These data strongly suggest that, 
at concentrations to which humans might be exposed, 
formaldehyde does not move beyond the nasal mucosa 
to cause effects at distant sites. Recent dosimetry, cyto-
toxicity, and genomics studies conducted by Andersen 
et al. (2010) suggest that exposure to formaldehyde con-
centrations of 1 to 2 ppm would not affect formaldehyde 
homeostasis or increase genotoxic and cytotoxic effects 
in the nose or in any other tissue. Andersen et al. (2010) 
developed  a  pharmacokinetic  model  to  estimate  vari-
ous forms of formaldehyde and glutathione (GSH) tis-
sue concentrations, accounting for enogenous levels of 
formaldehyde, and applied the model to compare tissue 
concentrations with histopathology and gene expression 
changes in the nasal epithelium of rats. The study found 
that at high exposure concentrations (6 to 15 ppm), gene 
expression changes reflected pathways involved in cell 
cycle  control,  DNA  repair,  and  apoptosis,  with  tissue 
responses including cell proliferation, erosion, necrosis, 
and increased severity of squamous metaplasia—cellular 
responses potentially associated with carcinogenesis. At 
lower exposure concentrations (less than 1 to 2 ppm), the 
gene expression changes likely represented extracellular 
responses (such as responses to irritancy and to export 
GSH to extracellular spaces), with tissue responses at 2 
ppm reflecting mild squamous metaplasia.
6.2.  Formaldehyde genotoxicity
Formaldehyde induces a variety of genotoxic and muta-
genic effects, including DNA protein cross-links (DPX), 
DNA adducts, point mutations, DNA strand breaks, chro-
mosomal  aberrations  (CA),  deletions,  sister-chromatid 
exchange  (SCE),  and  micronucleus  (MN)  formation 
(ATSDR, 1999; ATSDR, 2010; Heck and Casanova, 2004; 
IARC, 2006; US EPA, 2010).
6.2.1.  DNA adducts and protein cross-links
At high exposure concentrations, formaldehyde causes 
DNA-protein cross-links (DPX) in the nasal mucosa of rats, 
upper respiratory tract of monkeys, and in vitro in human 
cells (Heck and Casanova, 2004; ATSDR, 1999; ATSDR, 
2010; IARC, 2006; US EPA, 2010). Pharmacokinetic mod-
els have been used to study the disposition of inhaled 
[14C]formaldehyde in the respiratory tract. At very low 
concentrations of formaldehyde, nearly 100% is elimi-
nated  through  metabolism  or  through  non-saturable 
pathways other than DPX (such as protein adducts), with 
very little (7 × 10−6%) bound as DPX. At higher concentra-
tions (6 ppm, 6 hours) in rats and Rhesus monkeys, 91% 
and 96% of the [14C]formaldehyde in the DNA was due to 
metabolic incorporation, and approximately 9% and 4% 
of the [14C]formaldehyde in the DNA was bound as DPX 
in the nasal respiratory mucosa, respectively (Heck and 
Casanova, 2004). Studies suggest that formaldehyde-in-
duced DPX are rapidly removed (24 hours) from human 
blood cultures treated in vitro (Schmid and Speit, 2007), 
and from the nasal respiratory mucosa of rats exposed 
via inhalation to formaldehyde (6, 10 ppm) (Heck and 
Casanova, 2004).
There is no strong evidence to suggest that formalde-
hyde causes DPX in bone marrow or WBCs (discussed in 
more detail in the next section). A recent study by Wang 
et al. (2009a) found higher levels of the formaldehyde-
DNA  adduct  N6-hydroxymethyldeoxyadenosine  (N6-
HOMe-dA) in leukocytes of smokers vs. non-smokers. 
The authors suggest that N6-HOMe-dA adducts in leu-
kocyte DNA may be potentially important as a cause of 
cancer from smoking. A recent study by Lu et al. (2010), 
in which rats were exposed via inhalation to 10 ppm deu-
terium-labeled formaldehyde (i.e., [13CD2]formaldehyde) 
to  trace  the  disposition  of  exogenous  vs.  endogenous 
formaldehyde in DNA, found exogenous formaldehyde-
DNA adducts in the nasal respiratory mucosa but not 
at distant sites (including WBCs and bone marrow). In 
addition, Lu et al. (2010) found that exogenous formal-
dehyde caused only N2-HOMe-dG adducts in the nasal 
mucosa  and  no  N6-HOMe-dA  adducts;  however,  both 
adducts were found in distant sites but only from endog-
enous formaldehyde. Another study by Lu et al. (2011) 
examined molecular dosimetry (0.7, 2, 5.8, 9.1, and 15.2 
ppm  [13CD2]formaldehyde  for  6  hours)  of  endogenous 
and  exogenous  N2-HOMe-dG  adducts  in  the  nasal 
mucosa  of  rats.  The  authors  found  that  endogenous 
adducts  dominated  at  low  exposure  concentrations 
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respectively). Further, the authors examined the levels 
of endogenous and exogenous N2-HOMe-dG adducts in 
bone marrow from exposure to 15.2 ppm formaldehyde 
and found that exogenous adducts were not detectable. 
A similar study conducted by the same group (Moeller 
et  al.,  2011)  examined  the  levels  of  endogenous  and 
exogenous N2-HOMe-dG adducts in the nasal mucosa 
and bone marrow of cynomolgus macaques exposed to 
1.9 and 6.1 ppm [13CD2]formaldehyde for 6 hours a day 
for  2  consecutive  days.  The  authors  observed  readily 
detectable levels of exogenous and endogenous adducts 
in the nasal mucosa at both exposures; however, only 
endogenous adducts were detectable in the bone mar-
row. These data strongly suggest that the results observed 
by Wang et al. (2009a) may be specific to effects from 
cigarette  smoke  (i.e.,  the  generation  of  formaldehyde 
from  metabolism  of  N-nitrosodimethylamine  [NDMA] 
and  4-(methylnitorosamino)-1-(3-pyridyl)-1-butanone 
[NNK])  and  not  from  exogenous  formaldehyde.  In 
addition, Lu et al. (2010, 2011) and Moeller et al. (2011) 
provide strong evidence to support the biological implau-
sibility of distant site carcinogenicity, such as leukemia, 
from  inhaled  formaldehyde,  while  providing  evidence 
that formaldehyde inhalation can lead to DNA adducts 
in respiratory nasal epithelium. In addition, Neuss et al. 
(2010)  show  that  human  nasal  epithelial  cells  pre-ex-
posed in vitro to high concentrations of formaldehyde do 
not cause DNA damage (DPX) in co-cultivated isolated 
human lymphocytes, lending further support that form-
aldehyde that has entered the nasal epithelial cells does 
not move beyond these cells to damage DNA in other 
cells in close proximity (discussed in more detail below 
with respect to the NALT hypothesis).
6.2.2.  Clastogenic and cytogenetic effects
In  vivo  mammalian  formaldehyde  genotoxicity  assays 
have examined clastogenic and cytogenetic effects (CA, 
SCE,  and  MN  formation)  in  rodents  and  humans,  and 
the results have been summarized (ATSDR, 1999; ATSDR, 
2010; Heck and Casanova, 2004; IARC, 2006; US EPA, 2010). 
As presented in these reviews, the cytogenetic results in 
humans and animals are conflicting, showing both posi-
tive and negative effects. In humans, the majority of these 
studies have been carried out in nasal or oral mucosa (to 
examine site of direct contact) and in peripheral blood 
lymphocytes (PBLs) (to examine distant-site toxicity). As 
reviewed by Speit and Schmid (2006) and agency reviews 
(IARC, 2006; US EPA, 2010), the published studies suggest 
that inhalation of formaldehyde leads to increased MN 
frequencies in nasal and/or buccal mucosa cells. There are 
a number of issues with these studies, however, including 
incomplete information on study design, exposure, and 
potential confounding factors (Speit and Schmid, 2006). 
Speit and Schmid (2006) suggest that because of this, it is 
not yet possible to make meaningful conclusions regard-
ing local genotoxic effects of formaldehyde.
From our review of the current literature, and from 
studies  summarized  in  recent  agency  reviews  (IARC, 
2006; US EPA, 2010; Jakab et al., 2010; Jiang et al., 2010; 
Pala et al., 2008), to date, approximately 20 studies have 
examined  the  cytogenetic  effects  of  formaldehyde  in 
human PBLs, as a means for examining distant-site toxic-
ity. These data are insufficient and conflicting, with both 
positive  and  negative  results.  As  discussed  in  several 
recent reviews (Heck and Casanova, 2004; Pyatt et al., 
2008; Golden et al., 2006), and in more detail in the next 
section, interpretation of the positive findings in humans, 
particularly in the context of leukemia, is problematic 
given (1) potential confounding in the studies, including 
diet and life style differences, or the lack of good expo-
sure information; (2) the lack of evidence to suggest that 
DNA damage in human PBLs is a model for DNA damage 
in stem cells, since these effects have not been shown to 
occur in stem cells that can transition to leukemia; and 
(3) similar results have not been found in controlled ani-
mal studies. For example, Kligerman et al. (1984) found 
no  statistically  significant  increase  in  SCE  or  chromo-
some breakage in PBLs of rats exposed to formaldehyde 
(0.5, 6, or 15 ppm). A similar study carried out recently by 
Speit et al. (2009) found that formaldehyde (0.5, 1, 2, 6, 
10, and 15 ppm) did not induce any significant genotoxic 
effects (DPX, SCE, or MN) in PBLs of rats.
6.3. HBWoE evaluation of the proposed modes of 
action for formaldehyde as a leukemogen
The plausibility of the three proposed modes of action has 
been extensively reviewed by others (Pyatt et al., 2008; 
Golden et al., 2006). We have considered these reviews, 
in addition to the primary formaldehyde inhalation tox-
icity literature, and have come to the following questions 
with regard to the proposed modes of action:
What  is  the  evidence  that  formaldehyde  exposure  1. 
induces carcinogenic (or genotoxic) transformation 
directly in bone marrow?
What is the evidence that formaldehyde can induce  2. 
carcinogenic (or genotoxic) transformation in nasal-
associated  lymphoid  tissue  (NALT),  or  peripheral 
hematopoietic stem cells (HSCs)?
Is the DNA damage observed in the formaldehyde  3. 
genotoxicity  studies  consistent  with  DNA  damage 
associated with leukemia?
If formaldehyde could induce systemic DNA dam- 4. 
age, what concentrations in the nose would it take 
to reach levels higher than endogenous formalde-
hyde DNA adduct levels in the NALT or circulating 
HSCs to cause a sufficient level of DNA damage that 
would induce cell proliferation in the bone marrow? 
Would  these  concentrations  be  relevant  to  typical 
human formaldehyde exposures? How do these con-
centrations compare to levels that would also cause 
irritation?
If formaldehyde could induce DNA adducts above  5. 
endogenous levels in NALT or circulating HSCs, what 
is the likelihood that these cells would home back to 
healthy bone marrow to cause leukemia?Formaldehyde as a leukemogen—Weight of evidence  609
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 As a whole, considering these questions allows for an 
assessment of the extent to which the genotoxicity and 
mode-of-action data support either a causal association 
between  formaldehyde  exposure  and  leukemia  or  an 
alternative hypothesis. Importantly, one needs to con-
sider the mode-of-action data in the context of the epi-
demiology and hematotoxicity data, as each of the three 
lines of evidence inform interpretation of the other.
6.3.1.  There is no consistent evidence that inhaled 
formaldehyde induces genotoxicity in bone marrow, NALT, or 
peripheral HSCs that might lead to leukemia
Although the evidence clearly indicates that formalde-
hyde induces DPX in nasal mucosa of rats and the upper 
respiratory tract of monkeys (Heck and Casanova, 2004), 
a large body of evidence suggests that formaldehyde does 
not move beyond the respiratory mucosa to induce sys-
temic genotoxic effects and cellular transformation (Heck 
and Casanova, 2004; Pyatt et al., 2008; Golden et al., 2006, 
Andersen, et al., 2010). These data are discussed in more 
detail below in the context of the distant sites (bone mar-
row, NALT, or peripheral HSCs) relevant to the proposed 
formaldehyde leukemogenic modes of action.
6.3.1.1. Bone marrow  Zhang et al. (2009) hypothesize 
that formaldehyde may potentially reach the bone marrow 
in its hydrated methanediol form where some level of free 
formaldehyde may exist in equilibrium with methandiol 
so that it could react with bone marrow stem cells to cause 
leukemia. This is very unlikely, however, given that, as dis-
cussed above, the levels of formaldehyde in the blood do 
not increase even with reasonably high exposure levels in 
humans (2 ppm). As discussed below, there are studies to 
support the implausibility of this mechanism.
As discussed in Heck and Casanova (2004), studies 
using radiolabeled formaldehyde have shown that there 
is a lack of detectable DPX in the bone marrow of rats 
exposed  to  15  ppm  formaldehyde  (Casanova-Schmitz 
et  al.,  1984),  in  bone  marrow  of  GSH-depleted  rats 
exposed to 10 ppm formaldehyde (Casanova and Heck, 
1987), and in Rhesus monkeys exposed to formaldehyde 
at concentrations as high as 6 ppm (Heck and Casanova, 
2004).  Further,  as  discussed  above,  recent  studies  (Lu 
et al., 2010, 2011; Moeller et al., 2011), using [13CD2]form-
aldehyde, clearly indicate that exogenous formaldehyde 
does not induce DNA damage beyond the nasal tissue 
(i.e., bone marrow).
In  addition,  cytogenetic  assays  in  bone  marrow  of 
Sprague-Dawley rats (Dallas et al., 1992) exposed to 15 
ppm formaldehyde, and mice exposed to formaldehyde 
via  intraperitoneal  injection  (Natarajan  et  al.,  1983  as 
cited in US EPA, 2010; Gocke et al., 1981), observed no 
significant increase in CA or MN in bone marrow cells 
relative  to  controls.  In  contrast,  one  study  by  Kitaeva 
et al. (1990, abstract only) of Wistar rats exposed to very 
low  concentrations  of  formaldehyde  (0.4  to  1.2  ppm) 
observed an increased incidence of CA in bone marrow 
cells relative to controls. This one study is not supported 
by results from the other three studies discussed. In addi-
tion, as discussed in Heck and Casanova (2004) and in 
Golden et al. (2006), this study is hampered by a lack of 
critical experimental details (i.e., dose levels and other 
experimental  procedures  are  not  clear,  and  statistical 
methods were not described properly) that precludes its 
use in drawing any meaningful conclusions.
Overall, the weight of evidence does not support the 
proposed  mode  of  action  that  inhaled  formaldehyde 
moves  beyond  the  nasal  respiratory  mucosa  to  cause 
genotoxicity in the bone marrow.
6.3.1.2.  Stem  cells  in  the  NALT  Zhang  et  al.  (2009) 
hypothesize another potential mode of action involving 
direct  induction  of  mutations  in  the  pluripotent  stem 
cells of the nasal passage (or the NALT), and that these 
stem  cells  could  then  be  released  into  the  circulation 
where they could eventually make their way to the bone 
marrow. There are several lines of evidence, discussed 
below, that suggest the implausibility of this proposed 
mechanism.
First, if precursor cells in nasal tissue were acted upon 
in this way, there should also be generation of chloro-
mas in the nasal tissue, since isolated accumulations of 
myeloid tumor cells would be expected to originate from 
the same proposed precursor cells in nasal tissue. There 
is no sign of chloromas, however, among formaldehyde-
exposed workers in the current literature. Further, as dis-
cussed in Pyatt et al. (2008), all lymphoid tumors arising 
from the NALT have been classifiable as non-Hodgkin’s 
lymphoma (NHL), which is not elevated in the formal-
dehyde occupational epidemiology studies. The lack of 
chloromas and NHL arising in the NALT (nasal lympho-
mas) in the epidemiology data provide strong evidence 
against this mode of action.
Recent  experimental  evidence  directly  examining 
this  proposed  mechanism  suggests  its  implausibility. 
Kuper et al. (2009) examined the proliferative effect of 
formaldehyde on the NALT and local lymph nodes in 
F344 rats and B6C3F1 mice exposed to 0, 0.5, 1, 2, 6, 
10, and 15 ppm formaldehyde for 28 days. The authors 
found an increased proliferation rate in the nasal epi-
thelial cells and a slight to moderate simple hyperplasia 
of the NALT in rats exposed to 15 ppm but not at lower 
concentrations, and no increases were observed at any 
concentration  in  mice,  suggesting  that  at  concentra-
tions of less than 15 ppm formaldehyde, sufficient levels 
of formaldehyde do not move beyond the nasal mucosa 
to the NALT to induce cell proliferation. Given these 
observations, it is worth considering whether it is bio-
logically plausible to incur enough damage in the NALT 
tissue,  from  typical  human  formaldehyde  exposures, 
that would be sufficient to have other manifestations. 
Although levels lower than 15 ppm formaldehyde do 
not induce proliferation in the NALT, one might argue 
that DNA damage may still occur at low levels of expo-
sure; if this damage is in a pluripotent stem cell that is 
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damaged such that carcinogenic initiation could occur, 
this  cell  might  home  back  to  bone  marrow  to  cause 
leukemia. But, one must ask whether this is quantita-
tively  plausible,  particularly  since  mucosa-associated 
lymphoid  tissue  (such  as  the  NALT)  represent  small 
concentrations of tissue. Stochastic models of carcino-
genesis have been developed that suggest human can-
cers are the result of a multistage process requiring at 
least two genetic alterations for carcinogenic transfor-
mation (Moolgavkar et al., 1999). With the understand-
ing that malignant tumors arise from a single malignant 
progenitor cell, we must ask whether there is a strong 
enough stochastic argument to support the hypothesis 
that formaldehyde exposure (at typical human exposure 
concentrations of 2 ppm or less) would hit enough stem 
cells in the NALT such that there is a reasonable likeli-
hood that the critical genes, in at least one of the stem 
cells that is released into the circulation, would be suf-
ficiently damaged to cause carcinogenic initiation, and 
further that there is a reasonable likelihood that the ini-
tiated stem cell will home back to healthy bone marrow 
to cause leukemogenesis. Given the stochastic nature of 
carcinogenesis, the relatively small amount of NALT tis-
sue, and the gene expression results of Andersen et al. 
(2010) that suggest 2 ppm formaldehyde exposure is not 
likely to increase genotoxic and cytotoxic effects in the 
nose or in any other tissue, the probability that there is 
enough damage in the NALT to lead to further carcino-
genic manifestations beyond the nose is likely very small 
at typical human exposure concentrations. Further, the 
level of damage required to reach quantitative plausi-
bility would likely result in other manifestations in the 
nose, such as chloromas, which are rarely observed.
In another study, Neuss et al. (2010) show that human 
nasal epithelial cells pre-exposed in vitro to high con-
centrations of formaldehyde do not cause DNA damage 
(DPX)  in  co-cultivated  isolated  human  lymphocytes, 
lending  further  support  that  formaldehyde  that  has 
entered the nasal epithelial cells does not move beyond 
these cells to damage other cells in close proximity, such 
as progenitor stem cells in the nasal mucosa.
Zhang et al. (2009) cite a study by Murell et al. (2005) 
in support of the NALT mode of action, since this study 
provides some support for the ability of rat olfactory 
epithelial cells to repopulate hematopoietic tissue in 
bone marrow of irradiated rats. The olfactory mucosa 
stem cells used in the Murell et al. (2005) study, how-
ever, were tested for their ability to repopulate ablated 
irradiated  rat  bone  marrow.  As  discussed  in  more 
detail below, a number of studies (McKinney-Freeman 
and Goodell, 2004; Abkowitz et al., 2003; Edgren et al., 
2007) suggest that the majority of circulating stem cells 
do not efficiently home back to bone marrow under 
homeostatic conditions.
Overall, the weight of evidence does not support the 
proposed mode of action that formaldehyde exposure, at 
reasonably expected concentrations in humans, targets 
stem cells in the NALT, such that these cells would then 
be released into the circulation to home back to the bone 
marrow to cause leukemia.
6.3.1.3.  Circulating peripheral HSCs  Zhang et al. (2009) 
propose  another  mode  of  action  for  formaldehyde-
induced leukemia, suggesting that formaldehyde could 
move beyond the nasal tissue into the circulation where 
it may transform circulating HSCs that could travel back 
to the bone marrow.
As discussed already, many studies have examined 
the  cytogenetic  effects  of  formaldehyde  in  human 
PBLs  as  a  means  for  examining  distant-site  toxicity, 
but these data are conflicting, with both positive and 
negative results. In addition, controlled animal studies 
did not find any significant genotoxic effects (SCE, MN, 
or CA) in PBLs of rats exposed to high levels of form-
aldehyde (15 ppm) (Kligerman et al., 1984; Speit et al., 
2009). Furthermore, although it is not an unreasonable 
assumption,  observations  from  studies  of  circulating 
blood  lymphocytes  should  not  necessarily  be  taken 
to mean that the same effects will occur in circulating 
stem cells that then could transition to leukemia. Only 
one study to date has examined whether cytogenetic 
effects in cultured hematopoietic progenitor cells from 
peripheral blood were increased in workers exposed to 
formaldehyde (Zhang et al., 2010b), and as discussed 
in more detail below, there are several problems with 
interpretation  of  this  study.  Therefore,  interpretation 
of the positive cytogenetic findings (beyond the nasal 
mucosa) in humans, particularly in the context of leu-
kemia, is problematic.
First,  as  discussed  earlier,  there  is  a  large  body  of 
evidence  suggesting  that  inhaled  formaldehyde  does 
not move beyond the nasal respiratory mucosa to cause 
genotoxicity at distant sites, including lymphocytes (Heck 
and Casanova, 2004; Pyatt et al., 2008; Golden et al., 2006; 
Schmid and Speit, 2007; Speit et al., 2009; Lu et al., 2010, 
2011; Moeller et al., 2011; Neuss et al., 2010). Although 
Shaham et al. (1996, 1997, 2003) reported increased levels 
of protein-associated DNA (presumed to be DPX) in the 
lymphocytes of hospital workers (laboratory assistants 
and technicians, physicians, orderlies, and pathologists), 
as discussed by Heck and Casanova (2004) and Pyatt et al. 
(2008), there are many problems with these studies. For 
example, the authors claimed that DPX could be detected 
down to 0.001 mM; however, their data do not provide 
any evidence of a concentration-response relationship 
for  DPX  below  0.3 mM.  Further,  Shaham  et  al.  (1996, 
1997) indicate that DPX are persistent and can accumu-
late in lymphocytes. Their data, however, do not support 
their assertion and are contradictory to studies showing 
the rapid removal of DPX from formaldehyde-exposed 
human blood in culture (Schmid and Speit, 2007), and 
from  the  nasal  respiratory  mucosa  of  rats  exposed  to 
formaldehyde  via  inhalation  (Heck  and  Casanova, 
2004). Further, with regard to chromosomal aberrations 
observed in PBLs, as shown by Schmid and Speit (2007), 
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during S-phase in human blood cultures. These results 
suggest that, given the rapid removal of DPX, it is unlikely 
that a sufficient amount of formaldehyde-induced DPX 
would persist through DNA replication in occupationally 
exposed workers. This further suggests that reported SCE 
frequencies in PBLs of workers exposed to formaldehyde 
are unrelated to any formaldehyde exposure. The authors 
extend this argument for other cytogenetic events as well 
(MN and CA).
Second,  interpretation  of  many  of  the  human  PBL 
studies of formaldehyde-exposed workers is limited due 
to the lack of reliable exposure information and poten-
tial confounding by exposures to other chemicals in the 
workplace or other factors that may impact background 
levels of CA and MN. Several studies (Battershill et al., 
2008; Iarmarcovai et al., 2008, 2007) suggest that many 
factors, including age, gender, smoking status, alcohol 
consumption, disease conditions and infections, physical 
exercise, and vitamin B12 and folate status impact back-
ground levels of CA and MN in PBLs (albeit some factors 
stronger than others). Battershill et al. (2008) suggest that 
the evaluation of PBLs as genotoxicity biomarkers is com-
plex, requiring good exposure data, appropriate strati-
fication  of  exposed  groups,  and  appropriate  statistical 
power. Given the general limitations in the human PBL 
studies, it is not surprising that the results with respect to 
formaldehyde are inconsistent.
Third, observations from studies of circulating blood 
lymphocytes should not necessarily be taken to mean 
that the same effects will occur in circulating stem cells 
that then could transition to leukemia. In fact, CA and 
MN in PBLs are associated with many types of cancers, 
and they appear to be a general marker for increased 
cancer risk, not specific to leukemia (Bonassi et al., 2008; 
Murgia et al., 2008). In these studies, it is noteworthy 
that increased CA in PBLs are not associated with occu-
pational exposures to genotoxic agents. Further, as dis-
cussed in Pyatt et al. (2008), there are many commonly 
used drugs with clastogenic properties in vitro and in 
vivo (methotrexate), and in human lymphocytes in vitro 
(including antibiotics metronidazole, trimethoprin, and 
hydrochlorothiazide). Therefore, there is limited value in 
using clastogenic effects in human lymphocytes as being 
predictive of leukemic potential.
Only one study (Zhang et al., 2010b) reports increased 
cytogenetic  effects  (aneuploidy)  in  cultured  myeloid 
progenitor cells from 10 workers exposed to formalde-
hyde (mean of 2 ppm). Zhang et al. (2010b) report an 
increased loss of chromosome 7 (monosomy 7) and gain 
of chromosome 8 (trisomy 8) in exposed relative to the 
unexposed  control  group.  There  are  several  problems, 
however, with this study.
First, the study group was very small (10 exposed vs.  •	
12 control) and the results were pooled. Individual 
results for monosomy 7 and trisomy 8 should have 
been provided so that the exact nature of aneuploidy 
could have been assessed on an individual basis, and 
so it would be clear whether there was a consistent 
increase for all subjects, or if some were much higher 
than others, or if some had just one change or both, 
etc.
Second,  were  other  chromosome  changes  looked  •	
for and not found? Or did the authors only look for 
these particular changes? It is not clear, as there is no 
discussion beyond monosomy 7 and trisomy 8. This 
is particularly relevant because, although aneuploidy 
of  chromosomes  7  and  8  have  been  shown  to  be 
associated with leukemia (Johnson and Cotter, 1997; 
Rowley, 2000; Paulsson and Johansson, 2007), they 
are not the only chromosome changes that are associ-
ated with the disease. In fact, as discussed in Johnson 
and  Cotter  (1997)  and  Paulsson  and  Johansson 
(2007), monosomy 7 and trisomy 8 are not likely to 
be initiating events in leukemogenesis, and trisomy 
8 alone is not sufficient for leukemogenesis. Trisomy 
8 has been shown to occur as a secondary change to 
primary inversions of other chromosomes (i.e., chro-
mosomes 9 and 11) (Paulsson and Johansson, 2007).
Third, Zhang et al. (2010b) note a high monosomy 7  •	
incidence in the controls and indicate that this could 
be due to artifactual chromosome loss during meta-
phase spread preparation; therefore, there is inher-
ent bias in the sampling technique that could bias 
the results.
And finally, myeloid associated monosomy 7 and tri- •	
somy 8 have been shown to be correlated with other 
exposures. Smoking has been shown to cause trisomy 
8 (Paulsson and Johansson, 2007; Moorman, 2002), 
and other occupational exposures (e.g., pesticides, 
organic solvents, and petroleum compounds) have 
been  shown  to  cause  monosomy  7  (Johnson  and 
Cotter, 1997). A recent formaldehyde occupational 
exposure  study  (Iarmarcovai  et  al.,  2007),  where 
increased MN were observed in exposed vs. controls, 
found that alcohol consumption had a potential con-
founding effect on chromosome loss. Approximately 
40% of the control and exposed subjects in the Zhang 
et al. (2010b) study were smokers, and about 20% in 
each group consumed alcohol. Although the percent 
smokers  and  alcohol  consumers  was  roughly  the 
same in the exposed and control groups, there was 
no attempt to determine the degree of smoking or 
alcohol consumption among the subjects. Therefore, 
potential confounding from these exposures could 
have biased the results, particularly given the small 
sample  size.  Individual  data  could  provide  more 
insight into potential confounding associations.
Overall, given the small study group, lack of a thor- •	
ough examination of chromosomal effects, potential 
confounding of observed effects (i.e., other potential 
exposures,  smoking,  alcohol  consumption),  and 
the possibility of artifactual chromosome loss dur-
ing  sample  preparation,  it  is  possible  to  attribute 
the chromosomal changes reported by Zhang et al. 
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 Given the strong evidence that inhalation exposure to 
formaldehyde  (at  reasonably  expected  concentrations 
for humans) does not increase the level of formaldehyde 
in the blood and does not cause DNA damage and cellu-
lar transformation beyond the nasal respiratory mucosa, 
in combination with the inconsistent effects observed in 
PBLs  of  humans  occupationally  exposed  to  formalde-
hyde (likely due to confounding and lack of good form-
aldehyde exposure information), and the fact that there 
is little support for the use of PBLs as a marker for effects 
in HSCs and leukemia, the PBL data from formaldehyde 
occupation studies, taken as a whole, provide little (if any) 
support for the proposed modes of action for formalde-
hyde as a leukemogen. Finally, the recent study by Zhang 
et al. (2010b) is hampered by potential confounding, a 
small study group, sampling artifacts, and lacks reporting 
of critical information, such that the reported chromo-
some changes in this study are impossible to interpret.
Therefore, the weight of available evidence does not 
support the proposed mode of action that formaldehyde 
might target circulating HSCs that might then home back 
to the bone marrow to cause leukemia.
6.3.2. Formaldehyde exposure would have to be very high 
to induce DNA damage above endogenous levels in the 
bone marrow, NALT, or circulating HSCs, and would likely be 
associated with a high degree of irritation
As discussed already, there is a large body of supportive 
evidence  that  inhalation  exposure  to  formaldehyde  at 
reasonably  expected  concentrations  for  humans  (less 
than 2 ppm) does not result in increased blood levels of 
formaldehyde (Heck and Casanova, 2004; Franks, 2005; 
Andersen et al., 2010), likely due to normal metabolic 
processes that prevent formaldehyde from readily enter-
ing the circulation. Further, there is evidence to suggest 
that DNA damage does not occur in the blood or bone 
marrow  of  animals  even  at  concentrations  as  high  as 
6–15 ppm. Schmid and Speit (2007) propose that, due 
to the rapid removal of DPX, very high concentrations 
of formaldehyde would be required (higher than what 
would be expected for humans occupationally exposed 
to  formaldehyde)  to  produce  enough  DPX  that  would 
persist until DNA replication could lead to a permanent 
genotoxic effect (i.e., SCE, CA, or MN).
It  is  important  to  consider  these  concentrations  in 
the  context  of  what  concentrations  of  formaldehyde 
are known to cause sensory irritation. Arts et al. (2006) 
conducted a review of the formaldehyde respiratory irri-
tation and carcinogenicity data and found that overall, 
formaldehyde sensory irritation is first observed at 1 ppm 
in  animals  and  humans,  with  eye  and  nasal  irritation 
occurring at concentrations ≥1 and ≥2 ppm, and throat 
irritation occurring at ≥3 ppm, and more severe irritation 
occurring at concentrations ≥6 ppm. Therefore, sensory 
irritation occurs at concentrations well below those that 
would likely be necessary to cause sufficient DNA dam-
age in blood, NALT, or bone marrow, and therefore the 
formaldehyde  exposure  concentrations  necessary  to 
cause such DNA damage would likely not be tolerated by 
humans.
6.3.3.  Circulating HSCs may not readily home back to healthy 
bone marrow to cause leukemia
A critical assumption in the proposed modes of action 
that formaldehyde either targets stem cells in the NALT 
or circulating in the blood is that these damaged cells 
will travel back to and become incorporated into the 
bone marrow where they could then cause leukemia. 
Although much of the evidence suggests that these pro-
posed modes of action are not biologically plausible, 
there is still a general assumption that if the exposure 
conditions  were  such  that  even  one  cell  was  trans-
formed,  either  directly  in  circulating  HSCs  or  in  the 
NALT and then released into the circulation, that this 
cell would then readily home back to the bone marrow. 
The current evidence is not clear, however, with regard 
to this assumption for people with healthy bone mar-
row (McKinney-Freeman and Goodell, 2004; Abkowitz 
et  al.,  2003;  Abrams  et  al.,  1980;  Wright  et  al.,  2001; 
Schulz et al., 2009), which would be the majority of the 
population for which the regulatory outcome of these 
studies and proposed mechanisms would seek to pro-
tect. And, in fact, a number of studies suggest that the 
majority of circulating HSCs may not efficiently home 
to bone marrow.
For  example,  using  genetically  marked  parabiosed 
CD45  congenic  mice  (surgically  joined  and  sharing  a 
common circulation), McKinney-Freeman and Goodell 
(2004) found that although there was a small percent of 
partner-derived stem cells present in the bone marrow, 
the majority of animals were not stably engrafted with 
partner HSCs when tested for functional HSC activity, 
suggesting that although a small percent of circulating 
HSC can reenter the bone marrow during homeostasis 
(i.e., in the absence of cytokine mobilization), this reen-
trance  is  transient  and  unstable,  and  functional  HSCs 
do not persist in the bone marrow after returning from 
the circulation. The results of this study are supported by 
Abkowitz et al. (2003), who also used genetically marked 
parabiosed mice in a similar experiment and found simi-
lar results. These results suggest that HSC homeostasis 
is primarily maintained by endogenous stem cells in the 
bone marrow, and not from the return of stem cells from 
the circulation. The authors propose that “[b]ecause the 
HSC replication rate is high [in the bone marrow], the 
new HSCs outnumber the few HSCs entering the marrow 
from the peripheral blood. Once HSCs exit bone marrow, 
their lifespan in the circulation is extremely short, con-
tributing to the competitive advantage of endogenously 
generated cells.”
There may be additional support for the idea that 
circulating  HSCs  do  not  readily  home  back  to  bone 
marrow  in  that  that  there  is  no  evidence  that  blood 
transfusions  from  precancerous  (leukemia)  blood 
donors are associated with increased risk of leukemia 
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to assume that blood donors who were later diagnosed 
with leukemia had circulating progenitor cells that had 
genetic damage or were transformed. Although it would 
need to be confirmed that preleukemogenic individu-
als  have  precancerous  circulating  HSCs,  if  preleuke-
mogenic cells did exist in a blood donation, and these 
cells readily home back to bone marrow, Edgren et al. 
should have seen an increased risk of leukemia in the 
blood  recipients,  but  they  did  not.  The  authors  cite 
other studies that were inconclusive with regard to this 
question.
There are conflicting studies that appear to suggest that 
HSCs do efficiently home to bone marrow under homeo-
static conditions (Wright et al., 2001). A recent review by 
Schulz et al. (2009), however, indicates that the mecha-
nisms involved in the control of hematopoietic stem or 
progenitor  cell  function  remain  largely  unknown.  The 
authors indicate that, in addition to recirculation to the 
bone marrow, HSCs migrate to peripheral tissue during 
inflammation to respond to tissue damage. Therefore, it 
appears that there is much to learn with regard to mecha-
nisms involved in homing of HSCs to bone marrow under 
homeostatic conditions. Consequently, the assumption 
that  damaged  HSCs  or  NALT  stem  cells  would  read-
ily return to bone marrow where they could then cause 
leukemia should be questioned, and further studies are 
necessary to assess the extent to which this might occur 
under homeostatic conditions.
Therefore,  aside  from  the  questions  put  forth  with 
regard  to  the  implausibility  that  exogenous  formalde-
hyde could sufficiently damage NALT stem cells or cir-
culating HSCs, there are clearly also questions regarding 
the extent to which these stem cells would then migrate 
back to the bone marrow. Consequently, these studies 
add further to the questions regarding the plausibility of 
the proposed modes of action. Moreover, it is critical that 
we try to better understand HSC trafficking in and out 
of bone marrow under normal physiological conditions 
before accepting any mode of action that relies so heavily 
on this mechanism.
6.4.  Summary
As  a  whole,  the  available  formaldehyde  toxicokinetic, 
mode-of-action, and genotoxicity studies provide little 
evidence for support of the account that formaldehyde 
exposure is causally associated with leukemia. The ad 
hoc assumptions that have been put forth in support of 
the three proposed modes of action are not consistent 
with the full body of evidence. To support the proposed 
modes of action, one must assume,
with  regard  to  targeting  circulating  hematopoietic  1. 
stem cells, that formaldehyde can move beyond the 
nasal  respiratory  mucosa  to  increase  levels  in  the 
blood to a sufficient degree that would result in carci-
nogenic initiation of progenitor cells, and the weight 
of evidence does not suggest this, at least for levels 
to which humans are likely to be exposed and that 
could be tolerated (due to irritation at higher levels 
of exposure);
with regard to targeting bone marrow, that formal- 2. 
dehyde can travel in its hydrated methanediol form 
to the bone marrow where it will be in equilibrium 
with free formaldehyde that can cause DNA dam-
age and cellular transformation, even though this is 
biologically implausible and the weight of evidence 
strongly suggests that exogenous formaldehyde does 
not cause DNA damage in any tissue other than the 
nasal respiratory mucosa;
with regard to targeting stem cells in the NALT, that  3. 
formaldehyde  somehow  moves  beyond  the  nasal 
respiratory mucosa and causes sufficient damage to 
nasal stem cells, such that further carcinogenic man-
ifestations could occur (leukemia), without causing 
any nasal lymphomas or chloromas in the nasal tis-
sue, even though it is biologically and quantitatively 
implausible that the level of damage likely required 
in the NALT to cause further carcinogenic manifes-
tations would not also lead to chloromas and nasal 
lymphomas;
with regard to targeting circulating HSCs, that formal- 4. 
dehyde somehow moves beyond the nasal respiratory 
mucosa and causes DNA damage or transformation 
of circulating stem cells, even though the majority of 
evidence provided as support for this mechanism is 
from a large number of inconsistent PBL cytogenetic 
studies of formaldehyde-exposed workers and likely 
confounded by exposures to other chemicals in the 
workplace  or  by  effects  from  smoking  or  alcohol 
consumption  (in  addition  to  the  assumption  that 
chromosomal effects in PBLs are good biomarkers 
for effects in HSCs and leukemia, and there is little 
support for this in the literature); or
the  chromosome  aneuploidy  in  cultured  myeloid  5. 
progenitor cells of 10 formaldehyde exposed workers 
reported in the Zhang et al. (2010b) study somehow 
suggests that these workers may be at a higher risk 
for leukemia, even though this study is hampered 
by  potential  confounding,  a  small  study  group, 
sampling artifacts (e.g., possible artifactual chromo-
somal loss during metaphase spread preparation), 
and lacks reporting of critical information, such that 
the reported chromosome changes in this study are 
impossible to interpret; and
even if one accepts, or it is somehow shown, that  6. 
formaldehyde is capable of transforming stem cells 
in the NALT or circulating HSCs, that these cells will 
then readily home back to the bone marrow, even 
though  currently  there  is  evidence  to  suggest  that 
these cells infrequently home back to healthy bone 
marrow.
 Moreover, beyond the lack of support provided by the 
current  mechanistic  weight  of  evidence,  as  discussed, 
the epidemiology data, human and animal hematotoxic-
ity data, and animal leukemia studies do not provide any 614  L. R. Rhomberg et al.
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support for the proposed modes of action for formalde-
hyde leukemogenesis.
It is worth pointing out an inconsistency with respect 
to data that have been put forth in the context of the three 
proposed modes of action for formaldehyde leukemo-
genesis. That is, reported observations of formaldehyde-
induced hematotoxicity have been generally discussed 
as indicating a causal association with leukemia, and the 
proposed association has been discussed in the context 
of three possible modes of action. Bone marrow toxicity, 
however, can only occur if the chemical interacts directly 
with the bone marrow, which would only happen in the 
proposed mode of action that targets bone marrow. If the 
alternative modes of action are plausible (targeting circu-
lating hematopoietic stem cells or NALT stem cells), form-
aldehyde would not be expected to cause hematotoxicity 
because it would not be directly acting on bone marrow. 
Instead, it likely would not be until tumor formation in 
bone marrow that one would expect a change in blood cell 
counts (likely increase in WBCs). That is, hematotoxicity 
would not be expected to occur in the exposed workers in 
the Zhang et al. (2010b) study if the mode of action was 
through formaldehyde damage to circulating progenitor 
cells or NALT stem cells. Interestingly, there are no other 
leukemogens that do not also show hematotoxicity, and 
therefore these leukemogens likely act by directly dam-
aging the bone marrow. So, acceptance of one of these 
two modes of action (targeting circulating HSCs or NALT 
stem cells) suggests formaldehyde acts via a completely 
different mechanism from other leukemogens (i.e., in the 
absence of hematotoxicity), further suggesting biological 
implausibility.
Finally, it is informative to consider the phenomenon 
of apparent dependence of increased leukemia risk in 
certain  epidemiology  studies  on  peak  exposure  rather 
than on average or cumulative exposure. As we described 
in Section 4, in the NCI industrial worker cohort, Beane 
Freeman et al. (2009) found that the presence in a work-
er’s career of peak exposures >4 ppm was associated with 
increased leukemia risk. In that section, we questioned 
whether this dependence on peaks was merely a mat-
ter of choosing among several dose metrics considered 
based on its outcome. But if the dependence on peaks 
is a real effect—if it is a discovery of the epidemiology 
investigations—there  should  be  some  correspondent 
peak-dependent aspects evident when proposed modes 
of action are investigated. It is not clear from consider-
ation of the modes of action that have been proposed how 
such a peak dependence could work. If formaldehyde 
has to leave the respiratory tract and be redistributed to 
distant tissues such as marrow, the sharpness of a peak 
of exposure would be greatly attenuated as the absorbed 
formaldehyde  mixed  into  the  general  circulation. 
Similarly, if susceptible cells are to migrate from marrow 
to the respiratory tract and back to the marrow, or from 
NALT in the respiratory tract to the marrow—processes 
that are hypothesized to be occurring at a low but ongo-
ing level—it is not clear how peak inhalation exposures 
could have special effect. One would expect associations 
with other measures of exposure besides peak if this were 
the case. If genotoxic modes of action are proposed (so as 
to form the basis for concern regarding potential cancer 
risks  to  people  experiencing  low  environmental  expo-
sures), the accumulation of risk of transforming muta-
tions  similarly  must  be  an  ongoing  process  that  does 
not readily explain the apparent dependence on peak 
exposure as noted by Beane Freeman et al. (2009). In 
our view, such considerations illustrate the importance 
of integrating weight of evidence across disciplines, not 
just in combining conclusions from different disciplines, 
and in using a hypothesis-based framework to assess the 
consistency  of  analyses  and  their  interpretations  with 
mutual illumination across disciplines.
7.  Discussion
The most current draft of the US EPA assessment of form-
aldehyde’s human health risks (US EPA, 2010) states, “[h]
uman epidemiological evidence is sufficient to conclude 
a  causal  association  between  formaldehyde  exposure 
and … all leukemias, myeloid leukemia and lymphohe-
matopoietic cancers as a group,” but it also notes that 
“[l]imited  evidence  from  animal  bioassays  is  available 
to  support  the  conclusion  from  human  epidemiologic 
data that formaldehyde causes some types of lymphohe-
matopoietic cancers.” As is clear from the US EPA state-
ment, these conclusions are backed by evaluations based 
initially on a judgment about the human data alone, con-
ducted according to the approaches that epidemiologists 
use to evaluate whether the patterns observed among 
human studies of apparent associations between inhaled 
formaldehyde  and  lymphohematopoietic  cancers  are, 
in the judges’ view, sufficiently indicative of a causative 
process.  It  is  only  afterward  that  the  compatibility  of 
this conclusion with information from animal studies or 
mode-of-action data is considered, and, if the human-
data-only conclusion is one of causation, the presence or 
(as in the case of formaldehyde) lack of additional sup-
port is noted.
The most recent update of the IARC monograph (IARC, 
2009) states that, with regard to formaldehyde, “the epi-
demiological evidence on leukaemia has become stron-
ger, and new mechanistic studies support a conclusion of 
sufficient evidence in humans. This highlights the value of 
mechanistic studies, which in only 5 years have replaced 
previous assertions of biological implausibility with new 
evidence that formaldehyde can cause blood-cell abnor-
malities  that  are  characteristic  of  leukaemia  develop-
ment.” IARC further states that “[t]he Working Group was 
almost evenly split on the evaluation of formaldehyde 
causing leukaemias in humans, with the majority view-
ing the evidence as sufficient for carcinogenicity and the 
minority viewing the evidence as limited. Particularly rel-
evant to the discussions regarding sufficient evidence was 
a recent study accepted for publication which, for the first 
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characteristic of myeloid leukaemia and myelodysplas-
tic syndromes with supporting information suggesting 
a decrease in the major circulating blood cell types and 
in circulating haematological precursor cells.” Although 
the IARC monograph highlights mechanistic studies, it 
appears that “viewing the evidence as sufficient” stems 
predominantly  from  one  human  occupational  study 
(likely Zhang et al., 2010b, although not cited by IARC, 
2009).
Our concern with such a process is that it fails to 
appreciate  the  role  that  animal,  toxicokinetic,  and 
mode-of-action data can and should have, not just in 
the overall conclusion, but in the interpretation of the 
meaning of the epidemiological data themselves. If one 
concludes that the epidemiological data show causa-
tion,  then  there  is  an  implicit  conclusion  that  some 
mechanism for this causal process is not merely con-
ceivable or not yet disproven, but it must actually exist. 
If it is firmly concluded that something is causal, it must 
also be firmly concluded that a means for that causation 
exists, even if it is not named. If animal studies or other 
mode-of-action  studies  are  not  in  concordance  with 
the  human-data-only  conclusion  (epidemiology  and 
the key mechanistic occupational study referenced by 
IARC), acceptance of the apparent causation in humans 
necessarily includes a further conclusion that the dis-
cordance  is  explicable—that  the  causes  invoked  for 
the human data either do not operate in animals or, for 
some scientifically plausible reason, are not manifested 
in observable consequences.
Our HBWoE approach calls attention to this and rec-
ognizes  that  the  weight-of-evidence  evaluation  should 
evaluate  these  subsidiary  conclusions  about  the  plau-
sibility  of  human  mechanisms  and  their  concordance 
or lack of concordance with mechanisms in animals. It 
is  important  to  evaluate  these  subsidiary  conclusions 
explicitly rather than leave them implicit. It is particularly 
important  when,  as  is  the  case  for  formaldehyde,  our 
understanding of these other aspects is not merely non-
supporting of the human-data-only conclusion but actu-
ally conflicts with it. If inhaled formaldehyde is indeed 
a  human  leukemogen,  then  something  about  what  is 
commonly understood, related to possible mechanisms 
and their potential operation in humans and rodents, is 
in error. Conversely, if it is indeed right to doubt the sci-
entific plausibility of suggested mechanisms, their opera-
tion in human exposures, and their lack of operation in 
animal studies, then it is wrong to interpret the patterns 
among human studies as indicative of causality. Because 
the  epidemologists’  evaluation  of  causality  from  the 
human data entails judging how well a common causal 
explanation  is  supported  by  the  array  of  observations 
compared to alternative explanations that attribute the 
apparent patterns to other, non-causal influences (such 
as chance and confounding), the scientific plausibility 
of the causal interpretation of the human-data patterns 
in view of other, non-epidemiologic data is an important 
part of a sound evaluation.
We have attempted to carry out a more complete eval-
uation across scientific disciplines for the case of inhaled 
formaldehyde  and  hematopoietic  cancers  in  humans. 
In our reading of the weight of evidence, the conclusion 
that  formaldehyde  can  cause  such  effects  is  not  well 
supported.
In summary, the HBWoE evaluation for formaldehyde 
considers two alternative accounts. One account consists 
of  acceptance  of  the  epidemiology  evidence  as  suffi-
ciently compelling that, even in the face of weak hema-
tological and carcinogenic evidence in animals and weak 
and  inconsistent  hematological  evidence  in  humans, 
one of the proposed modes of action for formaldehyde 
leukemogenesis must be right, since its manifestations as 
increased leukemia risks are seen in the human studies. 
Moreover, the arguments against the biological plausibil-
ity of these modes of action must in some way be incor-
rect. Acceptance of this account is associated with many 
unanswered  questions  and  post  hoc  explanations  for 
how the current data should be interpreted as support-
ing it. This account requires that one accepts the reported 
exposure and disease information in the epidemiology 
studies as true, even though the lack of precise exposure 
data likely led to exposure measurement error and/or 
exposure misclassification that could have biased results, 
and disease misclassification in these studies likely led 
to unreliable risk estimates. It requires that all the many 
human studies that failed to show increased leukemia 
risk did so for plausible reasons, such that the lack of 
effects does not contradict formaldehyde’s asserted gen-
eral property of leukemogenicity. This account requires 
that one accepts an existence of an exposure-response 
relationship,  despite  the  lack  of  consistently  observed 
exposure-response  associations  within  or  among  the 
epidemiology  studies.  It  requires  that  one  accepts  the 
post hoc explanation of short latency for the increased 
risks associated with peak exposure observed in the NCI 
industrial worker cohort with follow-up through 1994, 
but  not  when  follow-up  was  continued  through  2004, 
even though this does not explain how this trend was 
not observed in the NCI embalmers cohort (Hauptmann 
et al., 2003; Walrath and Fraumeni, 1983, 1984) or gar-
ment workers cohort (Pinkerton et al., 2004), in whom 
risks were only observed with exposures over 20 years. 
This account requires that, although the epidemiology 
data were statistically analyzed in many different parallel 
ways with many finding no significant association, one 
chooses to focus only on the few marginally significant 
findings while ignoring the others as part of the evidence 
as a whole. For example, in the NCI industrial worker 
cohort, associations were reported with peak exposures, 
but there was no a priori reason to focus on peak expo-
sures. These results should at most be treated as hypoth-
esis-generating  observation  to  be  tested  empirically. 
Otherwise, it is post hoc and arbitrary.
Moreover,  this  account  (that  formaldehyde  is  caus-
ally  associated  with  leukemia)  requires  inclusion  of  an 
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to  show  hematological  or  leukemogenic  effects  at  high 
formaldehyde  exposure  concentrations  (6  to  15  ppm). 
That is, what is being argued to be happening in humans 
(to allow the leukemogenic effect) must for some reason 
not be happening in the experimental animals, or else they 
would have been seen to have parallel hematotoxic and 
leukemogenic effects, as well as evidence of other conse-
quences of operation of the proposed modes of action. It 
is not beyond reason that a leukemogenic effect of formal-
dehyde might be confined to humans, but there has been 
no explanation offered for why this might be so. Further, 
the proposed modes of action that would enable an effect 
in humans do not have any evident basis to be absent in 
rodents—indeed, some of the elements (migrating stem 
cells, effects on NALT), both consistent with or contrary to 
this account, are based on rat data. As it stands, the reasons 
for rodents not being subject to the proposed causative 
processes in humans constitutes an unstated corollary—
one without empirical support or plausible basis—to the 
theories of human leukemogenesis of formaldehyde.
One needs to account for the inconsistencies among 
studies regarding the hematological evidence in humans; 
if there is an effect of formaldehyde inhalation, then what 
reasons are proposed for why it is not seen in many of the 
studies (and not seen at all in animals)? Only some of the 
hypothesized modes of action entail hematotoxicity, and 
so a proposal of its role in human leukemia depends on 
the particular variety of proposed mode of action being 
considered, with observations in favor of one mode tend-
ing to contradict other modes and hence in need of expla-
nation for why such conflicts are not refuting. Finally, 
because of the weak and inconsistent epidemiological 
and toxicological evidence for a causal association, this 
account requires that one rely heavily on the truth of toxi-
cokinetic and mechanistic hypotheses that permit a plau-
sible biological mode of action. To accept this account as 
true, one must accept that somehow formaldehyde can 
move beyond the nasal respiratory mucosa to ultimately 
cause DNA damage and cellular transformation in bone 
marrow,  circulating  hematopoietic  stem  cells,  or  the 
NALT, even though there is a large body of evidence to 
suggest that inhaled formaldehyde (at reasonably high 
exposure concentrations for humans, 2 ppm) does not 
increase  levels  in  the  blood  and  does  not  cause  DNA 
damage in cells and tissues beyond the nasal respira-
tory mucosa to a sufficient degree that would manifest 
as leukemia. If one is to conclude that formaldehyde is a 
“known” human leukemogen, one must assert not only 
that these hypothesized modes of action are conceivably 
true but that it is indeed known that one of them is true, 
for otherwise an essential and utterly necessary element 
of the causal conclusion is missing.
For this account (formaldehyde is causally associated 
with leukemia), there is a very large degree of ad hoc 
argument. That is, the elements of this account are cho-
sen so as to fit the hypothesis already put forth, not based 
purely on an evaluation of the weight of the evidence as a 
whole and how it may (or may not) support the proposed 
hypothesis. Consequently, alternative accounts need to 
be considered.
An alternative, and contrasting, account is that it is 
not possible for formaldehyde to move beyond the nasal 
respiratory mucosa to cause systemic DNA damage and 
cellular transformation (in the bone marrow, circulating 
hematopoietic stem cells, or the NALT), and therefore 
there is no biologically plausible mechanism for form-
aldehyde leukemogenesis. This is supported by a large 
body of toxicokinetic and mechanistic data in animals 
and in vitro, and by inconsistent cytogenetic peripheral 
blood lymphocytes data in humans that are likely con-
founded by other exposures and a lack of reliable form-
aldehyde exposure information, in addition to the fact 
that there is little evidence to support the use of periph-
eral blood lymphocytes data as a biomarker for effects 
in hematopoietic stem cells or for leukemia. Further, the 
lack of toxicokinetic and mechanistic biological plausi-
bility is supported by the largely negative toxicological 
evidence and a significant number of null epidemiology 
findings, which are considered under this account to be 
the true results, whereas those relatively isolated and 
unrepeated positive results are considered as false posi-
tives attributable to confounding by other exposures or 
to chance. If this account is true, an association between 
inhalation  of  formaldehyde  and  leukemia  would  be 
understood as not plausible for humans, and the few 
positive  associations  that  have  been  observed  would 
be attributed to alternative explanations (i.e., to other 
chemical exposures in the workplace, or lifestyle-related 
exposures such as smoking or alcohol consumption, or 
simply to chance).
In comparing these two accounts, neither is proven 
or disproven, but when assessing the weight of the avail-
able evidence in support of either account, it is clear that 
the first account requires far more ad hoc assumptions 
and post hoc explanations. In the first account, the infer-
ences  regarding  potential  human  risk  are  not  coming 
from the data themselves, but from assumptions invoked 
after the fact to fit the hypotheses put forth and without 
the evidence that would tie the weak epidemiological, 
toxicological, and mode-of-action data causally to form-
aldehyde inhalation exposure. Therefore, the weight of 
evidence for this account (i.e., exposure to formaldehyde 
in air is causally associated with leukemia in humans) is 
weak in comparison to the more substantial weight of 
evidence supporting the lack of a causal association.
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